The Relationship between Insulin Resistance and the Atherogenic Lipoprotein Phenotype by Tan, Chee-Eng
The Relationship between Insulin Resistance
and
The Atherogenic Lipoprotein Phenotype
Chee-Eng Tan, M.B., B.S. (S'pore), M Med (Int Med) (S'pore), FAMS (S’pore)
Institute of Biochemistry 
Royal Infirmary 
Glasgow
Thesis submitted for the degree of Doctor of Philosophy in the Faculty of Medicine,
University of Glasgow, UK.
Submitted April 1996
1
ProQuest Number: 11007917
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 11007917
Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
(055^
Contents
Abstract Pg 3-4
Table of Contents Pg 5-8
Acknowledgements Pg9
Author's Declaration pglO
Dedication Pg 11
2
Abstract
The prevalence of the insulin resistance syndrome in a non diabetic population had been 
estimated to be about 25% whilst the prevalence of the atherogenic lipoprotein phenotype 
is thought to be about 30%. There are some evidence to suggest that there may be a close 
relationship between these two syndrome and that relationship was explored in this thesis. 
Risk factors for cardiovascular disease often show clustering that cannot be accounted for 
by chance occurrence. This has led to the hypothesis that clustering of risk factors such as 
insulin resistance and dyslipidaemia, may be an indication of an underlying metabolic 
disorder which increases the risk for premature atherosclerosis.
Plasma triglyceride was found to be the most important determinant of LDL subfraction 
distribution in a group of normal individuals. The least dense species, LDL-I, decreased 
as the level of this plasma lipid rose. LDL-II in both men and women exhibited a positive 
association with plasma triglyceride in the range 0.5 to 1.3 mmol/L; it increased from 
about 100 to 200 mg/dL. In contrast, within this triglyceride range the LDL-III 
concentration was low (about 30 mg/dL) and changed little. As plasma triglyceride rose 
from 1.3 mmol/L to 3.0 mmol/L there was a significant fall in LDL-II concentration in 
males but not in females. Conversely, above the triglyceride “threshold” of 1.3 mmol/L 
there was a steeper rise in LDL-III concentration in males than females; 42% of men had 
an LDL-III in the range associated with high risk of heart disease (> 100 mg 
lipoprotein/dL plasma) compared with only 17% of women. In a group of young 
Singaporean males, the relationship of plasma triglyceride with LDL-II failed to show a 
biphasic pattern but rather, increasing levels of plasma triglyceride was associated with 
decreasing levels of LDL-II. The LDL-I showed a similar negative relationship and the 
LDL-III a positive relationship with plasma triglyceride. Other influences of the LDL 
subfraction profile were the activities of lipases and parameters indicative of the presence 
of insulin resistance. Males on the average had twice the hepatic lipase activity of 
females. This enzyme in males was not strongly associated with variation in the LDL 
subfraction profile whereas in the females it was correlated with LDL-III and remained a 
significant predictor in multivariate analysis. Increased WHR, fasting insulin and glucose 
were shown to be correlated with LDL-I (negatively) and LDL-III (positively), primarily, 
at least in the case of LDL-III, through raising plasma triglyceride.
Subjects with proven coronary artery disease were also found to have impaired 
triglyceride metabolic capacity during the administration of an oral fat tolerance test. The 
triglyceride rose to a higher level when compared to age matched controls. The 
exaggerated hypertriglyceridaemia may be related to the preheparin lipoprotein lipase 
activity, which was demonstrated to be significantly lower in CAD patients compared to 
age matched controls. The CAD patients also demonstrated some features of insulin 
resistance, such as hyperinsulinaemic and hyperglycaemic response, both after the 
standardised fat meal as well as after a modified glucose meal carried in almost fat free 
yoghurt. Lipoprotein lipase activity is believed to be modulated by hormonal influence 
such as insulin and resistance of LPL to insulin may be responsible for the lower 
preheparin LPL documented in CAD patients. The metabolic implications of impaired
preheparin LPL during alimentary lipaemia is presently unclear as there is no correlation 
with adipose tissue and skeletal muscle LPL.
The prevalence of insulin resistance and the atherogenic lipoprotein phenotype in 
Singapore may be higher than other population because of the high prevalence of diabetes 
mellitus. A group of normal Singaporean male, aged 30 to 45 years old were studied and 
found to have a high prevalence of both syndromes. More than half of this sampled group 
had LDL-III concentraton that was above 100 mg lipoprotein/dL plasma and this may be 
related to the higher mean plasma triglyceride levels (1.8 mmol/L). Ethnic differences 
were noted and men with predominantly Asian ancestry had higher mean LDL-III 
concentrations and plasma triglyceride, while those with some European descent 
(Eurasians) had levels of LDL-III and plasma triglyceride similar to age matched Scottish 
cohort. There were also ethnic differences in markers of insulin resistance such as fasting 
insulin and fasting glucose and these difference paralleled that seen in LDL-III 
concentration. Ethnic differences suggest that genetic factors may determine 
manifestation of both the atherogenic lipoprotein phenotype and the insulin resistance 
syndrome, as socio-economic factors are similar between the various ethnic groups.
The data presented in this thesis suggest a strong relationship between the atherogenic 
lipoprotein phenotype and the insulin resistance syndrome. The clustering of coronary 
risk factors such as dyslipidaemia and insulin resistance in patients with premature 
atherosclerosis may be an indication of an underlying metabolic dyslipidaemic syndrome.
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Chapter 1 Introduction
The fear of the Lord is the beginning o f wisdom, And the knowledge o f the Holy One is understanding.
Proverbs 9:10
1.1 Historical Background of Insulin Resistance
The association between excessive concentrations of insulin and development of 
atherosclerosis first appeared in the mid 1960s and since then, numerous clinical and 
experimental data have accumulated, most of it supporting the link between insulin 
resistance and atherosclerosis. In the 1930's, Himsworth and Kerr introduced the first 
standard approach to measuring insulin sensitivity in vivo.1’2’3 Two oral glucose tolerance 
tests were performed in individual subjects, with and without a comcomitant intravenous 
insulin injection. Insulin sensitivity was expressed as the ratio of the areas under the 
respective glucose tolerance curves. Himsworth thus showed that young, thin, ketosis 
prone diabetics were more sensitive to exogenous insulin than older, nonketotic patients. 
He also reported relative insulin insensitivity to insulin for nondiabetic obese2 and elderly 
individuals4 and demonstrated that high carhohydrate, low fat diets increased insulin 
sensitivity.5*6 However, such measure of insulin sensitivity was viewed as inferential 
because of the absence of a sensitive specific measurement of plasma insulin and a 
variety of mechanisms could contribute to the differences observed. These include 
differential effects of insulin on gastrointestinal glucose absorption, differences in 
inhibition of endogenous insulin secretion during the test, and variability in clearance of 
exogenously administered insulin.
The development of the radioimunoassay (RIA) by Yalow and Berson7 satisfied the need 
for a sensitive specific measure of plasma insulin. This was soon followed by 
development of various methods for assessing in vivo effects of changes in plasma 
insulin, described in detail in subsequent sections.
1.11 Insulin Resistance in Diabetes Mellitus
For many years, diabetes was thought to be a disease of insulin deficiency and that those 
with diabetes had low circulating insulin levels. As our knowledge of diabetes advances, 
we know now that many non-insulin dependent diabetes mellitus (NIDDM) patients have 
insulin levels which are higher than nondiabetic subjects. The insulin response to an oral 
glucose tolerance test (OGTT) becomes elevated as glucose tolerance declines from 
normal.8’9 With severe glucose intolerance and fasting hyperglycaemia, insulin levels 
become normal or subnormal.8
In insulin-dependent diabetes mellitus (IDDM), there is a deficiency of insulin which may 
be absolute or relative. Unlike in NIDDM patients where there is resistance to insulin 
mediated glucose disposal, IDDM patients do not have much inherent insulin resistance. 
However, in the treatment of IDDM, insulin is delivered in non-physiological ways with 
respect to route and control of delivery. Insulin is secreted into the portal circulation, 
where 50% is cleared on first passage through the liver. Thus insulin concentrations in the 
portal vein are several times higher than the peripheral circulation.10 Subcutaneous insulin
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on the other hand, circulates in high concentration to achieve its desired effect on its main 
target organ i.e. the liver. With subcutaneous insulin injections, insulin levels remain high 
between meals and overnight,11*12 unlike in normal physiology where insulin secretion is 
finely regulated, with increase stimulated by meals and a rapid fall to basal levels after 
meals. The IDDM patients, like the NIDDM patients are thus exposed to higher levels of 
insulin as a consequence of therapy.
There is now a large body of evidence showing that the vast majority of patients with 
impaired glucose tolerance (IGT) or NIDDM are insulin resistant, compared with 
appropriately matched individuals with normal glucose tolerance.13 Different parameters 
of insulin resistance were used in various studies, but whether it be fasting insulin, 
insulin-glucose ratio, plasma C-peptide with or without glucagon stimulation, glucose and 
insulin response to OGTT, almost all reported studies have shown a relationship between 
such parameters and cardiovascular disease in both NIDDM and IDDM 
patients. 14»15»16*17*18*19 These studies show that insulin resistance in NIDDM predisposes to 
atherosclerosis and thereby to cardiovascular diseases. It is interesting to note that even 
IDDM patients demonstrate insulin resistance, possibly secondary to prolonged iatrogenic 
hyperinsulinemia during therapy and consequently IDDM patients also have increased 
risk of cardiovascular disease.
1.12 Insulin Resistance in Coronary Heart Disease
The knowledge that diabetes is associated with an increased frequency of cardiovascular 
disease prompted numerous studies looking at insulin resistance in patients with 
ischaemic heart disease. The findings of these studies are summarised in an excellent 
review by R W Stout,20 with the majority showing fasting hyperinsulinaemia or 
postglucose challenge hyperinsulinaemia. One of the largest study of insulin and 
cardiovascular disease was the Caerphilly, Wales, Heart Disease study, involving 2512 
men aged 45-59 years. This study showed an association between fasting plasma insulin 
levels and prevalent ischaemic heart disease independent of body mass index (BMI), age, 
systolic blood pressure, and triglyceride levels.21 It would appear that insulin resistant 
individuals may be able to limit the degree of deterioration in glucose tolerance by 
compensatory hyperinsulinaemia, although this is not without a price. Endogeneous 
hyperinsulinaemia has been shown to be a risk factor for coronary heart disease in 
prospective studies.22*23*24’25
1.13 Insulin Resistance in Essential Hypertension
Hypertension is an important risk factor for cardiovascular disease, particularly for stroke, 
myocardial infarction and peripheral vascular disease. One of the earliest study to suggest 
a relationship between insulin and hypertension found that hypertensive patients had 
higher insulin levels in the fasting state and after a 50g OGTT when compared with 
normotensive controls.26 Obesity and age are known to be confounding factors for 
hyperinsulinaemia in such hypertensive patients. However, we have found that even in 
the young (<35 years) and nonobese (BMI <26) hypertensive patients, 40% demonstrated 
insulin resistance after an intravenous glucose challenge (IVGTT).27 Insulin may be 
causally related to hypertension because of an effect of insulin on renal sodium
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reabsorption,28 enhanced sympathetic nervous system activity in hyperinsulinaemic 
states.29*30
1.14 Insulin Resistance in relatives of Diabetic patients
The high incidence of NIDDM among first degree relatives of type 2 diabetic patients and 
the high concordance in identical twins provide strong evidence that genetic factors 
underlie susceptibility to this disease.31 Normoglycaemic offspring of diabetic parents 
have defects in insulin sensitivity and glucose disposal, which are important predictors of 
their risk of NIDDM.32 This is further supported by other studies which showed that 
relatives of patients with NIDDM are also at risk of developing diabetes.33’34’35 Sarlund et 
al suggested that a family history of diabetes adds substantially to the risk of 
atherosclerosis, particularly in subjects with impaired glucose tolerance (IGT).36 Perhaps 
one of the reasons why relatives of NIDDM are more prone to develop diabetes and 
atherosclerosis is because they are insulin resistant, as studies have shown that first 
degree relatives of patients with NIDDM are more insulin resistant than subjects without 
a family history of diabetes37
1.15 Insulin Resistance in relatives of Hypertensive patients
Since hypertensive patients are known to be insulin resistant, and this is independent of 
obesity27’38 or treatment,39’40 and that hypertension is often clustered with coronary heart 
disease and diabetes mellitus, all of which have strong genetic elements, one would thus 
expect relatives of hypertensive patients to also show insulin resistance. The evidences to 
date are not as clear as those in relatives of NIDDM patients because of the confounding 
factors like obesity and age of the study population. In a study of 33 obese women41 who 
were neither diabetic or hypertensive, a significant positive correlation was seen between 
fasting serum insulin and diastolic blood pressure. Insulin levels were also slightly higher 
in those with a positive family history of hypertension. First degree relatives of patients 
with high blood pressure have been shown to be insulin resistant and hyperinsulinaemic 
when compared to a control group without a family history of hypertension.42
1.16 Genetic syndromes with extreme Insulin Resistance
The genes that determine an individual's susceptibility to NIDDM and insulin resistance 
have not been identified. Most of our understanding of insulin resistance stems from 
studies of patients with genetic syndromes associated with extreme insulin resistance and 
acanthosis nigricans. Hence this next section will highlight some of these genetic 
syndromes whilst the subsequent sections will elucidate some possible mechanisms for 
the insulin resistance.
Type A Insulin Resistance
This is characterised by the triad of insulin resistance(IR), acanthosis nigricans(AN) and 
hyperandrogenism(HA)43 in the absence of obesity or lipoatrophy and is sometimes also 
known as the HAIR-AN syndrome. The diagnosis of type A insulin resistance was 
originally reserved for females because of hyperandrogenism as one of the manifestations.
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However, it is now clear that males can also be affected by a similar syndrome.44 Most 
patients with type A insulin resistance are not overtly diabetic, although they are all 
hyperinsulinaemic and many have IGT.
Leprechaunism
This is a congenital syndrome associated with extreme insulin resistance and patients are 
glucose intolerant, often with peak insulin levels more than a 100-fold above the normal 
range. They have multiple abnormalities, including intrauterine growth retardation and 
fasting hypoglycaemia.45 Some cases of leprechaunism have been reported to live into 
childhood and adolescence with short stature but normal intellectual development.46
Rabson-Mendenhall syndrome
This syndrome is characterized by multiple features, including extreme insulin resistance, 
acanthosis nigricans, abnormalities of teeth and nails, and pineal hyperplasia.47 Clinically, 
it may be difficult to distinguish some patients with Rabson-Mendehall from patients 
with leprechaunism who have survived beyond the first year of life.
Other syndromes
Several other syndromes associated with insulin resistance have been described that 
appear to have a genetic aetiology but these need further research before such syndromes 
can be attributed to mutations in the insulin-receptor gene.
1.17 The Insulin Receptor
The insulin receptor has been identified as a membrane glycoprotein composed of two 
extracellular a-subunits and two transmembrane p-subunits (Fig 1). Kasuga, Karllson and 
Kahn demonstrated that the insulin receptor is an insulin activated enzyme, which 
undergoes autophosphorylation on tyrosine residues after insulin binding, which then 
becomes competent to phosphorylate cellular substrates on tyrosine residues.48*49 This 
suggested the likely existence of a kinase cascade, through which many or all of the 
effects of insulin might arise. It is also now known that the insulin receptor is the product 
of a very large gene on chromosome 19.5V
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Fig 1: The Insulin Receptor
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1.18 Mutations in the Insulin-Receptor Gene
Mutations of the Insulin-Receptor Gene can be classified into 5 categories summarised in 
Fig 2.52
Class 1: Mutations that impair receptor biosynthesis 
Class 2: Mutations that impair transport of receptors to cell surface 
Class 3: Mutations that decrease the affinity of insulin binding 
Class 4: Mutations that impair receptor Tyrosine kinase activity 
Class 5: Mutations that accelerate receptor degradation
Fig 2: Classifications of mutations in insulin-receptor gene
Lysosonri'
Endoplasmic
Reticulum
However, it would appear that the cellular defects of insulin resistance found in NIDDM 
and cardiovascular disease, cannot be explained by major impairments in the structure or
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function of the insulin-receptor gene. Although genetic factors are thought to play a 
significant role in insulin resistance and NIDDM, no deleterious mutations of candidates 
have yet been found to explain the disease.
1.19 Fasting insulin as a marker of insulin resistance
The fasting plasma insulin concentration is largely determined by the glucose 
concentration53 and the degree of basal hyperglycaemia is in turn determined by a 
combination of p-cell deficiency and insulin resistance. Fasting plasma insulin as a 
marker of insulin resistance is the simplest measure and large studies often employ this 
parameter because of ease of obtaining the sample. Hence it is important to consider 
whether fasting plasma insulin is a good measure of insulin resistance. Evidence suggest 
that in the absence of marked hyperglycaemia, fasting insulin correlated with other 
estimates of insulin resistance and the insulin concentration is a simple function of insulin 
resistance.54 Findings from published studies regarding fasting insulin as a risk factor for 
coronary heart disease have been inconsistent20 although two large prospective studies, 
the Helsinki Policeman Study22 and the Paris prospective study24 have shown a 
significant association between coronary heart disease and fasting insulin, with the later 
study showing fasting insulin to be the only independent risk factor for coronary heart 
disease in a multivariate analysis. It would appear that a single fasting insulin sample is 
unlikely to be a reliable guide to a subject's insulin resistance or p-cell function.
1.1.10 Oral Glucose Tolerance Test
Appropriately elevated plasma insulin, in the face of normal or supranormal plasma 
glucose pattern has been accepted as evidence for diminished overall tissue sensitivity to 
insulin.55’56*57 However, the heterogeneity of OGTT patterns amongst normal, glucose 
intolerant, and non-ketotic diabetic patients has been demonstrated.55
1.1.11 Intravenous Glucose Tolerance Test
The insulin response to intravenous glucose tolerance test (IVGTT) have been 
inconsistent although hyperinsulinaemia has been demonstrated in patients with coronary 
heart disease.28’58’59’60’61’62 The diverse response to IVGTT led investigators to suggest that 
a gastrointestinal stimulus mediated the exaggerated response to oral glucose.58’63
1.1.12 Insulin Suppression Test
The principle of the insulin suppression tests involves the pharmacologic inhibition of 
endogenous secretion of insulin during exogenous insulin and glucose infusion. Inhibition 
is accomplished with either epinephrine infusion and propranolol-induced P-adrenergic 
blockade (E/P)64 or with somatostatin (SRIF).65 In the E/P protocol, steady state glucose is 
achieved within 90 minutes of combined infusion of propranolol, epinephrine, glucose 
and insulin (propranolol and epinephrine being replaced by cyclic somatostatin in the 
SRIF protocol). Steady-state plasma glucose (SSPG) is defined as the average glucose 
during a steady-state observation period. SSPG is considered a measure of insulin 
resistance.64
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1.1.13 Glucose Clamp Studies
The principle of the glucose clamp employs the knowledge that blood glucose 
concentration is relatively constant in the postabsorptive state and thus the rate at which 
glucose is produced by the body (Ra) is equal to the rate of glucose utilisation (Ra). 
When insulin is administered exogenously, Ra normally increases, whilst Ra decreases, 
so that R a > Ra. The imbalance between glucose utilisation and endogenous production 
would normally result in a decline in plasma glucose which can be countered by a rate of 
exogenous glucose infusion calculated to equal the total of decreased glucose production 
production and increased glucose utilisation. The rate of glucose infusion needed to 
maintain basal glucose level is a measure of the net effect of the insulin infusion to alter 
the production and utilisation of glucose by the body. After an appropriate period, at 
which steady-state is presumed to be reached, the rate of glucose infusion is considered 
an indication of insulin action. In some instances, sequentially increasing rates of insulin 
infusion were used to establish a dose-response relationship between plasma insulin 
concentration and insulin action. Variations of the clamp protocol have been employed 
and glucose levels may be targeted at the fasting level,66 hypoglycaemic levels67 or in 
subjects with elevated fasting glucose, at hyperglycaemic levels68
1.1.14 Minimal Model Approach
Glucose achieves an elevated value after a glucose injection and thereafter begins to 
decline and the rate of decline is dependent on the abrupt insulin secretory response. 
Therefore the extent to which a given plasma insulin response accelerates the decline of 
glucose after injection is a measure of the insulin sensitivity. The minimal model is able 
to infer insulin sensitivity by the use of a computer model which simulates plasma 
glucose dynamics when plasma insulin dynamics are supplied. The dynamic insulin 
response to glucose injection is considered as the input whilst the observed plasma 
glucose pattern is the output. The computer model chosen is the simplest physiologically 
based representation which can account for the input-output relationship under various 
conditions.69 Although the measure of insulin sensitivity from the minimal model 
approach is not identical to that obtained from the glucose clamps, the good correlation 
between the two does suggest they measure closely related physiologic processes.
1.1.15 Homeostasis Model Assessment Method
This model is a computer-solved model of insulin: glucose interactions which had been 
used to plot an array of fasting plasma insulin and glucose concentration that would be 
expected for varying degrees of p-cell deficiency and insulin resistance. The p-cell 
function for any patient can be calculated from the formula: P-cell function (%)= 20 x 
insulin/(glucose - 3.5) and Insulin resistance = insulin/ (22.5 e _ln glucose) 54 The accuracy 
and precision of this model has been found to correlate well with independent measures 
of insulin resistance obtained by hyperglycaemic and euglycaemic clamps and 
intravenous glucose tolerance test. However, the model is limited by low precision and a 
single fasting sample taken in the outpatient clinic is unlikely to be a reliable guide to a
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subject's insulin resistance or (3-cell function. Rather, 3 separate samples over a 15 minute 
period at 5 minutes interval is advocated to improve precision.
1.1.16 The Insulin Resistance Syndrome
Reaven first proposed a widespread role of insulin resistance in human disease in the 
Banting Lecture in 1988. The introduction of the insulin resistance syndrome (IRS) or 
syndrome X as a plurimetabolic disorder related to increased coronary heart disease risk 
(CHD) associated with hypertriglyceridaemia, depressed high density lipoprotein (HDL) 
cholesterol, central obesity, hypertension, impaired glucose metabolism, has since been 
confirmed by other authors.70’71’72 It is now recognised that an insulin-resistant 
hyperinsulinaemic state is not associated with substantial changes in low density 
lipoprotein (LDL) cholesterol concentrations but rather with marked increases in LDL 
apolipoprotein (apo) B levels.73 Recently, insulin resistance has been shown to be 
associated with an increased proportion of small, dense, LDL particles.74’75 Both genetic 
and environmental factors play determinant roles in its development. Obesity has been 
associated with insulin resistance76 but the syndrome can also develop in nonobese 
individuals.13 Increasing age has also been shown to increase insulin resistance.77 Support 
for a genetic element in the development of insulin resistance can be seen from the 
Bogalusa Heart study involving 2856 children which showed positive relationships 
between insulin and other cardiovascular risk factors such as blood pressure, triglyceride 
and VLDL levels and an inverse relationship with HDL cholesterol, even at a young age.78
1.2 Lipids and Lipoproteins in Coronary Heart Disease
The Framingham Study is one of the most often quoted study on lipids, lipoproteins and 
risk of coronary heart disease. This study showed that amongst the identified host factors 
associated with increased susceptibility to coronary heart disease, blood lipids are among 
the strongest.79 The data suggested that in men, a moderately elevated cholesterol 
regardless of the metabolic aberrations responsible or how it is transported or partitioned 
among the lipoproteins, are associated with increased risk of coronary heart disease. The 
multiple risk factor intervention trial (MRFIT) then showed that the relationship between 
serum cholesterol and CHD is not one of threshold, with increased risk confined to the 
two highest quintiles, but rather a continuously graded relationship that powerfully affects 
risk for the great majority of middle-aged American men.80 Other studies have shown that 
LDL cholesterol is the main contributor to the relationship between cholesterol and CHD 
whilst HDL cholesterol levels are inversely related to CHD incidence.81*82 The 
association between plasma triglyceride and coronary heart disease have been consistently 
demonstrated83’84 but the interpretation of this relationship has been controversial. Recent 
re-evaluation has shown that the strength of the association between triglyceride and 
CHD has been significantly underestimated.85
1.21 Low Density Lipoprotein and atherogenesis
Lipoprotein phenotypes are now used extensively to diagnose and classify familial 
hyperlipidaemia. The mean level of LDL-cholesterol was found to be highest in survivors 
with familial hypercholesterolaemia, intermediate in those with familial combined
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hyperlipidaemia and lowest in those with familial hypertriglyceridaemia.86 Support for the 
atherogenic potential of LDL cholesterol is based on clinical observations in patients with 
familial hypercholesterolaemia. Such patients have a single, well-defined gene defect 
involving the LDL receptor, as shown by the work of Goldstein and Brown,87 and the 
premature atherosclerosis, is directly or indirectly, related to their elevated LDL levels, 
which in turn are due to the deficiency in LDL receptors. Fatty streaks are believed to be 
the first stage of the atherosclerotic process and consist predominantly of foam cells 
derived from circulating monocytes.88 Although LDL is the major atherogenic lipoprotein 
generating foam cell-rich lesions, incubations of monocytes/macrophages with LDL did 
not lead to foam cell formation.89 It is now recognised that LDL must undergo some form 
of modification in its structure and biological properties before it can be taken up by 
monocyte/macrophages at a rate sufficient to generate foam cells.90 A number of chemical 
modifications have been shown to have this effect89*91’92 but the biological evidences is 
strongest for oxidative modification.93*94*95*96 Oxidatively modified LDL is taken up by 
monocyte/macrophages three to ten times more rapidly than the native LDL and can 
therefore generate foam cells. The oxidatively modified LDL is chemotactic for 
circulating monocytes,97 inhibits the motility of tissue macrophages98 and is cytotoxic, and 
could contribute to atherogenesis by causing cell injury and cell death.99
1.22 HDL and reverse cholesterol transport
HDL is now considered a potentially modifiable risk factor and HDL has been shown to 
be inversely correlated with CHD risk. A higher HDL level confers a lower risk for CHD. 
Strong support for this is based on an aggregate analysis of the findings of several large 
studies i.e. The Framingham Study, The Lipid Research Clinics Coronary Primary 
Prevention Trial (LRC-CPPT), The Multiple Risk Factor Intervention Trial (MRFIT) and 
the Lipid Research Clinic Follow-up Study (LRCF).100 The inverse relation between level 
of HDL and risk for CHD was found to persist whether the population studied was male 
or female and whether the focus was on morbid or fatal coronary events. An increase in 
HDL of 1 mg/dL translates to a 2 to 3 % reduction in CHD risk. The level of HDL 
cholesterol is thought to reflect the efficiency of reverse cholesterol transport and hence 
the inverse relationship with CHD. Animal and human studies have shown that 
cholesterol is removed from atheromata when plasma LDL cholesterol levels are lowered 
and HDL levels are increased. It is likely that the regression mechanism involves 
cholesterol removal by HDL.101 In vivo studies of the turnover of HDL cholesterol 
showed that tissues exchange cholesterol primarily with HDL and not with VLDL or LDL 
and the HDL cholesterol in turn is rapidly exchanged with the liver cholesterol pool.102 
There is thus a net transfer of cholesterol from tissues to liver via HDL, of similar 
magnitude to the net transfer of HDL cholesteryl ester through LDL and VLDL to the 
liver. The nonesterified cholesterol diffuses from the tissue cell membrane to HDL 
through nonspecific lipid-lipid interactions. However, in adipocytes, macrophages, and 
fibroblasts, the mobilization of intracellular cholesterol pools and their translocation to 
the cell membrane are facilitated by the binding of specific HDL apolipoproteins (apo A-I 
and apo A-IV) to a particular recognition site on the cell surface.103,104 The nonesterified 
cholesterol is then taken up in the plasma by nascent HDL particles containing solely apo 
A-I, undergoing esterification by lecithin cholesterol acyltransferase (LCAT) within these 
particles.105 The cholesterol esters are then removed from HDL by the liver, where the
20
cholesterol is used for bile acid synthesis.101’106 These studies have shown that HDL 
cholesteryl ester can be removed and delivered to the liver by at least 4 mechanisms. A 
subpopulation of HDL requires apoE and is recognised by hepatic apo E receptors. HDL 
without apo E can be endocytosed by hepatocytes. Hepatic triglyceride lipase mediates 
uptake of cholesteryl esters into liver cells and finally cholesteryl ester transfer protein 
(CETP) catalyses the net transfer of HDL cholesteryl esters to VLDL, IDL and LDL. Thus 
HDL not only take up cholesterol from tissues, but also mediate cholesterol exchange into 
the apoB-containing lipoproteins, VLDL, IDL or LDL, from which cholesteryl esters can 
be removed when circulating VLDL, IDL and LDL particles are taken up by hepatic apo 
B and E receptors.
1.23 Role of Triglyceride in atherogenesis
The relationship between elevated plasma triglyceride and an increased risk of coronary 
heart disease has been consistently demonstrated by epidemiological studies.83’84’107 The 
interpretation of the relationship, however, has been controversial. A recent re-evaluation 
of the epidemiological data has suggested that the strength of the association has been 
significantly underestimated because of biological variation of this plasma lipid and 
shortcomings in the multivariant analytical appoach.85 It is postulated that increased 
levels of plasma triglyceride affect atherogenesis both directly and indirectly. Individuals 
with CHD fail to metabolise triglyceride-rich chylomicrons and VLDL efficiently, 108 
resulting in a prolonged residence time in the circulation and accumulation of cholesteryl 
esters in these lipoproteins resulting from loss of triglyceride into LDL and HDL via 
CETP and reciprocal transfer of cholesteryl ester. These cholesteryl ester enriched 
lipoproteins have increased likelihood of being ingested by macrophages109 at sites of 
lesion development. Recent work has also indicated that in the general population, LDL 
structure is strongly influenced by the level of plasma triglyceride. 110 Individuals with 
plasma triglyceride above approximately 1.1 mmol/L were more likely to express the 
'Pattern B' phenotype for LDL which is associated with a predominance of smaller 
particles and higher apo B concentrations. 'Pattern A' with a predominance of larger LDL 
particles are seen with triglyceride below 1.1 mmol/L. When hepatic triglyceride levels 
are high, large triglyceride-rich VLDL are produced which are delipidated to smaller 
VLDL and finally to slowly metabolised LDL. In the presence of a reduced hepatic 
triglyceride load, smaller VLDL are made which give rise to rapidly metabolised LDL.111 
Elevated levels of chylomicrons and large VLDL as mentioned previously, also enhances 
exchange of triglyceride into the core of circulating LDL112’113 and these are more suitable 
substrates for hepatic lipase which through lipolysis causes shrinkage of the particles. 114 
High plasma triglyceride is also thought to accelerate atherogenesis through its inverse 
relationship with HDL-cholesterol. In the presence of large triglyceride-rich VLDL 
particles, increased CETP mediated exchange will generate HDL that is triglyceride 
enriched and these are a more favourable substrate for HL. This enzyme acts to remove 
lipid from the core of HDL, reducing its size and results in the conversion of HDL2 to 
HDL3.115 HDL2 is thought to have a greater cardioprotective role compared to HDL3 116’117
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1.24 Very Low Density Lipoprotein subfractions
VLDL particles are known to consist of a core of triglycerides and cholesteryl esters 
surrounded by a monomolecular film of constant thickness composed of phospholipids 
and free cholesterol together with protein. 118 We now know that VLDL is not 
homogeneous, but rather consists of metabolically distinct groups. 119 The larger 
triglyceride particles (VLDLj) of Sf 60-400 are secreted from the liver and undergo rapid 
hydrolysis via lipoprotein lipase.120 The majority of these are converted to smaller 
remnant particles that are removed from the circulation by receptor-mediated 
mechanisms121 and hence make little contribution to the production of low density 
lipoprotein. The smaller, denser, less triglyceride-rich VLDL2 particles (Sf 20-60) are 
also secreted by the liver but the majority are rapidly metabolised by conversion through 
intermediate density lipoprotein (IDL) to LDL, and hepatic lipase is critical for this 
conversion122. It has also been demonstrated that there is preferential enrichment of the 
larger VLDL particles with cholesteryl esters, 123 the main source of cholesteryl esters 
being LDL. The VLDL particles enriched with cholesteryl ester are thought to be unable 
to complete the VLDL to LDL conversion process. 124 The smaller VLDL2 population is 
thought to have relatively more protein and phospholipid than the larger VLDLi 
population.125 The relationships between VLDL subfraction and LDL subfraction, and the 
role of VLDL subfraction in the atherogenic process are examined in this thesis.
1.25 Intermediate Density lipoprotein
Intermediate density lipoproteins are usually defined as lipoproteins of buoyant density of
1.006 to 1.019 g/ml.126 Human IDL was initially regarded as a single class of lipoproteins 
generated from VLDL by lipolysis. However, it has since been shown to consist of two 
subpopulations from gradient gel electrophoresis of ultracentrifugal fractions from normal 
subjects i.e. IDLj and IDL2 .127 Often no distinct transition was seen between the smaller 
VLDL and IDL^ The same study also demonstrated that IDL2 was cholesterol enriched 
and triglyceride depleted compared with IDLj. It has also been shown that small VLDL 
gives rise to particles of intermediate size which, in turn, form products with size and 
density characteristic of the LDL-II subclass.128
1.26 Low Density Lipoprotein Subfractions
Lindgren et al were the first to show that LDL (1.019- 1.063 g/ml) could be fractionated 
into at least 3 subgroups by preparative ultracentrifugation in a fixed angle rotor.129 
Subsequently, other investigators have demonstrated that LDL is a heterogeneous group 
of at least 3 to 7 subclasses. 130*131*132’133 With increasing density, mean particle diameters 
decreased progressively, while protein/phospholipid ratio increased. 132 The non­
denaturing, polyacrylamide, gradient gel electrophoresis describes a normal pattern 'A' 
characterised by a predominance of larger, less dense LDL and an abnormal pattern 'B' 
consisting mainly of small, dense LDL. 134 This method of LDL isolation provided a 
qualitative appraisal of LDL subspecies. 132 Isolation of LDL subfraction by density 
gradient ultracentrifugation separated LDL into 3 classes i.e. LDL-I, LDL-II and LDL-III 
with LDL-I being larger and buoyant LDL particles whilst LDL-III particles dense, less 
buoyant particles. This later method has the advantage of quantification of individual
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species. 133 A predominance of small, dense LDL in plasma has been associated with a 
three to seven fold increase in risk of coronary heart disease.135,136 It is postulated that at 
low triglyceride levels, LDL-I and LDL-II represent the major LDL species and these 
subfractions are cleared rapidly via receptor mediated mechanisms. 111 At higher 
triglyceride levels (>1.5 mmol/L), there is a decrease in LDL-II and a corresponding 
increase in small, dense LDL-III due to a combination of factors. There could be 
increased production of large, triglyceride-rich VLDLi giving rise to smaller and slowly 
metabolised LDL through delipidation and /or that the increased levels of triglyceride-rich 
VLDL in the circulation promote the exchange of cholesteryl esters in LDL for 
triglyceride, with the resultant action of hepatic lipase converting the larger LDL (LDL-II) 
into smaller LDL (LDL-III).136
1.27 High Density Lipoprotein subfraction
HDL, like the other lipoproteins are also known to be heterogeneous and can be classified 
into larger, less dense HDL2 (1.063 to 1.125 g/mL) or smaller, denser HDL3 (1.125 to
1.21 g/mL) . 137 The major proportion of HDL is normally present in HDL3 but individual 
variability in HDL levels in human populations usually reflects different amount of 
HDL2 .101 Women have also been found to have significantly higher HDL2 levels but 
similar HDL3 levels.138’139 The less dense HDL2 has a higher proportion of cholesterol, 
cholesteryl ester, and phospholipid content than the denser HDL3 ,140 which has a higher 
apolipoprotein content in proportion to total mass. 141 A third HDL subfraction, HDLj has 
been found within the lowest density range of HDL particles and has a higher cholesterol 
and cholesteryl ester content than HDL2 or HDL3 .142 Cholesteryl esters can be exchanged 
from HDL2 into VLDL or LDL by cholesteryl ester transfer protein (CETP). HDL 
particles have also been classified by apolipoprotein composition143 and Apolipoprotein 
A-I, the essential component of HDL particles is found in all HDL subfractions. 
Apolipoprotein A-II function is still undetermined, and is most abundant in HDL particles 
of intermediate density, but is also detected throughout the density range of HDL 
particles. Most LCAT and CETP activities are confined to Lp (A-I without A-II), 
suggesting that this apolipoprotein-defined subfraction is the key mediator of cholesterol 
transport. Unfortunately, this recent classification of HDL based on apolipoprotein 
content does not correspond to classification based on particle density or size; each 
classification overlaps with the other. 143 The action of lipoprotein lipase on triglyceride- 
rich particles eg. chylomicrons and VLDL, results in the formation of HDL2 from newly 
synthesized HDL precursors or from HDL3 .144 Removal of core cholesteryl ester from 
HDL2 by CETP results in the formation of a relatively triglyceride-rich particle that is 
further catabolized by hepatic lipase, 145 resulting in conversion of HDL2 to HDL3 .146 HDL 
subfraction metabolism is influenced by many factors. Increasing waist to hip ratio is 
associated with a lower HDL2 147 levels whilst intensive exercise, 148 oestrogen therapy149 
increases HDL2 levels. Abstinence from alcohol in moderate drinkers150 decreases HDL3 
levels but showed a disproportionate decline in HDL2 compared to HDL3 levels in 
alcoholic men. 151 However, the additional predictive value of subfraction levels, and the 
relative epidemiologic importance of HDL2 over HDL3 remains controversial.152
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1.2.8 The Atherogenic Lipoprotein Phenotype
The predominance of small dense LDL obtained by gradient gel electrophoresis has been 
described as phenotype B by Melissa Austin and is associated with high plasma 
triglyceride, apolipoprotein B, VLDL and IDL, and low HDL cholesterol. This clustering 
of risk factors has been described as the atherogenic lipoprotein phenotype(ALP) and 
appears to be inherited as a single gene trait with a dominant mode of inheritance. 
Phenotype B is often not expressed in young males and premenopausal women and hence 
hormonal factors have been suggested to affect the full penetrance of the phenotypic 
picture. Furthermore, environmental factors such as diet, exercise and the use of lipid 
altering medications may also affect the expression of the trait. 153 Interest in ALP is not 
simply because of clustering of coronary risk factors in families but there is evidence that 
predominance of small, dense LDL particles appears to be common in the general 
population, with a prevalence of at least 30%.154 The presence of small, dense LDL 
particles is associated with a 3 to 7 fold increased risk of myocardial infarction.135,136 Thus 
a combination of both genetic and environmental factors identifies the individuals 
susceptible to premature coronary artery disease.
1.3 Insulin Resistance and Lipid metabolism
What then is the link between insulin resistance and lipid metabolism? Available 
evidence suggest that both insulin resistance and ALP are associated with increased risk 
of coronary artery disease. Insulin resistance is associated with a number of metabolic 
disturbances and so is the ALP. Insulin resistant individuals have higher plasma 
triglyceride, lower HDL cholesterol and small, dense LDL particles,74 almost identical to 
the ALP. The only difference being the disturbance in glucose metabolism in insulin 
resistant individuals. One might ask whether they are just part of the same spectrum of 
metabolic abnormality or whether one is a subset of the other? Furthermore the 
prevalence of small, dense LDL estimated at approximately 30%154 in the general 
population is similar to the prevalence of 25% estimated for insulin resistance 
syndrome.13 Insulin suppresses the release of non-esterified fatty acids (NEFA) from 
adipose tissue and in insulin resistant states, the suppressive effects of insulin on fatty 
acid release from adipose tissue after a meal is impaired.155 Insulin resistance is also 
associated with a decreased responsiveness of lipoprotein lipase to the action of insulin.156 
This is particularly important for postprandial activation of LPL with resultant elevation 
of plasma TG. Prolonged residence of TG-rich particles in the circulation leads to 
increased exchange of their TG with cholesteryl ester in HDL through the action of CETP 
protein.157 The failure of suppression of NEFA during the postprandial period in insulin 
resistant individuals aggravates158 the increase in VLDL TG already present.159 The 
elevation in plasma TG concentrations reflects an increased number of the larger TG-rich 
VLDLi particles both in normals160 and in insulin resistant individuals. 161 The insulin 
resistant individuals with higher plasma TG levels would thus have a predominance of 
large TG-rich VLDLi particles and it is these particles that determines the rate of TG 
transfer into LDL and HDL since TG-rich VLDL has been shown to be the preferred 
substrate for CETP action. 160 The TG in such TG-enriched LDL particles may then be 
removed by HL, leading to small, dense LDL particles. 160 Thus we can see that the link 
between insulin resistance, hypertriglyceridaemia and decreased HDL cholesterol
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concentrations could be mediated through disruption of the normal multifactorial role of 
insulin in co-ordinating postprandial lipid metabolism.158 This thesis seeks to explore the 
link between insulin resistance and the atherogenic lipoprotein phenotype.
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Chapter 2 Materials and Methods
Happy is the man who finds wisdom, And the man who gains understanding.
Proverbs 3:13
2.1 Introduction
A great deal of research into the aetiology of coronary heart disease (CHD) has been done 
over the years and large studies have established the links between an elevated cholesterol 
level, and in particular LDL-cholesterol, and the development of CHD. Many patients 
with CHD have more than one risk factor and the aggregation of risk factors in patients 
have led investigators to explore the relationship between these risk factors. This led to 
the hypothesis that coronary risk factors may not occur in isolation and they may be 
linked aetiologically. CHD can no longer be considered as a vascular problem but that it 
represents an underlying metabolic disorder which culminates in the development of 
atherosclerosis.
There are also many publications recently on the insulin resistance syndrome (IRS) and 
the atherogenic lipoprotein phenotype (ALP) as metabolic disorders which accelerate the 
process of atherosclerosis. Such syndromes were thought to be inherited but subjected to 
modification by environmental factors. Personal interest in the IRS and current 
knowledge on the ALP and its relationship with atherosclerosis, had led to the subject for 
this particular thesis. The relationship between the IRS and the ALP were explored with 
data obtained from three studies, two of which were conducted in Scotland and the third 
was performed in Singapore.
Study, Aims and Objectives
The primary aim of the first study in Scotland was to determine the risk profile in family 
members of patients with coronary heart disease and the extent that these risk factors 
were influenced by lifestyle and socio-economic class. We were particularly interested in 
the lipid, lipoprotein and lipoprotein subfraction profile as well as glucose metabolism. 
These were correlated with markers of general obesity, central obesity as well as the post 
heparin lipase activity. Normals were recruited from various sources both within the 
hospital and also from newspaper advertisements and contacts of patients. This group of 
normals were to establish the reference ranges for lipid and lipoprotein parameters and for 
an exploration of the relationships between lipids, lipoprotein subfractions and 
anthropometry.
The second study was performed in Scotland and dealt primarily with the effects of 
alimentary lipaemia and its various ramifications in a group of middle aged men since 
many have argued that fasting lipids and lipoprotein profile do not represent the 
physiological state as most of us take several meals a day. The ability to handle fat meals 
is dependent on lipase activity, which in turn is modified by other factors amongst which 
is insulin and these issues are addressed.
The third study carried out in Singapore, involved a group of normal males from 
different ethnic groups with plasma cholesterol of less than 6.0 mmol/L. The primary aim
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was to determine the prevalence of the atherogenic lipoprotein phenotype in normal males 
aged 30 to 45 years and its relationship to the insulin resistance syndrome in a population 
with high prevalence of diabetes mellitus. What is unique to the Singapore society is that 
different races live under fairly similar social and economic conditions and a secondary 
aim of this third study was to look for ethnic differences with regards to the various lipid 
and lipoprotein risk markers.
2.2 Materials and Subjects
2.21 Materials
Names and addresses of suppliers of the reagents used in the studies are shown in 
Appendix 1 together with manufacturers and suppliers of hardware and software used for 
this work.
2.22 Coronary Heart Disease in Families Protocol (Scotland)
All subjects were required to come to the Glasgow Royal Infirmary for 2 visits and gave 
written informed consent for each visit (Appendix 3). During the first visit, 
anthropometric indices and blood pressures were recorded. Fasting blood samples were 
taken for a full lipid profile, serum urea/electrolytes, thyroid function tests, liver function 
tests, details of which are given in subsequent sections. In addition, total LDL and HDL 
fractions, VLDLi, VLDL2, IDL and LDL and LDL subfractions were isolated from fresh 
plasma. This was followed by the conduct of a standard glucose tolerance test (75g 
glucose) with blood samples for glucose and insulin.
The second visit took place at least 2 weeks after the initial visit. Subjects were assessed 
for suitability of heparin administration through a questionnaire (Appendix 4). For this 
visit, lOmL of blood was taken before and 12 minutes after heparin administration into 
lithium heparin tubes placed on ice. The aliquots were frozen immediately and stored at 
-70° C prior to analyses. During the second visit, all results of tests done during the first 
visit were given to the subjects and any abnormalities were explained in detail. 
Furthermore, all who took part were given general health education with regards to diet 
and exercises and those found to have specific abnormalities were given appropriate 
counsel for intervention. Some were found to have high levels of lipids, requiring dietary 
intervention. These subjects were invited back for further follow up and lipid analyses. In 
instances where the lipids did not show adequate fall after at least 6  months of good 
dietary changes, such individuals were then advised on drug therapy and their GPs 
informed accordingly.
2.23 Recruitment of Patients
The inclusion and exclusion criteria for probands in both patients and controls are listed 
in Appendix 2. Patient probands were recruited from the Department of Cardiothoracic 
surgery and Department of Cardiology, from patients who had proven coronary heart 
disease from coronary angiogram or had coronary bypass operations or angioplasty 
between 1991 and 1992. All who satisfied our inclusion and exclusion criteria were
27
invited to take part if they were agreeable. Control probands were recruited from age and 
sex matched friends of patient probands as well as from those who responded to 
advertisements put up in the local papers. A total of 13 extended families made up of 27 
nuclear families (total of 70 individuals) was finally recruited from patient probands. 
However, only 6  control families were recruited because of the stringent entry criteria. To 
make up for the lack of number in normal controls, independent individuals who satisfied 
the entry criteria were also recruited from staff at the Glasgow Royal Infirmary and 
friends of staff members. A total of 97 individuals were recruited as normals for the 
study. This number was added to the 6  control families already recruited. In addition, 
unrelated spouses of patient families were added into this pool of normal controls giving 
a total of 137 subjects. The number of normal subjects were increased with the addition 
of data from normal subjects recruited during previous studies done at the laboratory 
giving a total of 304 normal subjects.
2.24 Study Questionnaire
All subjects were asked to complete a lifestyle assessment questionnaire (see Appendix 5) 
during the first visit.
2.25 Blood pressure measurements
Blood pressure was taken by myself with an Accoson mercury sphygmomanometer 
during visit 1. All subjects were rested for at least 15 minutes after arrival and 5 minutes 
interval between blood pressure measurements. Korotkov phase V was taken as the 
diastolic blood pressure.
2.26 Anthropometric indices
Waist was recorded as the smallest circumference between the rib cage and iliac crest 
whilst the hip was recorded as the largest circumference between the waist and thigh, 
both being taken in the standing position.
2.27 Fasting blood samples
A total of 70 mL of blood was taken in the fasting state and put into five 10 mL EDTA 
tubes, one plain glass tube, one 4 mL EDTA tube and one 2.5 mL fluoride oxalate tube.
2.28 Oral Glucose Tolerance Test
75 gram of dextrose monohydrate diluted in 300 mL of water was prepared on the 
morning of the first visit. Subjects were fasted for at least 12 hours prior to the glucose 
tolerance test and encouraged to consume the glucose drink within a 5 to 10 minute 
period. Blood for glucose and insulin were sampled via a gauge 21 venflon into fluoride 
oxalate tubes and EDTA tubes respectively at half hourly interval. The venflon was 
flushed with 1 mL heparinised saline (10 units per mL) after each blood sampling to 
ensure patency. No food was allowed during the two hour period of the test but there was 
no restriction on clear fluids, coffee and tea taken without sugar or milk.
28
2.29 Post heparin Lipase sampling
Subjects were also instructed to fast for 12 hours prior to the second visit. Weight was 
retaken to ensure that heparin dose was according to present weight. A gauge 21 venflon 
was inserted into the cubital veins and 10 mL of blood was taken into a lithium heparin 
tube kept on ice. Heparin according to weight (70 u/kg body weight) was given through 
the venflon and a second 10 mL blood into lithium heparin tube kept on ice was taken 
after 12  minutes.
2.2.10 Data Analysis
All data analysis was done on the PC version of Minitab Release 10 for windows 
(Minitab Inc., PA). All variables were assessed for normality by drawing normality plots 
and in instances where they were not normally distributed, appropriate transformation 
were performed to obtain one. Models to explain the variability in cholesterol, 
triglyceride, LDL-cholesterol, HDL-cholesterol, VLDLi, VLDL2, IDL, LDL and LDL 
subtractions were developed with data from normal controls using an analysis of variance 
General Linear Model. Differences in mean values between groups were compared by 
Student unpaired t-test, using transformed normalised data where appropriate. A 
Bonferroni correction was employed to allow for multiple comparisons. Insulin resistance 
was calculated from fasting plasma glucose and insulin concentration (IR=fasting 
insulin/2 2 .5  e_ln fasting glucose using the computer solved homeostasis model assessment 
(HOMA) method as this method had been shown to correlate with values obtained by the 
use of euglycaemic and hyperglycaemic clamps.
2.2.11 Alimentary Lipaemia Protocol (Scotland)
Subjects were required to come to the Glasgow Royal Infirmary for 3 visits. During the 
first visit, subjects were asked to complete a questionnaire and anthropometric indices, 
blood pressure readings were recorded. This was followed by blood sampling after 
heparin administration according to methodology described in a preceding section. An 
oral fat tolerance test was done during the second visit and a modified glucose loading 
test was conducted during the 3rd visit.
2.2.12 Patient Recruitment
Male patients under the age of 55 with documented coronary heart disease on coronary 
angiograms were eligible for the study. They must not be previously treated for any form 
of dyslipidaemia, diabetes mellitus or hypertension. The first 10 patients who were 
eligible and agreeable to take part in the study were finally recruited. 7 male controls 
matched for age were also recruited from friends of patients and staff.
2.2.13 Study Questionnaire
Subjects were asked to complete a simple questionnaire on the first visit (Appendix 7).
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2.2.14 Anthropometric Indices and Blood pressure
Height, weight, waist and hip circumference were recorded during the first visit. 
Definitions for waist and hip was as in the previous study. Blood pressure was also 
recorded during the first visit after a 15 minutes rest and 2 readings were taken.
2.2.15 Visit 2: Fat meal
Subjects were given a standard fat meal after an overnight fast of 12 hours. The meal
consisted of 280 ml fresh double cream, 2 0 g sucrose, 2 0 g dried skimmed milk powder
and 20 ml of flavoured syrup. They were also instructed to refrain from smoking during 
the fast and from alcohol intake during the 3 preceding days. Blood was sampled into a 
10 mL lithium heparin tube kept on ice, 10 mL EDTA tube and 2.5 mL fluoride oxalate 
tube at 0, 1, 2, 4 and 6  hours after the fat meal. The bloods were later measured for 
hepatic lipase, lipoprotein lipase, plasma cholesterol and triglyceride, free fatty acids and 
insulin at each time point. At the end of the 6 th hour, intravenous heparin at 70u/kg were 
administered and the last sampling done 12  minutes later.
2.2.16 Visit 3: Glucose meal
After an overnight fast of 12 hours, subjects were given a 22 g glucose load carried in a 
virtually fat free yoghurt (0.1 g fat per 125 g tub). Blood sampling and intervals between 
sampling was done as in the fat meal.
2.2.17 Data Analysis
All data was subjected to test of normality as in the previous study and in instances where 
they were not normal, appropriate transformation was done. For the second and third 
visit, the lipase response, plasma cholesterol and triglyceride response, plasma glucose 
and insulin response were assessed by the area under the respective response curve. This 
was computed by using the trapezoid rule.
2.2.18 Coronary risk factors in Normal males in Singapore
The aims of this study are 1.) To establish normality ranges for lipids, Lp(a) and markers 
of insulin resistance in a group of Singaporean males. 2.) To look at the contribution of 
elevated triglyceride levels towards excess cardiovascular morbidity and mortality in the 
same group of normals. 3.) To explore the relationship between elevated plasma 
triglyceride and the presence of small, dense low density lipoproteins (LDL) subfraction, 
since the presence of small dense LDL is known to increase CAD risks by 3 to 7 fold. 4) 
To examine the metabolic links between the atherogenic lipoprotein phenotype and 
insulin resistance, which had been suggested in some recent research, but especially 
important in Singapore with a prevalence of diabetes mellitus at 8 .6 %.
2.2.19 Patient Recruitment
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A total of 150 males aged between 30 to 45 years of age were recruited from hospital 
staff, friends and relatives of hospital staff, as well as advertisements placed in various 
public places. All subjects must not have had any history of diabetes mellitus, 
hypertension, coronary heart disease or chest pains, or any other major illnesses. They 
must also not be on any long term medication which may affect the lipid profile.
2.2.20 Conduct of each phase of the study
All patients were required to fast for at least 10 hours on the night preceding the tests. On 
the morning of the tests, the following were done.
1. Blood pressure taken after a 5 minutes rest, from the right arm and Korotkoff V taken 
as the diastolic pressure. The average of two readings was taken as the blood pressure.
2. Waist and hip measurements
3. Height and weight
4. A gauge 21 venula was inserted into the cubital veins, whereby fasting bloods for 
total cholesterol, HDL, TG, LDL, insulin, glucose, Lp (a) and LDL subfractions was 
taken.
5. Two further samples at 5 minutes interval were taken for glucose and insulin.
6 . LDL subfractions was isolated from fresh plasma by non-equilibrium density gradient 
ultracentrifugation using a six-step, curvilinear salt gradient. Following centrifugation 
for 24 hours at 40,000 rpm, at 23°C in a swinging bucket rotor (SW40; Beckman 
Industries Inc.), the tube contents were eluted by upward displacement and the 
presence of LDL fractions detected by continuous monitoring at 280 nm. The 
subfraction areas under the concentration curve can be quantified (Data graphics, 
Beckman Industries Inc.) corrected for differences in extinction coefficient and 
expressed as percentage of total LDL.
7. Insulin resistance will be derived from mathematical modelling (Homeostasis model 
assessment; HOMA) using the 3 fasting samples of glucose and insulin, derived by D 
R Matthews et al, and this model had been validated against the glucose clamp 
technique, which is regarded as the gold standard for measurement of insulin 
resistance.
2.2.21 Data Analysis
Data were analysed using PC version of Minitab for windows version 10. As in the 
previous studies, all data will be assessed for normality and transformed appropriately if 
they were not normal.
2.2.22 Ethical Approval and funding
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The studies conducted at the Glasgow Royal Infirmary were approved by the ethical 
Committee of the Hospital and funded in part by a grant from the British Heart 
Foundation. The study conducted in Singapore was approved by the ethical committees of 
the Singapore General Hospital and the National Medical Research Council. The funding 
for the Singapore study was through a grant from the National Medical Research Council 
of Singapore.
2.3 Methods
The assays and measurements of lipids, lipoproteins, proteins, insulin and other 
laboratory techniques are described in detail in the subsequent sections.
2.31 p Quantification
Plasma total cholesterol, triglyceride, HDL cholesterol, VLDL cholesterol and LDL 
cholesterol measurements were performed by a modification of the standard Lipid 
Research Clinics Protocol. Five mL of plasma was placed in a Beckman Ultra-clear tube 
(13 x 64 mm) and overlayered with 2mL of d 1.006 g/mL solution. Tubes were capped 
and centrifuged overnight at 35, 000 rpm (4°C) in a Beckman 50.4 rotor. The supernatant 
was collected from the top 25 mm into a 3 mL flask, this being the VLDL. The contents 
of the bottom fraction were transferred to a 5.0 mL volumetric flask. The tube was 
washed with saline and the wash added to the flask and the final volume adjusted to 5.0 
mL with 0.15M NaCl. A 1.0 mL aliquot of this bottom fraction was then placed in a 
Beckman centrifuge tube and 50 pL of precipitating agent {9.56 g Mn CL2.4H20 + 1.05 g 
(approximately 5x 105 units) heparin sodium salt in 25 mL 0.15M NaCL} were added 
and mixed. This mixture was kept at 4°C for 15 minutes and then centrifuged at 10,000 
rpm for 30 minutes. This would precipitate the LDL fraction leaving the supernatant as 
the HDL fractions. The cholesterol content of whole plasma, top fraction (VLDL), bottom 
fractions(LDL + HDL) and heparin/Mn2+ precipitated supernatant (HDL) were then 
determined by enzymatic colorimetric assays as described in the next section. The total 
plasma cholesterol, triglyceride, LDL cholesterol and HDL cholesterol were measured by 
kind courtesy of the routine staff of the Lipid section of the Department of Pathological 
Biochemistry, at the Glasgow Royal Infirmary.
Calculations
Bottom fraction cholesterol - HDL cholesterol = calculated LDL 
Total cholesterol - Bottom fraction cholesterol = calculated VLDL 
Measured VLDL should agree with calculated VLDL by± 0.35 mmol/L
Lipid analysis done in Singapore
The plasma cholesterol, triglyceride and HDL cholesterol were done by dry chemistry 
methods using the Kodak Ektachem Clinical Chemistry Slide for cholesterol, triglyceride 
and HDL cholesterol read on the Kodak Ektachem 700 Analyzer. Lipid analysis was 
done by courtesy , of the routine staff at the Pathology department of the Singapore 
General Hospital.
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2.32 Compositional Analyses
Total cholesterol and triglyceride were determined in whole plasma and in the lipoprotein 
fractions by enzymatic colorimetric assays on a Hitachi 717 autoanalyser.
The principal of the cholesterol assay is shown diagramatically below:
P j i n l A C t A f A l  P C t A f Q C A
Cholesterol esters + H20 ------------------------------------ ^Cholesterol + RCOOH
Cholesterol oxidase
Cholesterol + 0 2 ------------------------------------ »A4-cholestenone + H20 2
POD
2H20 2 + 4-aminophenazone + phenol ---------------->4-(p-benzoquinone-mono-imino)-
phenazone + 4 H20 .
The principal of the triglyceride assay is as follows.
Lipase
Triglyceride + 3 H 2 0 ----------------> glycerol + 3 RCOOH
GK
Glycerol + ATP > glycerol-3-phosphate + ADP
GPO
Glycerol-3-phosphate + 0 2--------------- > dihydroxyacetone phosphate + H20 2
Peroxidase
H20 2 + 4-aminophenazone + 4-chlorophenol -------------- >4-(p-benzoquinone-mono-
imino)-phenazone + 2H20  + 
HCL.
The assay kits used for the cholesterol and triglyceride were Boehringer Kit No.704121 
and 704113 respectively and resultant colour changes were measured at 505 nm.
Free cholesterol and Phospholipid were estimated with Boehringer Kit No. 310328 and 
691844 respectively using enzymatic colorimetric assays on a Centrifichem Encore 
centrifugal analyser (Baker instruments).
2.33 Modified Lowry Protein Assay
Protein measurements were performed according to a modified Lowry Protein Assay. 
Reagents
1. Stock Reagents
Solution A- 2%  Na2C 0 3 in 0.1 M NaOH (w/v)
Solution B- 2% NaK Tartrate (w/v)
Solution C - 1% CuS04 (w/v)
Folin Ciocalteu Reagent- BDH
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2. Working Reagents
Biuret Reagent: 100 mL Solution A, 1 mL Solution B, 1 mL solution C 
If sample to be analysed is turbid, add 1 mg/mL sodium dodecyl (Lauryl) sulphate 
Dilute stock Folin Ciocalteu 1:1 with deionised water.
Standards
A stock solution of human albumin (Fraction V) sigma A-8763, Lot 127F-9037 1 mg/mL 
is stored at 20°C.
Working standards in the range 0-50 pg (0, 15, 25, 50 pg) were prepared by taking 
appropriate volumes of stock standard (0-50 pi) and adjusting the final volume to 400 pi 
with deionised water.
Quality Control
Bovine serum albumin (Fraction V) Sigma A4503, Lot 17F-0150.
Two stock solutions of bovine serum albumin at 0.15 mg/mL and 0.30 mg/mL were 
stored at 20°C. 100 pi will be equivalent to 15 pg and 30 pg respectively. The final 
volume in the assay was adjusted to 400 pi with deionised water.
Sample preparation
Sample requiring dilution were adjusted to a final volume of 400 pi with deionised water. 
For VLDLi and VLDL2 fractions, 100 pi sample was used whilst 50 pi sample was used 
for IDL fractions. In LDL fractions, 50 pi sample was diluted to 500pl with distilled 
water and 1 0 0  pi of this diluted sample was used for the assay.
Method
1. 2 mL of Biuret reagent were added to 400 pi standard, control and samples.
2. These were vortexed and then allowed to stand for 10 minutes.
3. 200 pi working Folin Ciocalteu reagent was added with immediate mixing.
4. Allowed to stand for 30 minutes.
5. Read optical density at 750 nm within 2 hours
Sigma Lowry Protein Assay done in Singapore
For the Lowry proteins done in Singapore, the Sigma Diagnostic Protein Assay kit were 
used but modified for our purposes.
Reagents
Modified Lowry reagent
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DOC solution. An aqueous solution of sodium deoxycholate, 1.5 mg/ ml 
TCA: Trichloroacetic Acid solution, 72% w/v 
Folin & Ciocalteu’s Phenol Reagent
Protein Standard, prepared from bovine serum albumin fraction V 
Working Folins
18 ml was transferred to a dark bottle and washed with 1 0  ml water, add 80 ml, stored at 
room temperature.
Lowry Reagent
40 ml water was added to Lowry reagent and mixed slowly to avoid foaming, then stored 
at room temperature.
Protein standard
Add volume of water and swill gently, stored at 4° C 
Assay standard curve
pg pi standard pi water
0 0 1 0 0 0
10 25 975
2 0 50 950
30 75 925
40 1 0 0 900
50 125 875
? 1 0 0 900
Procedure
1 Add sample or standard as above
2 Add volume of water
3 Add 1 ml Lowry reagent
4 Mix
5 Stand at room temperature for 20 minutes
6  With immediate mixing, add 500 pi Folins
7 Read OD at 750 nm (500-800) at 30 minutes
Standard curve should be straight line in this range
2.34 Analytical ultracentrifugation of HDL
Plasma concentrations of HDL2 and HDL3 were estimated by analytical 
ultracentrifugation in a Beckman Model L8-70 ultracentrifuge equipped with an
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ultraviolet scanning attachment, (Beckman Instruments) using an AnF rotor with double 
sector centrepiece. The HDL subfraction masses were estimated by kind courtesy of Mrs 
Elizabeth Murray (Institute of Biochemistry, Glasgow Royal Infirmary).
2.35 Sequential preparation of IDL, LDL and HDL
Density Solutions
Solution Density =1.006 g/mL
11.4 g NaCl + 0.1 g EDTA Naj + 500 mL H20  + 1 mL NNaOH
Dissolve solids and make up to 1 litre and add 3 mL additional H20 . Final NaCl 
concentration= 0.195 M
Solution Density = 1.182 g/mL
24.98 g NaBr +100 mL d=l/006 g/mL solution. Final NaBr concentration =2.44M 
Solution Density = 1.478 g/mL
78.32 g NaBr +100 mL d=1.006 g/mL solution. NaBr concentration = 7.65 M
Solution Density =1.019 g/mL
8 mL 1.182 + 100 mL saline
Solution Density = 1.063 g/mL
Add d =1.006 g/mL to d =1.182 g/mL at 2:1 ratio
Solution Density =1.21 g/mL
Add d = 1.063 g/mL to d =1.478 g/mL at 2:1 ratio.
All densities are checked with a digital densitometer DMA 35 
IDL 1.019 g/mL
To 4 mL plasma, add 0.32 mL d = 1.182 g/mL solution. This was mixed and overlayered 
with 1.68 mL d = 1.019 solution to give a total volume of 6  mL. Centrifuged in L7-55 
ultracentrifuge at 39,000 rpm at 4°C for 24 hours or at 15° for 16 hours. The top 2 mL is 
then removed.
LDL 1.063 g/mL
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To the remaining 4 mL, 1.47 mL of d =1.182 was added, mixed and transferred to new 
tubes. This was overlaid with 0.53 mL d =1.063 to give a final volume of 6  mL. 
Centrifuged in L7-55 ultracentrifuge as above. The top 2 mL is again removed.
HDL 1.21 g/mL
To the remaining 4 mL, add 2 mL d = 1.478 solution, mixed and transferred to new tubes. 
The final volume should again be 6  mL. Centrifuged as above and the top 1.2 mL is 
removed.
2.36 Method for LDL Subfraction Analysis
Density Solutions
Density solutions d =1.006 g/mL and d =1.182 g/mL were prepared as described in the 
preceding section. The respective density solutions were then prepared as follows.
Solutions Volume d = 1.006 g/mL Volume d = 1.182
1.019 100 mL + 8.5 mL
1.024 100 mL + 13.6 mL
1.034 100 mL + 18.6 mL
1.045 100 mL + 27.8 mL
1.056 100 mL + 42.9 mL
1.060 100 mL + 49.3 mL
All densities were checked with a digital densitometer. 
Methods
3 mL of fresh plasma was adjusted to a density of 1.09 g/mL by adding 0.25 g KBr and
0.3 mL of d =1.182 g/mL solution. The sample and 6 -step salt gradient were introduced 
sequentially into polyvinyl alcohol coated polyallomer SW-40 tubes by peristaltic pump. 
The gradient was prepared and centrifugation carried out at 23°C in a Beckman L8-60. 
The rotor was accelerated to 170 rpm and then centrifuged at 40, 000 rpm for 24 hours. 
On completion of the run the rotor was stopped with the brake off. After centrifugation, 
the LDL subfractions were eluted by upward displacement using dense hydrophobic 
material (Maxidens, 1.9 g/mL, Nyegaard Ltd) by a constant infusion pump (Sage 
instruments, Orion Research Incorp., USA) at a flow rate of 0.69 mL/min. The eluate was 
passed through a UV detector (MSE/Fisons, UK) and detected by continuous monitoring 
of absorbance at 280 nm. In most instances, it was possible to resolve three distinct 
subfractions i.e. LDL-I, LDL-II and LDL-III. The individual subfraction areas beneath the 
LDL profile were quantified using Beckman 'Data Graphics' software (Beckman, UK). 
The detection system measured LDL concentration as absorbance at 280 nm and this was 
corrected to lipoprotein mass equivalence by applying previously calculated extinction 
coefficient. LDL-I 1 optical density unit (OD) = 2.63 mg lipoprotein/ml, LDL-II 10D = 
2.94 mg lipoprotein/ml and LDL-III 1 OD =1.92 mg lipoprotein/ml. For the LDL
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subfractions done in Singapore, the DU650 spectrophotometer was used to resolve the 
subfractions. However, the data captured on the DU650 (as duf.files) were not compatible 
with the Beckman ‘Data Graphics’ software (bsf.files). Hence Beckman USA had to write 
a conversion program in order to facilitate the conversion of data captured on the DU650 
into a format (BSF) which can be read by the existing ‘Data Graphics’ software. Mrs 
Muriel Caslake from the Department of Pathological Biochemistry (Glasgow) was also 
flown in during the setting up of the LDL subfraction system to ensure consistency and 
compatibility between the LDL subfractions obtained in Glasgow and in Singapore. The 
integrated areas were corrected for differences in extinction coefficient and expressed as 
percentage of total LDL concentrations in mg of lipoprotein/dL plasma. The total value 
for total LDL (d 1.019-1.063) lipoprotein mass (free cholesterol + cholesteryl ester + 
triglyceride + phospholipid + protein) was then used to generate individual subfraction 
concentration. Cholesteryl ester was calculated from (total cholesterol minus free 
cholesterol) times 1 .6 8 .
2.37 Very Low Density Lipoprotein Subfraction isolation
VLDLi and VLDL2 were prepared from plasma by a modification of the cumulative 
gradient centrifugation technique described by Lindgren et al.
Density solutions
The density solutions for the gradient was prepared from d =1.006 g/mL and d = 1.182 
g/mL solutions.
Density (g/mL) Volume d = 1.006 g/mL Volume d =
1.0988 25 mL + 27.89 mL
1.0860 25 mL + 20.83 mL
1.0790 25 mL + 17.72 mL
1.0722 25 mL + 50.05 mL
1.0641 25 mL + 12.31 mL
1.0588 25 mL + 10.73 mL
Methods
2 mL of plasma was adjusted to a density of 1.118 g/mL with 0.341 g NaCl. This was 
mixed well and allowed to stand for a short time before sampling. 0.5 mL of d = 1.182 
g/mL solution was pipetted into the bottom of the tube and then plasma and density 
solutions overlayered in the order and volumes shown below using an AAII pump.
Density in g/mL Volumes in mL
1.182 0.5
Plasma 2
1.0988 1
1.0860 1
1.0970 2
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1.0722
1.0641
1.0588
2
2
2
When the gradient was prepared, centrifugation was carried out in a Beckman SW 40 
rotor at 39,000 rpm at 23°C for 1 hour and 38 minutes. The top 1 mL was carefully 
removed using a long-form glass pipette at the end of the run. This was then replaced 
with 1 mL d =1.0588 solution and centrifuged at 18,500 rpm for 15 hours and 41 minutes. 
At the end of this second run, the top 0.5 mL is removed with the long-form glass pipette.
2.38 Insulin assay
The insulin assay used in Scotland was an in-house immunoradiometric assay employing 
2  antibody reagents, one of which was labelled and the other coupled to a solid phase 
matrix. The antibodies are directed at different sites on the protein to be measured and 
only when both are attached to the protein molecule is a signal generated. The antibodies 
used are 125I-monoclonal anti-insulin antibody prepared from mouse hybridoma 
monoclonal and solid phase guinea-pig anti-insulin coupled to sepharose gel. The insulin 
assays were done by myself with the assistance of a summer student, Ms Balsam 
Alabassi.
Reagents
1. Stock Buffer
Dissolve 50.5 g of EPPS and 2.0 g sodium azide in approximately 1400 ml of distilled 
water. The pH was adjusted to 8.0 by adding sodium hydroxide pellets (approximately 5 
g) and made up to 21 with distilled water. 4 mL of Tween-20 is added and stored at room 
temperature (2  weeks).
2. Assay Diluent
The assay diluent was prepared fresh for each assay by adding 500 pi of normal sheep 
serum per 100 mL of stock buffer. Approximately 100 mL was required for each assay.
3. 125I-Monoclonal Anti-insulin
The antibody (ID 1 /CIO) is a mouse hybridoma monoclonal prepared by Scottish 
Antibody Production Unit and diluted 1:100 in assay diluent for routine use.
4. Solid-Phase Guinea-Pig Anti-insulin
This antibody was also supplied by Scottish Antibody Production Unit and was coupled 
to sepharose gel. The preparation was diluted 1:2 in 0.9% NaCl for use. Saline was added 
to the stock and well mixed and centrifuged for 15 minutes. The supernatant was 
aspirated and made up to twice the original stock volume with assay diluent e.g. 6  mL 
stock was made up to final volume of 12 mL.
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5. Wash solution
The assay was washed four times with 0.9% saline/0.2% Tween i.e. 9 g NaCl per litre of 
distilled water with 2 mL of Tween.
Standards
1. Stock standard: MRC Standard 66/304 and one ampoule contains 3IU.
2. Working Stock A:
3. Working Stock B:
4. Working Standard:
(2U/mL). Dissolve the contents of stock standard ampoule 
in 1.5 mL 0.01N HC1 (0.25% BSA) and stored at -70°C in 
1 0 0  pi aliquots.
(2mU/mL). Dilute 100 pi of A to 100 mL with assay 
diluent and store at -70°C in 5 mL aliquots.
(100 mU/L). Dilute Stock standard B 1:20 with assay 
diluent and store in 1 mL aliquots at -70°C. For use in the 
assay, this standard is diluted serially with assay diluent to 
give 8 standards: 50, 25, 12.5, 6.25, 3.12, 1.6, 0.8, 0 mU/L.
Quality Controls 
Internal
Human serum screened for HIV and Hepatitis viruses was spiked with insulin standards 
as shown below:
Basal, +10, +20, +40 mU/L
These QCs were stored at -70°C in 600 pi aliquots. QC's were run at the beginning and 
end of the assay.
External
The UK NEQAS has a scheme for insulin which the laboratory participates in and was 
run from Guildford, Surrey. Results were routed through the QA officer.
Method
1. Dispense 100 pi of standards, QC, samples in duplicate into plastic tubes
2. Add 100 pi of labelled antibody.
3. Mix and incubate overnight at room temperature.
4. Add 100 pi of solid-phase antibody and shake on a Denley shaker for 1 hour at 
room temperature.
4. Wash tubes four times with 0.9% saline/Tween using in-house system.
5. Count tubes using Pharmacia gamma counter.
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Calculation
Calculation of results was done using the software package RiaCalc and the INS RIA 
protocol, whilst counting was taking place.
1. Standard curve was presented on screen for approval, editing or rejection.
2. When standard curve was accepted, QC and unknown results were printed.
3. Precision profile and trend analyses were presented.
Insulin assays done in Singapore
This was done by the Abbot Imx® Insulin assay, which is a microparticle enzyme 
immunoassay (MEIA).
Biological Principles of the procedure
The Imx insulin reagents were added to the reaction cell in the following sequence:
The probe/electrode assembly delivered the sample, anti-insulin (mouse, monoclonal) 
coated microparticles and the assay buffer to the incubation well of the reaction cell 
forming an antibody-insulin complex.
An aliquot of the reaction mixture containing insulin bound to the anti-insulin coated 
microparticles was transferred to the glass fibre matrix.
The matrix was washed to remove unbound materials.
The Anti-insulin: alkaline Phosphatase conjugate was dispensed onto the matrix and 
binds to the antibody-antigen complex.
The matrix was washed to remove unbound materials.
The substrate, 4-methylumbelliferyl Phosphate, was added to the matrix and the 
fluorescent product was measured by the MEIA optical assembly.
Reagents
1 1 bottle (7ml) anti-insulin (mouse, monoclonal) coated microparticles in buffer
with protein stabilisers. Preservative: 0.1% sodium Azide and antimicrobial 
agents.
2 1 bottle (9ml) anti-insulin (mouse, monoclonal) : alkaline phosphatase conjugate
in buffer with protein stabilisers. Minimum concentration: 3 pg/ml. Preservatives: 
0 .1% sodium azide and antimicrobial agents.
3 1 bottle (10ml) 4 Methylumbelliferyl phosphate, 1.2mM, in buffer. Preservative:
0 .1% sodium azide.
4 1 bottle (14ml) assay buffer in calf serum. Preservative: 0.1% sodium azide and
antimicrobial agents.
Imx Insulin MODE 1 Calibrator
1 bottle (4ml) MODE 1 calibrator (D). Concentration: 30 pU/mL insulin (human) in 
buffer. Preservative: 0.1% sodium azide and antimicrobial agents.
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Calibrators
IMx insulin calibrators
The 6  bottles (4 ml each) of IMx Insulin calibrators are referenced against WHO insulin 
IRP at 92.5%  of the WHO concentration. The IMx Insulin calibrators contain insulin 
(human) prepared in buffer at the following concentrations:
Bottle Insulin concentration (pU/mL)
A 0
B 3
C 10
D 30
E 100
F 300
2.39 Lipase assay
Post heparin plasma was incubated with a 14C-labelled triglyceride/gum arabic emulsion; 
free fatty acids released by lipase activity were captured by albumin and extracted into a 
solvent. The ratio of radioactivity in the extracted fraction to the total present in blank 
incubations provided the basis of calculating the activity of the enzyme source. Selective 
measurement of Lipoprotein Lipase (LPL) is facilitated by preincubation of post heparin 
plasma with sodium dodecyl sulphate (SDS) to inactivate hepatic triglyceride lipase (HL) 
and the inclusion of serum as a source of LPL activator (apo C-II). HL activity is 
measured in 1.0 M sodium chloride to ensure inactivation of LPL. The lipase assays were 
done by Mr Michael McConnell at the Institute of Biochemistry, Glasgow Royal 
Infirmary.
Reagents
Glycerol Tri (1-14C) oleate in toluene, 250 pCi (Amersham CFA 258)
Triolene (Sigma T-7140)
Gum Arabic (Sigma G-9752)
Bovine Serum Albumin Fraction V (Sigma A-4503)
Trizma Base (Sigma T-3253)
Sodium Dodecyl Sulphate (BDH 44244)
Potassium sulfate (Sigma P-4020)
Thrombin (Sigma T-4265)
Preparation of stock reagents
Cold Triolein (20 mg/mL in toulene).- Dissolve 0.5 g triolein in 25 mL toluene. 
Radioactive Triolein
To 50 pCi (0.5 mL) glycerol tri (1-14C) oleate add 24.5 mL toluene.
Divide into 7 x 3.5 mL aliquots in round bottom glass flasks.
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To each aliquot, add 3.5 mL cold triolein.
Dry under nitrogen.
Wash each flask three times with 3 mL heptane. Dry down under nitrogen between 
washes and keep the flask in a hot water bath.
Store the tubes dried down under nitrogen and sealed at -20°C.
5% Gum Arabic in 0.2 M Tris-HCl pH 8.4
5 g gum arabic in 100 mL volumetric flask, made up to volume with 0.2 M Tris-HCl (T- 
1503) pH to 8.4.
Filter through cotton gauze.
Divide into 18 x 5.5 mL aliquots and freeze at -20°C.
10% BSA in 0.2 M Tris-HCl pH8.4 
Weigh out 10 g BSA
Make up 20 mL of 1M Tris-HCl (2.422 g om 20 mL).
To 20 mL of 1M Tris-HCl, add approximately 40 mL of water, add 10 g BSA.
When the BSA has dissolved, adjust pH to 8.4.
Dilute to 100 mL with distilled water and divide into 18 x 5.5 mL aliquots and freeze at - 
20°C.
Extraction solution
Methanol : 1.41 parts (141 mL)
Chloroform : 1.25 parts (125 mL)
Heptane : 1.00 parts (100 mL)
Extraction Buffer
0.14M potassium carbonate, 0.14M boric acid, pH 10.5
Dissolve 3.8699 g K2C 0 3 and 1.7312 g H3B 0 3 in 200 mL distilled water.
Adjust pH to 10.5 with 2M KOH.
Serum
Collect 100 mL of fasted blood into EDTA from a number of individuals.
Add 0.1% w/v CaC12 bovine thrombin lU/mL.
Incubate at 39°C for 30 minutes.
Remove the clot.
Dialyse against 0.15M NaCl in distilled water, pH7.0, using 6,000-8,000 MWCO 
membrane.
Heat at 56°C for 30 minutes.
Dialyse against PBS.
Store as 1 mL aliquots at -20°C.
SDS reagent
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0.2M Tris-HCl, 25 mM SDS (50 mM SDS for horses)
0.360 g SDS, 1.21 g Tris-Base in 40 mL distilled water.
Correct pH to 8.2, then make up volume to 50 mL in a volumetric flask.
Low salt buffer: 0.2M Tris, 0.216M NaCl, pH 8.4
12.11 g Tris Base, 6.31 g NaCl in 500 mL distilled water. This gives a final NaCl
concentration of 0.1 M in the reaction solution.
High Salt buffer: 0.2M Tris, 2.16M NaCl, pH 8.4
12.1 lg Tris Base, 63.11 g NaCl in 500 mL distilled water. This gives a final NaCl
concentration of 1M in the reaction solution.
Assay Design
Low salt assay (4 tubes) High salt assay (2 tubes)
Tubes 1,2 Tubes 3,4 Tubes 5,6
-SDS +SDS
30 pi 0.15M NaCl 20 pi 0.15M NaCl 30 pi 0.15M NaCl
10 pi PHP 20 pi Preincubation mixture 10 pi PHP
NB: Each sample run in duplicate.
All tubes, samples, substrate and serum kept on ice prior to incubation.
Include two tubes with 40 pi 0.15M NaCl (no PHP) in each assay half to measure 
blank (B) and total counts (TC).
Assay Procedure
Preincubation with SDS reagent
Place 0.5 ml post heparin plasma in TMU tube and add 0.5 mL SDS reagent and vortex. 
Incubate in the water bath at 26°C for 60 minutes and remove 20 pi for the low salt assay. 
2 0  pi is removed for the assay.
Preparation of substrate mixture (30 minutes before required)
Radioactive triolein was placed in a glass flask and 5.5 ml gum arabic solution was 
added. This was sonicated on ice at 18 microns for 4 minutes so that no fat droplets are 
visible on the surface. (Sonicator tip 1/2 cm from bottom of flask). Add 5.5 ml of 10% 
BSA solution, mixed and vortex and keep on ice.
Reaction mixtures
Tubes 1,2,3,4 : To each add 200 pi substrate
: To each add 250 pi low salt buffer (0.2M Tris/0.1M NaCl)
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To each add 50 pi serum.
Tubes 5,6 : To each add 200 j j .1 substrate
: To each add 250 pi high salt buffer (0.2M Tris/1.0M NaCl)
: To each add 50 pi 0.15 NaCl
Incubation
Cap all tubes and incubate in water bath at 28° C for 60 minutes and return to ice 
immediately. Add 3.25 ml extraction solution to each tube. Add 0.75 ml extraction buffer 
to each tube, mix on vortex. Then centrifuged at 4°C, 3K for 30 minutes. Take 1 ml of 
upper phase for counting in scintillation vial. Add 10 ml Ultima Gold (Packard) 
scintillation fluid and 200 pi acetic acid. For blank, take 1ml upper phase and for total 
counts, take 1 ml of lower phase.
Calculation of results
Lipase activity in pmol FFA released/ ml/ hr= fCPM samples-CPM blanks X 755.1
CPM total- Background
Modification of the lipase assay for the measurement of lipoprotein lipase (LPL) and 
hepatic lipase (HL) in preheparin plasma
1. Samples were collected into lithium heparin tubes and kept on ice. Plasma should 
be separated at 4° C and frozen at -70° C within one hour of collection.
2. Samples are assayed in triplicate for LPL, HL and blanks.
3. For the measurement of LPL, plasma was pre-incubated with 35 mM SDS
(instead of 25 mM) in 0.2M tris base, pH 8.2. which was made up fresh on the day 
of assay. Incubation was for 60 minutes at 26° C as per the standard assay.
4. 40 pi of the plasma-SDS mixture (instead of 20 pi) was taken for the LPL
incubation: the LPL substrates contains 0.2M NaCl as per the standard assay.
5. The HL incubation contains 20 pi of plasma (instead of 10 pi) with substrate
containing 2.0 M NaCl as per the standard assay.
6 . Both the LPL and HL incubations were for 1.5 hours (instead of 1 hour).
7. Following solvent extraction, 2 mL of the upper layer (instead of 1 mL) was taken
for liquid scintillation counting (added to 10 mL Ultima Gold, 200 pi of acetic 
acid). Use 1 ml of blank lower phase for total counts.
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Calculation of results
Lipase activity = fCPM samples - CPM blanks X 755.1 X 1/1.5 X 1000 X 0.5
(CPM Total- Background) X 2
2.3.10 Lipoprotein (a) assay
Lp (a ) assay was done with Innotest Lp (a) kit (Innogenetics NV, Belgium), which is an
enzyme immunoassay (Elisa) for the quantitative determination of lipoprotein (a) levels
in human plasma or serum.
Reagents:
1. 1 sachet containing a strip-holder with 12 x 8 anti-Lp (a) (mouse monoclonal)
coated test wells and a silica gel bag as drying agent.
2. 1 vial containing 0.250 ml of a prediluted Lp (a) standard labelled as 100 mg/dl
(phosphate buffer with stabilising proteins, containing 0.05% Kathon CG as 
preservative).
3. 1 vial containing 0.25 ml of prediluted control serum level I (human serum,
prediluted in sample diluent + preservatives).
4. 1 vial containing 0.25 ml of prediluted control serum level II (human serum
prediluted in sample diluent + preservatives).
5. 1 vial containing 50 ml of concentrated sample diluent (phosphate buffer with
stabilising proteins, containing 0.05% Kathon CG as preservative), to be diluted 
10  times before use.
6 . 1 vial containing 0.4 ml of concentrated conjugate (sheep anti-apo B polyclonal
antibody labelled with horse-radish peroxidase, containing 0.05% Kathon CG as 
preservative), to be diluted 1 0 0  times before use.
7. 1 vial containing 20 ml of conjugate diluent (phosphate buffer with stabilising
proteins,, containing 0.05% Kathon CG as preservative).
8 . 1 vial containing 0.3 ml of concentrated TMB substrate solution
(tetramethylbenzidine dissolved in dimethyl sulfoxide), to be diluted 1 0 0  times 
before use.
9. 1 vial containing 20 ml of substrate buffer (phosphate citrate buffer containing
0.006% hydrogen peroxide); ready to use.
1 0 . 1 vial containing 60 ml of concentrated wash solution (phosphate buffer
containing detergent and 0.17% Kathon CG as preservative) to be diluted 25 times 
before use.
Procedure
1. Sample diluent
30 ml concentrate was made up to 300 ml with deionised distilled water.
2. Standards
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Standards were prepared by serial 2-fold dilution with sample diluent.
lOOmg/dl undiluted
50 mg/dl 1 0 0  pi diluent and 1 0 0  pi 1 0 0  mg/dl standard
25 mg/dl 100 pi diluent and 100 pi of 50 mg/dl standard
12.5 mg/dl 100 pi diluent and 100 pi of 25 mg/dl standard
6.3 mg/dl 100 pi diluent and 100 pi of 12.5 mg/dl standard
3.1 mg/dl 100 pi diluent and 100 pi of 6.3 mg/dl standard
0  standard sample diluent
3. First sample dilution 1:200
10 pi sample and QCs were added to 1990 pi diluent and mixed.
4. Second sample dilution 1:10
30 pi diluted samples, QCs and standards was added to 270 pi diluent and mixed.
5. 100 pi of diluted samples, QCs and standards were added to each well and
incubated at 37° C for 2 hours. The wash solution was placed in the incubator to
dissolve any crystals. Then 24 ml of concentrate is diluted to 600 ml with
deionised distilled water.
6 . After incubation, wash each well 4 times leaving 30 seconds soak for each wash.
7. Conjugate
120 pi concentrate was made up to 12 ml with diluent. Add 100 pi to each well 
using multidispenser and incubate for 1 hour at 37° C.
8 . Substrate
120 pi concentrate TMB substrate was made up to 12 ml with substrate buffer. 
Each well was washed 4 times as before. Add 100 pi substrate to each well and 
incubate for 30 minutes at room temperature, allowing 10 seconds between each 
addition.
9. After incubation, add 100 pi 1.5M sulphuric acid to each well to stop the reaction.
10. Read absorbance at 450 nm on Dynatech within 15 minutes.
The Lp(a) done in Singapore uses the Beckman LPA lipoprotein (a) reagent kit.
2.3.11 Non esterified Free Fatty acid assay: Microtitre Method
Reagents and Materials
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96 well Microtitre plate 
pi 0  pipette
Gilson micro-pipetter tips 
Dynatech MR 5000 
BCL 8000 Repeater pipette
Wako NEFA C kit consisting of colour reagents A and B, and diluents for these and 1 
bottle of NEFA standard solution
QC material: using seronorm Lipid which gives a value of 0.650 mmol/L, actual range of 
0.640-0.680 mmol/L
Method
1 Allow standards, samples and reagents to reach room temperature.
Switch on plate mixer/incubator and allow temperature to equilibrate at 37°C
2 Standards
In wells A1 to A12, prepare a range of standards from 0 to 1.0 mmol/L in 
duplicate as follows:
Standard concentration Standard volume Volume of dFLO
(mmol/L) (pL) (PL)
0 0 5
0 .2 1 4
0.4 2 3
0 .6 3 2
0 .8 4 1
1 .0
Samples:
5 0
Working in duplicate, pipette 5p of QC and samples into the wells on the 
microtitre plate.
4 To each well add 50pL of solution A using the repeater pipette with a pipette tip 
attachment touching the side of the well to ensure complete dispension of the 
solution.
5 Cover with polyethylene plate seal. Immediately place in the plate mixer and 
incubate at 37°C for 10 minutes exactly.
6  Remove from incubator and add lOOpL of solution B.
7 Place in plate mixer and incubate for a further 10 minutes at 37°C.
8 After exactly 10 minutes, remove from incubator and allow plate to equilibrate to 
room temperature for 10  minutes.
9 Remove plate seal cover carefully arid read absorbance at 540 nm on the Dynatech
MR5000 (stored as test No. 1)
2.3.12 Surface modification of Beckman Ultraclear centrifuge tubes
This was a procedure for coating the interior surface of Beckman ultraclear centrifuge
tubes (in particular those used in swing-out rotors) with polyvinyl alcohol. Once coated,
salt solutions are then able to run smoothly down the sides of the tubes.
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Preparation of coating reagents
10 g polyvinyl alcohol was dissolved in 250 ml distilled water by stirring and heated to a 
gentle reflux. 250 ml of propan-2-ol is slowly added to the hot solution with stirring and 
heating until a clear solution is obtained.
The solution was cooled to room temperature. Beckman ultraclear tubes are filled with 
the solution and left for 15 minutes before the solution was removed. After removing the 
small amount of solution which collected at the bottom on standing, the tubes were dried 
overnight.
The tubes were filled with distilled water which was poured out after standing overnight 
at room temperature. Finally the tubes were briefly flushed with water, tapped to remove 
excess liquid and left to dry.
In Singapore, the coating reagents were prepared as above at the Department of 
Biochemistry, National University of Singapore and the use of the reflux system at the 
department was by kind permission of Associate Professor Kon Oi Lian, Head of the 
Department of Biochemistry.
Department of Clinical Biochemistry, Singapore General Hospital
All the laboratory tests done in Singapore were carried out at the department of Clinical 
Biochemistry, the laboratory participates in several quality assurances schemes to ensure 
a high standard of quality control. These included
1 Randox (from UK)
2 Murex (from UK)
3 WHO (World Health Organisation)
4 CAP (College of American Pathologist)
5 NQCS (National Quality Control Assurance Scheme)
Grateful thanks also to Dr Chio Lee Foon and Mr Roland Chu for assistance in the 
laboratory procedures.
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Chapter 3 Lipoprotein Subfraction Metabolism
The heart o f the prudent acquires knowledge, And the ear o f the wise seeks knowledge.
Proverbs 18:15
3.1 Introduction
Plasma lipoproteins are known to play a causative role in atherosclerosis and its clinical 
manifestation, coronary heart disease (CHD). Raised plasma cholesterol levels, 
particularly of low density lipoprotein (LDL) cholesterol, correlate positively with the 
incidence of CHD whilst high density lipoprotein (HDL) displays a negative association. 
The nature of the risk associated with elevations in plasma triglyceride, carried mainly in 
very low density lipoproteins (VLDL) is currently controversial. However, it is 
increasingly clear that one way in which this plasma lipid relates to CHD is through its 
influence on the structure of LDL and HDL, in particular its relationship to the 
subtraction distribution within these density classes. Recent improvements in methods for 
separating and quantifying lipoprotein subclasses have improved our understanding of the 
role of lipoproteins in the pathophysiology of CHD. The VLDL fraction can be divided 
into at least two components of differing size, density and metabolic properties. 162*163 
LDL is thought to consist of at least 3 to 7 subpopulations132, 133 while the intermediate 
density class (intermediate density lipoprotein, IDL) has been reported to contain larger 
IDLj and smaller IDL2  particles. 127 The heterogeneity observed within these density 
intervals may be linked since it has been suggested that the conversion of VLDL to LDL 
does not occur via a single delipidation chain. Rather, parallel processing pathways 
operate within the delipidation cascade. 111*164 For example, large VLDL when delipidated 
give rise to remnants in the smaller VLDL2  and IDL density intervals and these are 
inefficiently converted to a class of LDL which is cleared slowly from the plasma. Newly 
synthesised small VLDL (VLDL2 ), on the other hand, is rapidly and almost quantitatively 
delipidated to LDL which is catabolised rapidly.
Metabolic studies of LDL have been complemented in recent years by examination of its 
subfraction distribution by the high resolution subfraction techniques of gradient gel 
electrophoresis and density gradient ultracentrifugation. Austin et al,35demonstrated an 
association between a particular LDL phenotype and CHD risk. The atherogenic 
lipoprotein phenotype (ALP), defined by the predominance of small, dense LDL ('pattern 
B'), a moderately elevated plasma triglyceride and a low HDL cholesterol was associated 
with a 3-fold increase in CHD risk. Using the density gradient technique to quantify 
individual LDL species, we have translated the ALP into a plasma concentration of LDL- 
III (d 1.045-1.065 kg/L) of greater than 100 mg lipoprotein/dl plasma, 136 and shown that 
this, when present, gives a 7-fold increased risk in a case control study of myocardial 
infarct (MI) survivors versus normals. The ALP has also been recently been linked to 
presence of insulin resistance as an underlying metabolic disorder.74 This insulin 
resistance syndrome (IRS), characterised by fasting hyperinsulinaemia and exaggerated 
insulin response to a glucose challenge13 is considered an independent risk factor for 
CHD. Furthermore insulin resistant individuals, especially those with frank non-insulin 
dependent diabetes mellitus (NIDDM), have alterations in VLDL structure and 
metabolism with an abundance of the larger, triglyceride-rich VLDL species. 165 IRS is 
associated with an increase in central obesity as indicated by increased body mass index
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(BMI) and waist/hip ratio (WHR). However, the precise effects of changes in 
anthropometric indices on plasma lipoprotein subfraction distributions are unknown 
although it has been linked to an LDL pattern dominated by small dense LDL.75 
Epidemiological studies have further shown that ALP expression is age and sex 
dependent.110
In our study of a large group of subjects whose plasma lipid values spanned the normal 
range, we sought to understand the relationships between apolipoprotein B containing 
lipoproteins in terms of their overall concentration, composition and subfraction 
distribution. These parameters were also related to total plasma lipid levels, 
anthropometric indices and gender. Our principal hypothesis was that the presence of 
elevated plasma triglyceride (possibly associated with insulin resistance) and the activity 
of lipolytic enzymes together were responsible for the accumulation of small, dense LDL. 
Further, the extent to which the male-female difference in CHD risk could be explained 
by the variation in lipoprotein subtractions profiles were examined.
3.11 Statistical methods
Statistical analysis and manipulations were performed using the PC version of MINITAB 
Release 10 for Windows (Minitab Inc., PA). All variables were assessed by drawing 
normality plots and in instances where they were not normally distributed, appropriate 
transformations were performed to obtain one. The following were subjected to loge 
transformations; BMI, WHR, plasma triglyceride, HDL cholesterol, fasting insulin, LPL, 
HL, VLDLi and VLDL2, LDL-I, LDL-II and LDL-III concentrations. Plasma VLDL 
cholesterol was normalised by taking the square root whilst fasting glucose was 
normalised by squaring it. Associations between variables were tested by calculating the 
Pearson correlation coefficient and the coefficient of determination (r2) which was 
expressed as a percentage, i.e. r2 gives the percentage of variation in the dependent 
variable which is explained by variation in the independent variable). The significance of 
association between pairs of variables was determined by linear regression. Multivariate 
analysis was employed to determine the extent to which age, sex, general obesity (BMI), 
central obesity (WHR) and markers of insulin resistance (fasting glucose and insulin) 
explained the variability in post-heparin plasma LPL and HL activity, VLDLi, VLDL2, 
IDL, LDL and LDL subfraction concentrations. This was conducted using the analysis of 
variance General Linear Model (GLM) in Minitab which permitted the inclusion of 
categorical variables (i.e. sex) and multiple regression which generated overall coefficient 
of determination for a given set of variables. It should be noted that GLM gives r2 values 
that related to the independent contribution of variables while the overall r2 determined by 
multiple regression is usually higher and takes account of potential interaction between 
correlated variables. For consistency the same panel of variables (anthropometric indices, 
markers of insulin resistance and lipases) were included as predictors in all GLM models 
of lipoprotein subfraction distributions. Plasma triglyceride was added to the models for 
IDL, LDL and LDL subfractions in order to explore previously identified relationship.
Anthropometric indices, plasma lipids and lipoproteins were compared between males 
and females, using transformed data where appropriate, by student’s unpaired t-tests. A 
Bonferroni correction was employed to allow for multiple comparisons. Comparison of
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slopes for the regression of VLDLi, VLDL2 or LDL-III versus plasma triglyceride and 
LDL triglyceride versus hepatic lipase in males and females was done using the pairwise- 
slopes routine in Minitab and tested for significance with the Mann-Whitney test. There 
were 18 peri and post-menopausal women of which four were on hormonal replacement 
therapy (HRT), and the hormonal status of the remaining 14 was unknown. The effect 
that the menopause as well as HRT has on lipids and lipases is well documented and 
hence in each instance, analyses were performed with and without these 18 subjects to 
ensure that the menopausal state or HRT was not unduly influencing the results. Their 
inclusion did not affect the overall findings. Ninety-seven of the volunteers came from 19 
different families and were related. The results were initially analysed with all related 
family members excluded and than again with the 97 included. The data was not skewed 
by the inclusion of these family members and they were present in the final analyses.
3.2 Anthropometric indices and plasma lipids
Age, systolic blood pressure, BMI and hip circumference, plasma cholesterol, LDL 
cholesterol, VLDL cholesterol and HDL3 were similar between the sexes (Table 1). 
Males were generally heavier but this was in keeping with their height since there was no 
sex difference in BMI. However, men had a significantly greater waist circumference and 
consequently a bigger WHR. Males had higher plasma triglyceride, plasma 
cholesterol/HDL ratio and a lower total HDL cholesterol and HDLr  The mean 
postheparin HL activity was twice as high in males compared to females but there were 
no difference in LPL activity.
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Table 1. Anthropometric indices, plasma lipids, lipoproteins and lipases in the 
study group
Variable Males § (n) Females§ (n)
Age 35.6±11.2 (140) 37.0±11.0 (164)
Weight (kg) 76.7±9.9 (93) 63.5±10.7 (98)*
BMI 24.9±3.0 (138) 24.6±3.9 (162)
BP systolic (mmHg) 125±13 (93) 121±16 (98)
BP diastolic (mmHg) 81±9 (93) 77±10 (98)t
Waist (cm) 86±9 (93) 75±10 (96)*
Hip (cm) 98±7 (93) 98±8 (96)
WHR 0.9±0.1 (93) 0.8±0.1 (96)*
Total cholesterol (mmol/1) 5.3±1.1 (139) 5.211.0(164)
Triglyceride (mmol/1) 1.2±0.6 (139) 1.0±0.5 (164)t
HDL-C (mmol/1) 1.2±0.3 (139) . 1.5±0.3 (164)*
LDL-C (mmol/1) 3.5±1.0 (139) 3.210.9 (157)
VLDL-C (mmol/1) 0.610.3 (139) 0.5±0.3 (157)
Chol/HDL ratio 4.6±1.4 (139) 3.7±1.2 (164)*
HDL2 mass(mg/dL) 51133(133) 91±48(153)*
HDL3 mass(mg/dL) 246160(133) 254158 (153)
Hepatic lipase (pmolFA/mL/h) 19.518.1 (70) 11.415.4(67)*
Lipoprotein lipase (pmolFA/mL/h) 4.411.6 (70) 5.012.5 (67)
BMI, body mass index; BP, blood pressure; WHR, waist/hip ratio; HDL-C, high density lipoprotein- 
cholesterol; LDL-C, low density lipoprotein-cholesterol; VLDL-C, very low density lipoprotein-cholesterol; 
Chol/HDL ratio, Total plasma cholesterol/ high density lipoprotein-cholesterol ratio; HDL2 mass, high 
density lipoprotein2 subfraction mass; HDL3 mass, high density lipoproteii^ subfraction mass;
* pO.OOl, T p<0.01, t  p<0.05 refer to significance of difference between males and females as determined 
by student's unpaired t-test using transformed data where appropriate, corrected for multiple comparisons. § 
Means and standard deviations shown were determined on non-transformed data, n refers to number of 
subjects included in measurement.
3.3 Factors predicting plasma lipids, lipoproteins and lipases
In this normolipaemic group of men and women, age, BMI, WHR and plasma triglyceride 
showed significant positive relationships to plasma and LDL cholesterol in univariate 
analysis (Table 2). In the multivariate model, only age and triglyceride remained 
significant predictors of plasma cholesterol and LDL cholesterol and together accounted 
for 44% and 35% of its variability respectively. In univariate analysis, age, BMI, WHR, 
fasting insulin and LPL showed significant associations with plasma triglyceride. 
However only age, LPL and fasting insulin remained significant predictors in multivariate 
analysis, accounting for 20%of the variability in this lipid. BMI, WHR, fasting insulin, 
LPL, HL and plasma triglyceride all showed significant relationships with HDL 
cholesterol in univariate analysis. In the multivariate model only fasting insulin, LPL, HL
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and triglyceride remained significant predictors and together accounted for 39% of its 
variability.
Postheparin hepatic lipase activity had significant associations with BMI, WHR, fasting 
insulin in univariate analysis (Table 3). Using the GLM, sex alone accounted for 28.5% 
of the variability in HL. When included in a model with age, measures of obesity and 
insulin resistance, sex was still the most significant predictor (GLM (A) Table 3). The 
multivariate model (GLM B) in which sex was excluded to reveal the impact of other 
potential factors, indicated that age and WHR were significant predictors and together 
accounted for 23% of the enzyme’s variability. BMI and fasting insulin had significant 
association with LPL activity in univariate analysis but none were significant in the 
multivariate model.
Table 2. Determinants of plasma lipids and lipoprotein concentrations
Variable n Plasma
Cholesterol
Plasma
Triglyceride
LDL-C HDL-C
Uni
r2
GLM
r2
Uni
r2
GLM Uni
r2
GLM
r2
Uni
i*
GLM
r2
Age 303 22(+)¥ 11.9* 5.2(+)* 1.9? 20.1(+)’ 9.1¥ 0.4 1.5
Sex 303 - 0 - 3.1 - 0 - 0.11
BMI 299 10.8(+)* 0 22.7(+)* 0.2 11.4(+)* 0.1 7.7 (-)* 0.0
WHR 188 5.6(+)* 0.3 10.8(+)* 2.0 10.3(+)* 0.6 9.0(-)* 0.0
Fasting
glucose
186 L5(+) 0.4 2.4(+)t 0.2 2.2(+)t 0.4 1.7(-) 0
Fasting
insulin
186 1.2 0.1 12.0(+)* 2.5? 2.0 0.2 9.5(-)* 2 .1%
LPL 127 0 1.3 6.1(-)t 3.8t 0.1 0.2 17.8(+)* 5.2*
HL 127 0 0.1 0.5 0 0.8 0.1 19.3(-)* 3.5t
Triglyceride 303 29.9(+)* 10.0* - - 20.5(+)* 4.0t 13.9(-)* 3.7+
Overall r2 44.1 20.0 35.0 39.0
BMI, body mass index; WHR, waist/hip ratio; LPL, lipoprotein lipase activity; HL, hepatic lipase activity; 
LDL-C, low density lipoprotein-cholesterol; HDL-C, high density lipoprotein-cholesterol; Uni, univariate 
analysis; GLM, general linear model
* PO.OOl, t  PO .O l, t  P<0.05 refer to the significance of the association r2 (correlation coefficient 
squared) determined by linear regression in univariate analysis or by a multivariate analysis of variance 
General Linear Model including all of the tabled parameters. In the general linear model r2 values provided 
estimates of the independent contribution of a variable, i.e. when all others have been entered into the 
model. The overall r2, generated by including all variables in the table in a multiple regression analysis, 
usually exceeded the sum of the individual r2 values due to the contribution from interaction between terms. 
The sign refer to the direction of the relationship. Sex was included as a categorical variable in the General 
Linear Model.
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Table 3. Determinants of lipase activities
Variable n Hepatic lipase activity Lipoprotein lipase 
activity
Uni
r2
GLM(A)
r2
GLM(B)
r2
Uni
r2
GLM
r2
Age 137 1.9(-) 2 3 % 4.8* 0.9 2.3
Sex 137 - 8 .6 * - - 0 .2
BMI 137 3.6(+)t 1 .6 0 2 .8 (-)t 0
WHR 137 16.8(+)* 
5.2(+)f .
0.5 14.5* 1.9 0 .8
Fasting Insulin 133 0.5 0.3 2 .90* 1 .0
Fasting glucose 130 1.1 0 0 0.7 1 .2
Overall r2 31.1 2 2 .6 4.3
BMI, body mass index; WHR, waist/hip ratio; HDL-C, high density lipoprotein-cholesterol; Uni, univariate 
analysis; GLM, general linear model
* P<0.001, t PO .O l, t  P<0.05 refer to the significance of the association r2 (correlation coefficient 
squared) determined by univariate analysis or by a multivariate analysis of variance General Linear Model 
including all of the tabled parameters. The sign refer to the direction of the relationship. Sex was included 
as a categorical variable in the General Linear Model, but since it is an over-riding determinant of hepatic 
lipase activity, predictors of HL were sought when it was excluded in GLM (B). For explanation of r2 
values see legend to table 2.
3.4 Chemical compositions of apolipoprotein B containing lipoproteins
The percentage contribution of protein (Table 4) to lipoprotein mass increased steadily 
from VLDLj to VLDL2 to IDL and LDL in both males and females, with LDL containing 
almost twice as much protein as VLDLj. Triglyceride content, on the other hand, 
decreased from VLDLj to LDL. The percentage of cholesteryl ester increased steadily 
across the lipoproteins and was maximal in IDL. The free cholesterol showed similar 
patterns with increases in the IDL and LDL. Phospholipid content was relatively 
consistei^across the lipoproteins. These data are in good agreement with previous 
findings. Significant male-female differences in compositions were found in the 
VLDLj phospholipid, VLDL2 phospholipid and LDL triglyceride but only VLDL2 
phospholipid remained significantly different after Bonferroni correction.
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Table 4. Chemical compositions of apolipoprotein B containing lipoproteins
Males
Lipoproteins(n) Proteins Triglyceride Chol esters Free chol Phospholipid
VLDLi § (91) 13.0±0.7 57.7+1.5 11.1+0.6 1.3+0.2 17.7+1.9
VLDL2§ (91) 15.9±0.5 36.3+1.0 23.8+0.9 3.2+0.3 21.6+1.4
IDL§ (53) 19.6±0.3 12.4+0.6 44.6+0.7 5.9+0.3 17.4+0.7
LDL§ (69) 27.0±0.6 5.1+0.1 34.8+0.7 12.6+0.4 30.6+1.8
Females
Lipoproteins(n) Proteins Triglyceride Chol esters Free chol Phospholipid
VLDLi § (98) 14.5+0.6 61.0+1.0 12.5+0.7 1.2+0.2 11.6±1.0t
VLDL2§ (98) 17.3+0.5 39.6+0.9 25.0+0.9 2.5+0.2 16.2±0.8*
IDL§ (44) 20.0+0.3 13.0+0.7 42.2+0.7 6.1+0.2 18.8±0.3
LDL§ (83) 28.1+1.3 5.7±0.2t 35.7+0.7 12.7+0.4 33.1+1.4
VLDLi, very low density lipoprotein^; VLDL2, very low density lipoprotein^ ; IDL, intermediate density 
lipoprotein; LDL, low density lipoprotein; Choi esters, ,cholesteryl esters; Free chol, free cholesterol
§ Values are means ± standard error of means expressed as percent composition, n refers to number of 
subjects included in measurements. * PO.OOl, t  P<0.01 refer to the significance of difference between 
males and females as determined by student's unpaired t-test, before correction for multiple comparisons. 
Only VLDL2 Phospholipid remained significantly different (p<0.05) after Bonferroni correction
3.5 Regulation of VLDL subfraction composition and distribution
As plasma triglyceride rises across the normal range, both VLDLi and VLDL2 
concentrations increased but the increment in VLDLi is much greater than that of VLDL2 
(Fig 3). The ratio of VLDLi to VLDL2 rises from about 1.0 at 0.5 mmol/L to about 2.0 at 
2.0 mmol/L plasma triglyceride respectively. The steeper increment in VLDLi compared 
to VLDL2 is also reflected by a comparison of the regression slopes (VLDLi= 80.4 TG - 
37.9, 64.9% vs VLDL2= 26.3 TG +13.5, i^= 32.3%, p<0.001). The relationships were
similar in both males and females with the ratio of VLDLi to VLDL2 total lipoprotein 
rising from about 1.0 at 0.5 mmol/L to about 2.0 at 2.0 mmol/L plasma triglyceride.
In univariate analysis, anthropometric indices like BMI, WHR as well as fasting glucose 
and insulin levels, LPL and HL were significantly associated with VLDLi concentrations 
(Table 5). Similarly, the same variables with the exception of HL also had significant 
relationships with VLDL2, but the addition of age as another factor. In multivariate 
analysis, only the HL was a significant predictor of VLDLi while age and LPL were the 
significant predictors of VLDL2 concentration.
A similar preferential rise occured in VLDL1/VLDL2 triglyceride across the plasma 
triglyceride range (Fig 4). The VLDL1/VLDL2 triglyceride ratio rose from 1.7 at 0.5 
mmol/L to 3.5 at 2.0 mmol/L plasma triglyceride (Fig 5). Examination of VLDLi and 
VLDL2 compositions and calculations of the core to coat ratio remained relatively 
constant across the plasma triglyceride range. Linear regression of core:coat ratios versus
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plasma triglyceride revealed regression equations o f V L D L i  core:coat ratio =2.74 - 0.4 
TG, r= 0.14, NS and VLDL2 corexoat ratio =1.37 - 0.1TG, r= 0.16, p<0.05). This implied 
that the increase in VLDL triglyceride as well as VLDL mass was the result of increasing 
particle number and not particle size. Likewise the cholesterol to protein ratio was 
unchanged throughout the plasma triglyceride range. Increasing levels of plasma 
cholesterol were not associated with changes in concentration of VLDLi and VLDL2.
Table 5. Determinants of very low density lipoprotein subfraction concentrations
Variable n VLDL, VLDL2
Uni GLM Uni GLM
r2 r2 r2 r2
Age 189 1 .6 (+) 2.5 2.5(+) 3.3 J
Sex 189 - 0.5 - 0
BMI 189 13.8(+)* 0 5.8(+)* 0.4
WHR 189 9.6(+)* 0 .6 10.3(+)* 0 .2
Fasting insulin 173 11.5(+)* 2 .0 4.4(+)f 0 .2
Fasting glucose 169 4.4(+)f 0 2.7(+)t 0.4
LPL 129 5.4(-)t 2.3 8 .0 (-)* 7.2
HL 129 10.5(+)* 5.4f 2 .2 0 .6
Overall r2 15.5 12.3
BMI, body mass index; WHR, waist/hip ratio; LPL, lipoprotein lipase activity; HL, hepatic lipase activity; 
VLDLi, very low density lipoprotein 1; VLDL2, very low density lipoprotein2 subfraction; Uni, univariate 
analysis; GLM, general linear model
*P<0.001, fP,0.01, t  p<0.05 refer to the significance of the association r2 (correlation coefficient squared) 
determined by univariate analysis or by a multivariate analysis of variance General Linear Model including 
all of the tabled parameters. The sign refer to the direction of the relationship. Sex was included as a 
categorical variable in the General Linear Model. For explanation of 12 values see legend to table 2.
3.6 Regulation of IDL composition and concentration
There was a strong positive relationship between plasma cholesterol and IDL 
concentration (r=0.71, p<0.001)(Fig 6 ), and the plasma concentration of IDL rose as the 
plasma cholesterol increased across the normal range. The association between 
concentration of the lipoprotein and plasma triglyceride levels was weaker (r=0.41, 
p<0.001, data not shown). In univariate analysis, age, BMI, WHR, fasting glucose, 
plasma triglyceride were important predictors of IDL concentration (Table 6 ). Plasma 
triglyceride and HL were the only significant predictors in the multivariate model and 
together accounted for 36.2% of its variability.
Increasing plasma cholesterol was due to the increments in both IDL and LDL masses 
(Fig 7). The IDL core to coat ratio changed little across the range of plasma cholesterol 
seen in the present study (r=-0.2, p=0.05) implying that the particle decreased slightly in 
size as the plasma cholesterol rose while the IDL cholesterol to protein ratio showed a 
steady increase with increasing cholesterol levels (r=0.55, pO.OOl). Further analysis 
showed that as plasma cholesterol increased IDL became enriched in cholesterol and
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cholesteryl esters and depleted in triglyceride as illustrated by the change in the 
cholesteryl ester to triglyceride ratio (r=0.46, p<0.001) (Fig 8 ). In contrast, the cholesteryl 
ester to triglyceride ratio for VLDLi, VLDL2 and LDL remained constant across the 
cholesterol range. Again, these relationships were the same in men and women.
Table 6. Determinants of intermediate density lipoprotein and low density 
lipoprotein plasma concentration
Variable n IDL n LDL
Uni
1*
GLM
1*
Uni
r2
GLM
r2
Age 97 13.8(+)* 4.0 177 15.0(+)* 6 .2 t
Sex 97 - 2.3 177 - 1.7
BMI 97 16.1(+)*
6.4(+)T
0 177 12.7(+)*
6 .1  ( + r
0 .2
WHR 97 3.1 176 0.4
Fasting insulin 93 1.1 0 174 2.4(+)t 0 .2
Fasting glucose 91 7.2(+)t 0 170 0.3 1.5
Plasma triglyceride 97 16.8(+)* 7.31 177 2 1 .0 (+)* 6 .2 t
LPL 47 3.2 2 .6 130 1 .0 0
HL 47 5.0(-) 9.9t 130 0 .0 0
Overall r2 36.2 2 0 .0
BMI, body mass index; WHR, waist/hip ratio; LPL, lipoprotein lipase activity; HL, hepatic lipase activity; 
IDL, intermediate density lipoprotein; LDL, low density lipoprotein; Uni, univariate analysis; GLM, general 
linear model
PO.OOl, t  PO .O l, t  P<0.05 refer to the significance of the association r2 (correlation coefficient 
squared) determined by univariate analysis or by a multivariate analysis of variance General Linear Model 
including all of the tabled parameters. The sign refer to the direction of the relationship, n refers to the 
number of subjects included in the measurements. Sex was included as a categorical variable in the General 
Linear Model. For explanation of r2 values see legend to table 2.
3.7 Regulation of LDL concentration, composition and subfraction distribution
The total LDL concentration showed a significant positive relationship with plasma 
triglyceride levels (Fig 9) below 1.3 mmol/L (r=0.30, p<0.01) but no significant 
relationship above that value (r=0.17, NS) in both men and women There were strong 
positive relationships between plasma cholesterol and total LDL concentrations (r=0.73, 
p<0.001). Age, BMI, WHR and fasting insulin were also significant correlates of total 
LDL concentration in univariate analyses (Table 6 ) but only plasma triglyceride and age 
remained a significant predictor in multivariate analyses, accounting for 2 0 % of its 
variability. There was little variation in LDL composition as plasma lipid levels changed. 
The cholesterol:protein ratio (0.81±0.01) and the core to coat ratio (0.46±0.01) remained 
constant across the plasma cholesterol range in contrast to the changes seen in IDL (see 
above). It was, however noted that the percent LDL triglyceride content was strongly 
inversely correlated with HL activity in females (r=-0.48, p<0.001) but the association in 
males was less strong r=-0.29, p<0.05). A comparison of the regression slopes was 
further support of the male-female differences ( LDLTG= 6.0 - 0.04HL vs LDLTG= 8.0 - 
0.1 HL, respectively, p<0.001) (Fig 10).
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Age, BMI, WHR, plasma triglyceride, fasting glucose, fasting insulin, LPL and HL all 
exhibited associations with LDL-I plasma concentration in univariate analysis (Table 7). 
In the multivariate model, age, sex, LPL, plasma triglyceride and fasting glucose were 
significant predictors with the last being the most important and when all the parameters 
in Table 7 were included in a multiple regression analysis, they accounted for 26% of 
variability in LDL-I. LDL-II exhibited significant correlations with age, BMI, plasma 
triglyceride but none of these remained significant predictors in the multivariate model. 
BMI,‘ WHR, plasma triglyceride and HL exhibited the strongest relationships with LDL- 
III in univariate analysis. Other factors of significance included age, fasting glucose, 
fasting insulin, and LPL. In the multivariate model GLM (A), sex and plasma triglyceride 
were the only significant independent. When these together with the other parameters in 
Table 7, were included in multiple regression analysis, 42% of LDL-III variability was 
accounted for. When sex was excluded from the model GLM (B), the HL and plasma 
triglyceride were significant predictors of LDL-III, and this reduced group of parameters 
still explained 39% of the variability in this subfraction. In an alternative approach to 
estimating the impact of plasma triglyceride and HL on LDL-III levels, the sexes were 
divided and separate multiple regression performed with just these two variables. In men, 
plasma triglyceride alone explained 40% of LDL-III variability (p<0.001) and HL was not 
a significant predictor. In contrast, in women both plasma triglyceride and HL were 
significant predictors (p=0.002 and p<0.0001 respectively) and together explained 37% of 
LDL-III variation. The sex difference can be visualised by examining the relationship 
between HL and LDL-III concentrations adjusted for plasma triglyceride level. HL 
activity was an important correlate in females but not in males (r=0.38, p<0 .0 0 1  and 
r=0.05, NS respectively)(Fig 13)
Plasma triglyceride was, therefore, a strong predictor of all three LDL subfractions in 
both univariate analysis and multivariate analysis. When the changes in individual LDL 
subfraction distribution across the plasma triglyceride range were examined, it was noted 
that LDL-I exhibited a fall off from mean concentration values of 100 mg/dL at plasma 
triglyceride of 0.5 mmol/L to 40 mg/dL at a plasma triglyceride of 2.3 mmol/L. LDL-II 
showed a positive relationship (r=0.47, p<0.001) at triglyceride levels below 1.3 mmol/L 
and a negative relationship (r=-0.23, p<0.001) above 1.3 mmol/L in confirmation with 
previous findings . However a gender difference was noted in these associations. 
Specifically, the LDL-II concentration in females showed no significant relationship (r=- 
0.1, NS) with plasma triglyceride above 1.3 mmol/L whilst a significant negative 
relationship was demonstrated in males (r=-0.45, p<0.001) (Fig 11). The concentration of 
LDL-III was generally low at a mean of 30 mg/dL in the range of plasma triglyceride 
levels from 0.5 to 1.3 mmol/L. Above the latter value, there was a dramatic rise in LDL- 
III concentration in males but a smaller increase in females (Fig 12). Linear regression 
analysis in subjects with plasma triglyceride above 1.3 mmol/L generated equations for 
LDL-III concentration versus plasma triglyceride of LDL-III= 119TG - 6 6 .6 , r=0.63 in 
males and LDL-III= 47.4TG -11.0, r=0.49; the slopes of these lines differed significantly 
(pO .0 0 1 ).
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Table 7. Determinants of low density lipoprotein subfraction concentration
Variable n LDL I LDL II LDL III
yni
r
qLM
r
Ijni
r
GLM
r2
Uni
r2
GLM(A)
1*
GLM(B)
r2
Age 289 3.6(+)’ 3.2* 5.2(+)* 0.3* 2.3(+)f 0 0 .1
Sex 289 - 2 .6 * - 1.4 - 3.0* -
BMI 285 1.5(-)t 0 5.0(+)* 0.5 8 .6 (+)* 0 0 .8
WHR 175 3.5(-)t 0.4 0 0 15.7(+)* 0.5 0 .2
Plasma 289 4.8(-)t 2 .6 * 4.4(+)* 0 34.5(+)* 19.7* 16.9*
Triglyceride 
Fasting Glucose 169 8 .2 (-)* 10.4* 0 .0 0 2.9(+)* 0 0.5
Fasting Insulin 173 2 .6 (-)t 0 0.7 0 4.2(+)t 0 0
HL 129 7.6(-)t 0.3 0.5 0 .1 7.9(+)t 1 .6 4.0t
LPL 129 5.4(+)t 3.6* ' 0.5 1.5 3.3(+)t 0 0
Overall r2 26.1 0 41.5 38.8
BMI, body mass index; WHR, waist/hip ratio; HL, hepatic lipase activity; LPL, lipoprotein lipase activity; 
LDL-I, low density lipoprotein-I, LDL-II, low density lipoprotein-II, LDL-III, low density lipoprotein-III; 
Uni, univariate analysis; GLM, general linear model
* P<0.001, t  P<0.01, * P<0.05 refer to the significance of the association r^ (correlation coefficient 
squared) determined by univariate analysis or by a multivariate analysis of variance General Linear Model 
including all of the tabled parameters. The sign refer to the direction of the relationship. Sex was included 
as a categorical variable in the General Linear Model. For explanation of i2 values see legend to table 2.
3.8 The impact of plasma triglycerides on lipids and lipoprotein subfractions
This group of normal subjects were then divided into 2 groups based on a plasma 
triglyceride level of 1.5 mmol/L. Griffin et al136 had previously shown that above the 
threshold of 1.5 mmol/L, the LDL subfractions were predominantly dense, LDL-III. In 
order to assess the effects of triglycerides on the lipids and lipoprotein subfractions, the 
two groups were compared as shown in table 8 . It was apparent that the group with 
triglyceride above 1.5 mmol/L had the more atherogenic profile. The levels of total 
cholesterol, VLDLi, VLDL2 and LDL-III were significantly higher whilst the HDL 
cholesterol, HDL2 cholesterol and LDL-I were significantly lower. What is particularly 
interesting is the lack of difference in HDL3 mass whilst the HDL2 mass is significantly 
lower and it is obvious that apart from the effects of triglyceride on HDL cholesterol, 
there is significant effects on HDL subfraction distribution. The mean LDL-III 
concentration in the hypertriglyceridaemic group was above 100 mg/dL, which was 
previously demonstrated by Griffin et al, to be the level whereby risk for coronary artery 
disease are increased.
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Table 8 : Comparing those with high and low triglyceride levels
TG <1.5mmol/L 
(mean±sem)
TG >1.5 mmol/1 
(meanlsem)
Cholesterol (mmol/1) 4.96±0.1 6.0410.1*
H D L  cholesterol (mmol/1) 1.42±0.01 1.1310.03*
V L D L i (mg/dl) 37.9±2.1 114.819.0*
V L D L 2 (mg/dl) 30.6±1.5 67.413.8*
H D L 2  mass (mg/dl) 82.0±3.2 43.813.7*
H D L 3  mass (mg/dl) 247.0±4.2 261.916.3
L D L - I  (mg/dl) 76.112.7 55.214.0*
L D L - I I  (mg/dl) 168.614.3 189.2110
L D L - I I I  (mg/dl) 42.912.3 129.7111*
*p<0.001 refer to significance of difference between males and females as determined by student's unpaired 
t-test using transformed data where appropriate, corrected for multiple comparisons.
VLDLb very low density lipoprotein j; VLDL2, very low density lipoprotein^ IDL, intermediate density 
lipoprotein; LDL, low density lipoprotein; HDL, high density lipoprotein
3.9 Differences between males and females
The males produced more VLDLi and VLDL2 when compared to the females and there 
was a suggestion that the increase in VLDLi was more than that of VLDL2, as 
demonstrated by the VLDL] to VLDL2 ratio which was 1.53±0.1 and 1.42±0.1 for males 
and females respectively, although this failed to achieve statistical significance. In the 
analysis of LDL subtractions, females had significantly higher LDL-I levels and lower 
LDL-III levels. The females had mean LDL-III levels which were half the levels in the 
male subjects. There were no significant differences in IDL concentration between males 
and females. Data in table 1 had also demonstrated that males had significantly lower 
levels of HDL2 mass but there was no difference in HDL3 mass. Interestingly, the mean 
glucose level was significantly higher in males and the insulin level was also higher but 
this failed to achieve statistical significance.
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Table 9: Differences between males and females
Males
(mean ± sem)
Females 
(mean ± sem)
VLDL! (mg/dL) 61.5±4.6 49.7±5.2t
VLDL2 (mg/dL) 43.2±2.7 35.1±2.4t
LDL-I (mg/dL) 58.6±3.1 81.4±3.2*
LDL-II (mg/dL) 172.1±5.8 174.6±5.7
LDL-III (mg/dL) 87.8±7.1 43.9±2.9*
IDL (mg/dL) 44.9±2.4 42.7±2.4
Glucose (mmol/L) 4.9±0.1 4.6±0.1*
Insulin (mU/L) 8.6±0.5 7.7±0.4
*p<0.001, TpO.Ol refer to significance of difference between males and females as determined by student's 
unpaired t-test using transformed data where appropriate, corrected for multiple comparisons.
VLDLb very low density lipoprotein VLDL2, very low density lipoprotein^ IDL, intermediate density 
lipoprotein; LDL, low density lipoprotein
3.10 Discussion
Age was not an entry criterion for this study but due to the nature of the recruitment 
process the majority of participants were young to middle aged adults. Only a few men 
and post-menopausal women were over the age of 55 years. The two sexes were well 
matched for age and exhibited the expected differences in body habitus. It was notable 
that while the BMI was virtually identical in both groups, the WHR was higher in males 
as a result of increased central obesity. Plasma lipids were comparable with the lower 
LDL cholesterol in women being balanced by the higher HDL (and HDL2) level. Hepatic 
lipase activity showed a marked sex difference whereas lipoprotein lipase activity did not. 
The subjects were therefore representative of the general population and an appropriate 
group in which to seek further the basis of the male-female difference in CHD risk. A 
number of questions were asked of the data. First, as total plasma cholesterol and 
triglyceride varied across the range of values seen in the normal population, how did the 
contents of the lipids in VLDLj, VLDL2, IDL and LDL alter? Second, what inter­
relationships existed between plasma lipids, VLDL and LDL subfractions? Third, to what 
extent were changes in lipoprotein levels related to the presence of IRS as revealed by the 
presence of central obesity and/or raised fasting insulin concentrations? Fourth, did the 
above associations depend on gender?
Increasing plasma cholesterol from the bottom to top quintiles of the distribution (3.5 
mmol/L to 7.0 mmol/L) was associated with a two-fold rise in LDL plasma concentration 
and a similar increment in IDL. No relationship was seen with VLDLj and VLDL2 
concentrations. The rise in LDL from low-normal to high-normal was not accompanied 
by any pertubation in the composition of the particle, either its core to coat ratio or its 
cholesterol :protein ratio. That is, the increase was attributable to greater number of 
particles in the circulation. In contrast to the situation for LDL, we found that IDL 
exhibited distinct compositional variations in those with differing plasma cholesterol 
levels. As plasma cholesterol rose, so did the cholesteryl ester:triglyceride ratio, 
indicating a change in the make-up of the particle core. Further, there was also a slight but
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significant downward trend in particle size as judged by the core:coat ratio. Either IDL 
particles as a whole are being increasingly modified by lipid exchange as their 
concentration increases in the circulation, possibly because of their longer residence time 
or, as reported by Musliner et al, IDL also is heterogeneous and composed of two 
subtractions, IDLj which is triglyceride rich and IDL2 which is cholesterol rich. It can be 
postulated that at higher plasma cholesterol levels, there is a selective accumulation of the 
cholesterol enriched IDL particles.
As plasma triglyceride rose across the range seen in this cross-sectional survey, the 
plasma concentration of VLDLj increased more rapidly than VLDLr  Closer examination 
of the scattergrams, suggested that while VLDLj and VLDL2 both increased at the same 
rate over the plasma triglyceride range 0.5-1.0 mmol/L, above this value VLDLj 
continued to rise but VLDL2 showed a smaller increment. Kinetic studies166 of VLDL 
triglyceride turnover in normal subject revealed that it is the synthesis of the lipid rather 
than its clearance rate that controls the plasma levels. Thus, we interpret our observations 
to indicate that in subjects with high-normal plasma triglyceride levels the liver releases 
larger VLDLj in preference to smaller VLDLr  This allo^g the transport of more lipid per 
lipoprotein particle. As reported in a previous study, the total LDL concentration 
exhibited a positive correlation with plasma triglyceride. Again, the relationship appeared 
biphasic in that a positive correlation was seen at lower plasma triglyceride levels but 
above 1.3 mmol/L, the association was lost, suggesting that a plateau value had been 
reached. These associations between VLDLj, VLDL2 , LDL and plasma triglyceride were 
present in both males and females and we could not detect any significant gender based 
differences in the correlation coefficients. What did differ between the sexes, however 
was the LDL subfraction distribution, as a function of plasma triglyceride concentration.
LDL-I concentration was influenced by a number of factors including age, features of 
insulin resistance (increased fasting insulin and glucose), increased obesity, plasma 
triglyceride and the activities of the two lipases. In multivariate analysis, fasting glucose 
was the most important predictor followed by age, plasma triglyceride, LPL activity and 
WHR. The metabolic mechanisms underlying these associations are not yet clear. It is 
possible that the negative association with plasma triglyceride is due to CETP mediated 
transfer of triglyceride from VLDL to LDL-I which improves its qualities as a substrate 
for HL. The enzyme then lipolyses the particle to a denser species (LDL-II or LDL-III). 
LPL activity, on the other hand, demonstrated a positive association with LDL-I possibly 
because when it is high, the circulating levels of large triglyceride-rich lipoproteins 
(including chylomicrons which were not represented in the fasting triglyceride 
measurement) are kept low, thus limiting triglyceride exchange into LDL-I. Alternatively, 
high LPL activity may favour the conversion of smaller VLDL particles to LDL-I. The 
impact of factors associated with insulin resistance i.e. higher plasma glucose levels, and 
WHR, which was present in both sexes is, as yet, inexplicable.
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LDL-II in both males and females exhibited as reported previously a positive 
association with plasma triglyceride when the latter was less than 1.3 mmol/L (the zenith 
of the quadratic regression line which was used to fit the LDL-II to plasma triglyceride in 
men). At higher plasma tri^ceride  levels (from 1.3 to 3.0 mmol/L) in men, there was 
fall off in LDL-II as before with a significant negative correlation and LDL-III which
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had been low when plasma triglyceride was less than 1.3 mmol/L, rose steeply. The data, 
therefore, suggest that the formation of LDL-III, possibly by remodelling of LDL-II, is 
increasingly favoured in men as plasma triglyceride rose above 1.3 mmol/L “threshold”. 
In women, the picture was different. At levels of triglyceride above 1.3 mmol/L, the LDL-
II did not fall and little LDL-III was formed. Only 17% of females with plasma 
triglyceride above the threshold had an LDL-III >100 mg lipoprotein/dl plasma (the level 
which significant CHD risk occurs) compared to 42% in men.
The sex difference and the findings in Table 7 and 9 strongly suggests that hepatic lipase 
may play an important role in determining the relative concentrations of LDL-II and LDL-
III in plasma. Activity of the enzyme is twice as high in men as women and when LDL-III 
in the whole group was adjusted for variation in plasma triglyceride, HL activity emerged 
as the strongest predictor of LDL-III concentration. Generally, a combination of a plasma 
triglyceride greater than 1.3 mmol/L and a HL of >15 U/L was required to generate LDL- 
III above the risk level of 100 mg lipoprotein/dL plasma. Further support for the pivotal 
role of HL activity in LDL subfraction distribution can be gained from examination of the 
composition of total LDL. The percent LDL triglyceride showed a significant inverse 
correlation with HL activity which was stronger in females than in males indicating that 
in the former sex the activity of this enzyme was important in determining the triglyceride 
content of LDL; women with low HL had relatively triglyceride-enriched LDL. HL is also 
known to strongly influence HDL cholesterol and HDL2 67 level, with high activity of the 
enzyme being associated with a low HDL2 concentration. These putative HL-driven 
changes in LDL-III and HDL subfraction distributions go a long way to explaining the 
risk differences between the sexes with women having less “atherogenic” LDL-III and 
more “cardioprotective” HDL2. It is likely that the same mechanism that causes the 
generation of smaller, denser particles within the HDL operates in the LDL density range. 
That is, the lipoprotein is first made susceptible to the action of HL by CETP mediated 
triglyceride transfer and we postulate that it is the VLDLi concentration that determines 
the rate of transfer of triglyceride into LDL since large triglyceride-rich VLDL has been 
shown to be a preferred substrate for CETP action. HL then acts on LDL-II to 
hydrolyse the triglyceride enriched core and generate LDL-III. On the other hand, if the 
enzyme activity is low, then LDL-II remains the major species in plasma and is relatively 
triglyceride enriched. HL is known to be regulated by sex steroid hormones and so this 
final step is possibly a function of androgen/oestrogen status between and within the 
sexes. The present findings amplify ^ d  set in context the earlier reports of Zambon et 
al, 168 Jansen et al169 and Watson et al on the role of HL in determining LDL subfraction 
distribution. The importance of the enzyme becomes clear only when the subject group 
exhibit a wide range ^ for its activity e.g^ when both sexes are examined. 171 The previous 
data of Zambon et al and Jansen et al were collected in men. The latter study in 326 
male subjects reported no overall independent effect of HL on LDL subfraction pattern 
and our findings agree with this. The former report was on a small group (n=44) with a 
wide distribution of HL activity that included enough subjects with low HL to see the 
effect.
IRS has been linked to the appearance of raised plasma triglycericj^ lower HDL 
cholesterol and the presence of small LDL in gel electrophoresis patterns. Here we find 
features of IRS (WHR, raised fasting insulin or glucose) are correlated with LDL
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subfraction concentrations, particularly LDL-I (negatively) and LDL-III (positively). 
Based on the data in Table 7, we suggest that IRS has its effect primarily by raising 
plasma triglyceride and VLDLj levels since it h ^  been shown previously that VLDLj but 
not VLDL2 synthesis is influenced by insulin. It is thought jt^at the hormone acts to 
inhibit hepatic triglyceride release in the form of large VLDL. Furthermore, it would 
appear that the males are more insulin resistant because of the higher glucose and insulin 
levels (Table 9). Resistance to insulin mediated glucose disposal would result in higher 
fasting glucose levels and a compensatory hyperinsulinaemia. We also know that LPL ' 
activity can be influenced by insulin sensitivity and this may contribute to the VLDL 
subfraction distribution being predominantly the larger VLDLi particles in males. 
Conversely, the higher LPL activity in females who are less insulin resistant, would 
favour the conversion of smaller VLDL particles to LDL-I. The impact of insulin 
resistance on coronary risk may thus be mediated through several pathways. Firstly, 
resistance of LPL activities to insulin may result in higher triglyceride levels, especially in 
the postprandial phase. Second, the insulin itself may inhibit the release of large VLDL 
particles and insulin resistance (akin to a lack of insulin) may thus result in a failure of 
this inhibition and favour a shift towards release of larger VLDL particles. Third, the 
resultant hypertriglyceridaemia can modulate the LDL subtraction distribution, favouring 
a predominance of dense LDL particles. In conclusion, the generation of small, dense 
LDL may in many subjects, be viewed as the result of two hormonal effects. First, failure 
of insulin action leading to higher VLDLj levels and increased neutral lipid exchange 
with LDL-II. Second, high androgen activity leading to enhanced HL activity and the 
conversion of LDL-II to LDL-III. It is noteworthy also that WHR was correlated with HL 
activity and that IRS itself and the presence of central obesity can lead to changes in 
androgen/oestrogen balance. 173
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Chapter 4 Relationship between insulin resistance, anthropometry, lipids, 
lipoproteins and lipases
A wise man is strong, Yes, a man of knowledge increases strength Proverbs 24:5
4.1 Introduction
Insulin resistance is closely associated with non-insulin dependent diabetes mellitus, 
hypertension, obesity, premature atherosclerosis, and dyslipidaemia. 13 Two major factors 
known to influence the appearance of the disorder are age and obesity20. It had been 
recognised for many years that ageing is associated with declining glucose tolerance and 
begins at about 40 years and progresses throughout adulthood.77 The reason for this 
declining function is target tissue unresponsiveness to the action of insulin. 174,175,176 The 
underlying cause of insulin resistance, however, remains uncertain. Some have suggested 
it may be attributable to age related changes in body composition and level of physical 
activity rather than to age itself. 177 For example, it has been shown that insulin sensitivity 
in men until around 60 to 70 years of age appears to be determined principally by body 
fat. 178 It is also known that weight loss and physical training improves the body’s 
sensitivity to insulin. 179,180 Nonetheless, all studies agreed that insulin resistance was a
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hallmark of obesity. ’ Various markers of obesity have been used and there are no 
consensus on what constitutes an ideal choice. In the past, markers of obesity took into 
consideration the height, weight and body mass index (BMI) but recent evidences suggest
183 184that the distribution of obesity may be more important than obesity per se. ’ Both 
environmental and genetic factors contribute to the development of obesity. In some 
individuals, the obesity and related insulin resistance are related to excessive caloric 
intake, whilst in others the obesity results from an inherited disturbance in thermogenesis 
or intermediary metabolism.185
A close relationship between hyperinsulinaemia and hypertriglyceridaemia has been 
described in population based studies in healthy normal-weight subjects.20 There is much 
evidence to suggest that insulin resistance, working through hyperinsulinaemia, enhances 
hepatic VLDL synthesis and contributes to the elevated plasma triglyceride levels 
observed in normal-weight healthy subjects, obese nondiabetic subjects, and NIDDM 
subjects. 186 It is now recognised that the insulin-resistant hyperinsulinaemic state is not 
associated with substantial changes in LDL-cholesterol concentrations, but rather with
187increases m LDL apolipoprotein (apo) B levels. Studies have also shown that hyperapo
B condition is frequently associated with hypertriglyceridaemia in the general 
188population, which is likely to be due to a high proportion of small, dense (i.e. lipid 
poor) LDL particles in the circulation. 189 The presence of the dense LDL phenotype is
O f
associated with hypertriglyceridaemia and low HDL-cholesterol levels as well as with 
insulin resistance74 and abdominal obesity.75 Furthermore, it is of interest to note that the 
prevalence of the dense LDL phenotype is quite similar to the insulin resistance syndrome 
(30% versus 25% respectively) . 13,85
Lipoprotein lipase(LPL) serves two major functions in the body, the assimilation of 
triglyceride fatty acid into tissues and the regulation of plasma concentrations of 
lipoprotein classes. 190 LPL activity in the adipose tissue has been shown to be influenced
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by hormonal factors such as insulin191, insulin/glucose ratio, insulin-like growth factors 
and thyroxine. 192 Animal studies suggest that the increase in LPL activity by insulin 
and/or glucose in rat adipose tissue is due to the activation of a proenzyme to an active 
enzyme within the adipose tissue. 193 Type I diabetic patients with poor glucose control 
have depressed levels of adipose tissue LPL, 194 with chronic administration of insulin and 
adequate glycaemic control, the enzyme activity is normal. 195 Likewise, type II diabetics 
have also been shown to have lower adipose tissue LPL activity during periods of 
suboptimal glycaemic control. 196,197 Simsolo et al had shown that the improved glycaemic 
control was associated with an increase in LPL immunoreactive mass and LPL synthesis 
but no change in LPL mRNA levels. 198 They suggest that LPL regulation in these 
diabetics occured at a translational level or through a possible change in degradation. LPL 
activity in skeletal muscle has also been shown to be related to insulin sensitivity.199 
Insulin deficiency or a relative insulin deficiency, such as that which occurs in insulin 
resistance, could affect LPL activity in both adipose tissue and skeletal muscle. This link 
between insulin and a major lipolytic enzyme provides a potential mechanism for the 
observed lipoprotein abnormalities seen as part of the insulin resistance syndrome. This 
chapter seeks to explore the impact of insulin resistance on lipids, lipoproteins and the 
lipolytic enzymes as well as the relationship with the various markers of obesity. The 
subjects and data were from the large group of normal previously described in chapter 3.
4.2 Anthropometric indices
It had been observed that both men and women are susceptible to weight gain. However, 
when men become obese, they deposit fat around the waist, resulting in what is termed as 
central or “apple-shaped” obesity. When women become obese, they deposit fat around 
the hips and that is termed “pear-shaped” obesity. Such descriptions are not merely for 
cosmetic reasons for studies have shown that apple-shaped obesity is associated with a 
higher risk for coronary heart disease whilst the pear-shaped obesity have lower coronary 
risk.200,201,202,203 It is believed that the differences in body fat distribution may be due to 
the variation in adipose tissue LPL activity. There is little variation in adipose tissue LPL 
activity in men204 but women have been shown to have higher adipose tissue LPL activity 
in the gluteal and femoral depots compared to the abdominal depots. These regional 
differences in adipose tissue LPL activity are thought to lead to the preferential 
accumulation of fat in the gluteal-femoral region in women whereas men tend to
207accumulate excess body fat in the abdominal region. ’ The differences in body fat 
distribution and the regional differences in adipose tissue LPL activity are thought to be
20Rassociated with the sex hormone balance associated with the plasma lipoprotein-lipid 
profile.209 Many markers of obesity have been used and associated with increased 
coronary risk. The commonest, BMI is derived from the weight in kilograms divided by 
the square of the height in metres. Most data which relate the level of fatness to total 
mortality have shown a U-shaped risk curve i.e. greatest risk of death is experienced by
the very lean and the very fat. 10 BMI of between 25 to 30 kg/m2 is deemed overweight
2 211 and those above 30 kg/m as obese.
However, the use of BMI may not truly represent the anthropometric risk since obese 
women have lower risk than obese men. Various parameters have been devised to
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indicate the type of obesity present. The WHR is one such measure that has been used 
extensively. Many definitions for measuring waist and hip have been suggested but for 
purpose of the present work a commonly accepted definition has been employed, namely: 
waist is defined as the narrowest circumference below the subcostal margin and the 
anterior superior iliac crest. Hips on the other hand is defined as the widest circumference 
below the waist. Males should have an ideal WHR of 0.9 or below whilst females should 
have WHR of 0.85 and below. Individuals with WHR above 0.9 and 0.85 in males and 
females respectively, were deemed to be centrally obese. The insulin resistance syndrome 
first described by G M Reaven, encompasses central obesity, insulin resistance, 
hypertension, raised triglyceride and low HDL cholesterol. The syndrome is associated 
with higher than normal risk of developing CHD. Reaven postulated that the underlying 
problem was insulin resistance syndrome and that all others features of the syndrome are 
derived from this metabolic problem.
The gold standard for measuring insulin resistance is the insulin clamp technique, either 
the euglycaemic clamps or hyperglycaemic clamps for diabetic patients. Due to 
constraints of manpower and time, I have used other indices of insulin resistance 
including the fasting levels of insulin, glucose, and the parameter calculated by the 
HOMA model (as discussed in chapter 1), as well as presence of low HDL, high 
triglyceride and dense, LDL-III.
4.3 The impact of body fat distribution on plasma lipids
BMI, WHR and waist circumference and their association with lipids, lipoproteins, 
lipases and markers of insulin resistance were explored and results are tabulated tables 
10, 11 and 12 respectively. For BMI, normal subjects were divided into two groups, i.e. 
those with BMI below 27 kg/m2 and those equal or above 27 kg/m2. A BMI of 27 kg/m2 
and above was taken as indicative of obesity. Likewise, a WHR of 0.9 and above was 
taken to signify central obesity and again the normals were divided into two groups based 
on the WHR of 0.9. As for waist circumference, it was difficult to decide what was 
normality. The mean waist circumference for all subjects was about 80 cm and if mean 
plus one standard deviation was taken as normal, then the upper limit of normality for 
waist circumference would be about 90 cm. Hence, I have opted to divide the normals 
into two groups using a waist circumference of 90 cm and above as a second index of 
central obesity.
It was interesting to note that in the obese group, whether one used BMI, WHR or just 
waist circumference, the total cholesterol, LDL cholesterol, triglycerides were higher and 
HDL cholesterol were lower when compared to the non-obese group. Likewise when for 
all 3 parameters of obesity, the obese group had significantly lower HDL2 mass but no 
significant differences in HDL3 mass. All three parameters of obesity were also associated 
with differences in postheparin lipoprotein lipase(LPL) activity and hepatic lipase(HL) 
activity. Lipoprotein subfractions showed significant differences between the obese and 
non obese groups. The obese groups had higher VLDLi, VLDL2 as well as LDL-III, and 
hence a more atherogenic profile. The mean levels of LDL-III concentration in the obese 
group (BMI>27 kg/m2) or centrally obese group (waist >90 cm) were also noted to be 
above 100 mg lipoprotein/dL plasma, the level at which significant atherogenesis is
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believed to occur. 136 LDL-I on the other hand, tended to be lower in the obese group, 
although this failed to achieve significance, except in the group with waist > 90 cm.
The group with BMI>27 kg/m2 had a higher fasting insulin and IR but did not show any 
difference in fasting glucose. Using WHR, there were no difference between the groups 
whilst the group with waist circumference > 90 cm showed higher levels of insulin, IR 
and glucose, and these were highly significant. The data suggested that waist 
circumference was a better discriminator of central obesity compared to WHR since there 
seemed to be greater distinction between the groups with respect to the lipids and 
lipoprotein profile as well as markers of insulin resistance.
The differences in lipids and lipoproteins between the obese and non-obese groups (using 
BMI and waist circumference as indices) were then explored for possible gender 
differences. Results showed that the differences between the groups were similar for both 
males and females (data not shown), with the exception of VLDL2 and HL which failed to 
show a statistically significant difference in the females between those with BMI above 
and below 27 kg/m2 although maintaining the trend seen in the whole group analysis. The 
LDL-III concentration and HL did not show any statistical difference in females with 
waist circumference above and below 90 cm. The mean concentration of LDL-III and 
levels of HL activity however, continues to be higher in those with waist circumference 
greater than 90 cm, similar to that seen in the whole group analysis. The HL in males did 
not show any difference between groups with waist circumference above and below 90 
cm. The differences between the groups with and without obesity were maintained when 
analysed by gender.
Waist circumference showed significant positive correlations with VLDLi and VLDL2 in 
both males and females (Fig 14 and Fig 15). The regression of VLDLi with waist 
circumference was highly significant in both sexes (1^ = 11.7%, p<0.001 for males and r2= 
19.8%, p<0.001 for females). As the waist circumference increased, the concentration of 
LDL-III increased in both males and females (Fig 16). The regression of LDL-III with 
waist circumference was highly significant with r2 = 13.9%, p = 0.001 and r2 = 10.5%, p= 
0 .0 0 2  for males and females respectively.
80
Table 10: Effects of Body Mass Index on Lipids, Lipoproteins, lipases and Insulin
resistance
Variable BMI<27kg/m2 (n) BMI > 27kg/m2 (n) p
Total cholesterol (mmol/L) 5.06±0.07 (233) 5.7310.14(57) <0 .0 0 0 1
Triglyceride (mmol/L) 0.99±0.03 (233) 1.5710.07 (67) <0 .0 0 0 1
LDL cholesterol (mmol/L) 3.20±0.06 (229) 3.8410.13 (64) <0 .0 0 0 1
HDL cholesterol (mmol/L) 1.40±0.02 (233) 1.1910.04 (67) <0 .0 0 0 1
HDL2 mass (mg/dL) 78.613.1 (218) 52.615.5 (65) <0 .0 0 0 1
HDL3 mass (mg/dL) 250.4±42 (218) 251.016.7 (65) ns
VLDLi (mg/dL) 46.6±3.3 (151) 90.319.8 (38) <0 .0 0 0 1
VLDL2 (mg/dL) 36.212.1 (151) 50.013.3 (38) 0 .0 0 1
HL (pmolFA/ml/h) 14.4710.7(112) 19.0511.8 (28) 0.05
LPL (pmolFA/ml/h) 4.9410.21 (112) 3.3810.18(28) <0 .0 0 0 1
Fasting Insulin (mU/L) 7.3710.32 (149) 10.8610.73 (38) <0 .0 0 0 1
Fasting glucose (mmol/L) 4.7710.04 (146) 4.7910.09 (38) ns
Insulin resistance 1.6010.08(144) 2.3410.16(37) <0 .0 0 0 1
LDLI (mg/dL) 73.312.8 (224) 63.914.4 (63) ns
LDLII (mg/dL) 168.714.5 (224) 186.519.8 (63) ns
LDLIII (mg/dL) 52.813.7 (224) 101.8110.0 (63) <0 .0 0 0 1
p value refers to the significance of difference between groups as determined by student’s unpaired t-test 
LDL; low density lipoprotein, HDL; high density lipoprotein, VLDL; very low density lipoprotein, HL; 
hepatic lipase, LPL; lipoprotein lipase
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Table 11: Effects of waist to hip ratio on lipids, lipoproteins, lipases and insulin
resistance
Variable WHR<0.9 (n) W HR >0.9 (n) P
Total cholesterol (mmol/L) 5.04±0.10 (135) 5.3710.14(54) <0.05
Triglyceride (mmol/L) 1.02±0.04 (135) 1.3210.08 (54) <0 .0 0 1
LDL cholesterol (mmol/L) 3.21±0.09 (134) 3.6610.13 (54) <0 .0 0 1
HDL cholesterol (mmol/L) 1.38±0.03 (135) 1.1910.04 (54) <0 .0 0 1
HDL2 mass (mg/dL) 73.5±4.1 (1 2 2 ) 44.014.8 (54) <0 .0 0 0 1
HDL3 mass (mg/dL) 240.8±5.2 (122) 235.318.2 (54) ns
VLDLi (mg/dL) 49.7±3.8 (134) 69.217.4 (54) <0 .0 0 1
VLDL2 (mg/dL) 36.7±2.1 (134) 44.013.6 (54) <0.05
HL (pmolFA/ml/h) 13.04±0.7 (93) 19.9111.3 (44) <0 .0 0 0 1
LPL (pmolFA/ml/h) 4.95±0.24 (93) 3.9710.20 (44) <0 .0 1
Fasting Insulin (mU/L) 7.71±0.35 (132) 8.7710.61 (54) ns
Fasting glucose (mmol/L) 4.77±0.05 (129) 4.8210.06 (54) ns
Insulin resistance 1.68±0.09 (127) 1.9110.14(53) ns
LDLI (mg/dL) 70.9±3.8 (124) 65.315.5 (52) ns
LDLII (mg/dL) 175.6±6.5 (124) 165.019.6 (52) ns
LDLIII (mg/dL) 46.314.4 (124) 97.9112.0 (52) <0 .0 0 0 1
p value refers to the significance of difference between groups as determined by student’s unpaired t-test 
LDL; low density lipoprotein, HDL; high density lipoprotein, VLDL; very low density lipoprotein, HL; 
hepatic lipase, LPL; lipoprotein lipase
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Table 12: Effects of Waist on lipids, lipoproteins, lipases and insulin resistance
Variable Waist <90 (n) Waist > 90 (n) P
Total cholesterol (mmol/L) 4.96±0.09 (149) 5.8110.16(39) <0 .0 0 0 1
Triglyceride (mmol/L) 0.98±0.04 (149) 1.5710.10(39) <0 .0 0 0 1
LDL cholesterol (mmol/L) 3.15±0.08 (148) 4.0510.15(39) <0 .0 0 0 1
HDL cholesterol (mmol/L) 1.38±0.03 (149) 1.1110.04 (39) <0 .0 0 0 1
HDL2 mass (mg/dL) 71.7±3.8 (140) 36.014.4 (35) <0 .0 0 0 1
HDL3 mass (mg/dL) 237.7±5.0 (140) 243.018.6 (35) ns
VLDLi (mg/dL) 45.9±3.3 (148) 91.519.2 (39) <0 .0 0 0 1
VLDL2 (mg/dL) 34.8±1.9 (148) 54.114.0 (39) <0 .0 0 0 1
HL (pmolFA/ml/h) 14.66±0.8 (107) 17.3611.3 (30) <0 .0 1
LPL (pmolFA/ml/h) 4.8110.22(107) 4.0010.23 (30) <0 .0 1
Fasting Insulin (mU/L) 7.2710.32 (143) 10.6810.64 (39) <0 .0 0 0 1
Fasting glucose (mmol/L) 4.7010.04 (146) 5.0810.07 (39) <0 .0 0 0 1
Insulin resistance 1.5510.08 (141) 2.4410.15 (38) <0 .0 0 0 1
LDLI (mg/dL) 72.813.6 (140) 55.815.7 (63) <0 .0 1
LDLII (mg/dL) 168.815.9(140) 187.8113.0 (63) ns
LDLIII (mg/dL) 48.814.7 (140) 113.0114.0 (63) <0 .0 0 0 1
p value refers to the significance of difference between groups as determined by student’s unpaired t-test 
LDL; low density lipoprotein, HDL; high density lipoprotein, VLDL; very low density lipoprotein, HL; 
hepatic lipase, LPL; lipoprotein lipase
4.4 Insulin Resistance and Lipases
LPL is present mainly in adipose tissue and to some extent in other tissues. It is the rate 
limiting enzyme for tissue uptake of plasma triglyceride. ’ * In a number of animal 
studies, adipose tissue LPL has been shown to be sensitive to caloric and hormonal
215 216balance and particularly dependent on availability of glucose and insulin. * The 
lipoprotein lipase hydrolyzes triglycerides in chylomicrons and VLDL whilst HL 
hydrolyzes triglycerides in IDL and HDL, as well as phospholipids in HDL. Together 
with lecithin:cholesterol acyltransferase (LCAT), these enzymes participate in reverse 
cholesterol transport, which results in movement of cholesterol from peripheral tissues to 
the liver. LPL and HL function whilst bound to the luminal surface of endothelial cells in 
peripheral tissues and the liver. Studies have suggested that HL may play a role in 
chylomicrons remnant removal. Cell-surface LPL can also play a role in the binding of 
VLDL and LDL to the cells, similar to the HL-remnant interactions.217 However the 
activity of LPL in human tissues have usually been estimated only indirectly as 
postheparin plasma lipolytic activity, as in our study. In most instances, but not all, low 
postheparin plasma lipolytic activity has been associated with impaired triglyceride 
removal and hypertriglyceridaemia. However we must bear in mind that total postheparin 
plasma lipolytic activity may not be an accurate index of adipose tissue LPL, which is the 
major determinant of peripheral triglyceride removal.
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Data taken from the group of normal individuals showed that the postheparin LPL 
activity had a weak but significant negative correlation with body mass index (r2=3.3%, 
p<0.05 ) and waist (r2=2.9%, p<0.05) but no significant correlation with WHR. HL on the 
other hand showed a strong positive correlation with markers of central obesity i.e. WHR 
(rz=16.8%, pO.OOl) and waist (r2= 13.1%, p<0.001). There was a weaker but significant 
correlation with general obesity, BMI (r2=3.7%, p<0.05). LPL activity also had a weak 
but significant negative correlation with fasting insulin (r2=2.9%, p<0.05) but no 
correlation with fasting glucose, glucose area under curve or insulin area under curve or 
insulin resistance (IR) as calculated by HOMA model. HL activity had a strongly 
significant positive correlation with fasting insulin (^=5.2%, p<0.01) as well as IR 
(r =5.4%, p< 0.01). The group of normal individuals were next divided into two groups 
based on their levels of insulin resistance. The mean fasting insulin for the whole group 
was noted to be 8.0 mU/L whilst the IR was noted to be 1.7. Hence the group was divided 
into two groups based on the fasting insulin and IR above and below the mean, as shown 
in table 13. There were no difference between the two groups in the postheparin LPL 
activity, whether fasting insulin or IR were used as the marker of insulin resistance. 
However, the two groups showed significant difference in postheparin HL activity, with 
the hyperinsulinaemic or insulin resistant group having higher HL levels.
Table 13: Insulin resistance and the lipolytic enzymes
Lipoprotein lipase 
(pmolFA/ml/h)
Hepatic lipase 
(pmolFA/ml/h)
10 < 8.0 (mU/L) 4.8±0.3 13.9±0.8
10 > 8.0 (mU/L) 4.4±0.3 17.111.2J
IR< 1.7 4.7±0.3 13.610.8
IR> 1.7 4.3±0.3 17.9ll.2f
f  P< 0.01, X p<0.05, refers to the significance of difference between the two groups using student’s 
unpaired t-test.
10; fasting insulin, IR; insulin resistance as derived by HOMA model.
4.5 Insulin Resistance and VLDL subfractions
Indices of insulin resistance such as fasting insulin, fasting glucose as well as IR, all 
showed significant positive univariate correlation with the VLDL subtractions. It was also 
interesting to note that the correlation with the larger VLDLi subfraction were stronger 
than the correlation with VLDL2 subfraction. The regression of VLDLi and VLDL2 were 
shown in Figure 14 with regression equations of VLDLi= 28.4 + 15.8 IR and VLDL2= 
30.3 + 5.27 IR. A comparison of the regression slopes showed that the difference was 
statistically significant (pO.OOl).
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Table 14: Univariate correlation of markers of insulin resistance with VLDL 
subfraction
Variable VLDLi (r2) P VLDL2(r2) P
10 (mU/L) 9% <0 .0 0 1 3.2% <0.05
GO (mmol/L) 4.7% <0 .0 1 4.5% <0 .0 1
IR 10.4% <0 .0 0 1 4.2% <0 .0 1
t 1 (correlation coefficient squared) was determined by linear regression in univariate analysis. P refers to the 
significance of r2. 10; fasting insulin, GO; fasting glucose, IR; insulin resistance.
4.6 Insulin Resistance and LDL subfraction
Indices of insulin resistance (Table 15) showed a significant negative univariate 
correlation with LDL-I subfraction concentration and a positive univariate correlation 
with LDL-III. There were no significant correlation with LDL-II subtractions (data not 
shown). The insulin resistant individuals were characterised by a predominance of dense 
LDL-III subtractions in preference to the buoyant LDL-I subfractions. When the group of 
normals were divided into the atherogenic group, who carried a predominance of LDL-III 
subfractions (defined as LDL-III above 100 mg/dL), and the non atherogenic group 
(Table 16), it was noted that the atherogenic group were more insulin resistant as 
reflected by the fasting insulin and insulin resistance. The atherogenic group also had 
higher postheparin HL activity and lowered LPL activity.
Table 15: Univariate correlation 
subfractions
of markers of insulin resistance with LDL
Variable LDL-I(r2) P L D L -III^ ) P
10 (mU/L) 2.5% <0.05 4.2% <0 .0 1
GO (mmol/L) 4.3% <0 .0 1 3.0% <0.05
IR 3.8% <0 .0 1 5.1% <0 .0 1
r2 (correlation coefficient squared) was determined by linear regression in univariate analysis. P refers to the 
significance of r2. 10; fasting insulin, GO; fasting glucose, IR; insulin resistance.
Table 16: Comparisons of markers of insulin resistance between those with and 
without dense LDL-III
Variable LDL-III<100 mg/dl LDL-III> 100 mg/dl P
10 (mU/L) 7.6±0.34 10.5310.93 <0 .0 1
IR 1.64±0.08 2.3310.23 <0 .0 1
HL(jimolFA/ml/h) 14.510.75 18.7511.7 <0.05
LPL(pmolFA/ml/h) 4.710.2 3.8510.24 <0 .0 1
Concentrations of LDL-III above 100 mg lipoprotein/ dL plasma gave a relative risk of 7.0 for myocardial 
infarction and the group was divided based on this concentration of LDL-III.136
p value refers to the significance of difference between groups as determined by student’s unpaired t-test. 
10; fasting insulin, IR; insulin resistance, HL; hepatic lipase, LPL; hepatic lipase.
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4.7 Comparing the normoinsulinaemic and hyperinsulinaemic
The results in table 17 gives a summary of the differences between groups with normal 
fasting insulin and the groups with hyperinsulinaemia. Hyperinsulinaemia was defined by 
the mean fasting insulin ± 2 standard deviation and this was calculated to be 13.4 mU/L. 
•The insulin resistant group had higher triglyceride, VLDLi, LDL-III and lower HDL 
cholesterol and HDL2. This was supportive of the hypothesis that insulin resistance 
confers a more atherogenic profile in affected individuals.
Table 17: Comparing the normoinsulinaemic and hyperinsulinaemic
Normal insulin 
(mean±sem)
High insulin 
(mean±sem)
P
Cholesterol (mmol/L) 5.11±0.1 5.30+0.3 ns
Triglyceride (mmol/L) 1.07±0.04 1.4810.16 <0.05
HDL-C (mmol/L) 1.35±0.03 1.1310.04 <0 .0 1
HDL2 (mg/dL) 67.0±3.6 44.318.8 <0.05
HDL3 (mg/dL) 239±4.5 230.7114 ns
VLDLi (mg/dLO 52.2±3.5 80.8114.0 <0.05
VLDL2 (mg/dL) 38.1±2.0 46.515.3 ns
LDL-I (mg/dL) 70.4±3.4 61.917.1 ns
LDL-III (mg/dL) 58.6±5.3 87.6116.0 <0.05
HDL; high density lipoprotein, VLDL; very low density lipoprotein, LDL; low density lipoprotein 
P values refers to the significance of difference between groups using student’s unpaired t-test.
4.8 Discussion
Obesity is usually a descriptive term for excess body fat. Assessment of the presence and 
extent of obesity is often subjective and influenced by cosmetic and cultural 
considerations. In recent years, both the extent and pattern of obesity has received 
increasing attention because of the increased mortality and morbidity associated with 
both. Obesity is clearly associated with hypertension, hypercholesterolaemia, non-insulin 
dependent diabetes mellitus, excess of certain cancers and other medical problems. 
Obesity is defined as a body fat content greater than 25% of total body weight for men 
and greater than 30% for women. Methods such as underwater weighing can accurately 
determine percent body fat but are expensive and tedious. Other methods such as body 
impedance meters have been shown to correlate well with other laboratory methods. Body 
fat contents can also be estimated by skin fold thickness using callipers but this method is 
often time consuming and imprecise. The most simple and commonly used method is the 
body mass index, using height and weight for calculation. However the use of BMI is 
fraught with errors as the heavily muscled athlete will have high values using this index 
whilst having a low body fat content and the sedentary individual may not be overweight 
but have decreased lean mass and consequently greater metabolic disturbance. Recently, 
it has been recognised that the pattern of distribution of adipose tissue throughout the
86
body affects metabolic consequences and may be a more important factor than total 
adipose tissue mass. Kissebah et al demonstrated that a person with fat located 
predominantly in the abdominal region may be at greater risk of insulin resistance, 
hypertension, heart disease and diabetes than another individual with a greater total 
amount of adipose issue that is located predominantly in the gluteal region.218 In our 
group of normals, obesity conferred a greater coronary risks by affecting all lipid 
parameters. Three indices of body fat distribution were used to create sub-groups, ie. 
BMI, WHR and waist circumference. Whichever index was used to identify the obese 
group it was associated with higher plasma cholesterol and triglyceride, higher LDL 
cholesterol and lower HDL cholesterol. Furthermore, obesity affected the subfraction 
distribution of both LDL and HDL with a predominance of the dense, atherogenic, LDL- 
III subtraction and lower HDL2 mass. The mean LDL-III concentration of those with 
obesity, as determined by BMI and waist circumference, was consistently above 100 mg 
lipoprotein/dL plasma. Hence, obesity not only increased the LDL-cholesterol but also 
shifted the subfraction distribution towards the more atherogenic dense LDL. This would 
further contribute to the coronary risk in those with obesity. The data further showed that 
obesity decreased HDL2 but did not appear to affect the HDL3 mass. Thus apart from the 
reduction in HDL cholesterol, the reduction in HDL2 compared to HDL3 aggravated the 
atherogenic potential as HDL3 is not as efficacious in reverse cholesterol as HDL2. The 
obese group was also noted to have higher VLDLi concentration, probably associated 
with the higher plasma triglyceride. As the waist circumference increased, the 
concentration of VLDLi, VLDL2 and LDL-III increased (fig 14 to fig 16). The rise in both • 
VLDLi and VLDL2 subfractions with increasing waist circumference occured in both 
males and females. LDL-III concentrations in males showed a significant rise with 
increasing waist circumference. Females demonstrated a similar correlation with waist 
circumference but the gradient of the regression curve in males was greater than that 
demonstrated in the females. This difference between the gender is probably due to HL 
activity which differed between the sexes.
General obesity as reflected by BMI appeared to decrease LPL activity whilst central
obesity, as reflected by WHR and particularly waist circumference, had greater effect on
HL activity. From the data, it would appear that waist circumference was a better
reflection of central obesity compared to WHR in that there was greater distinction with
regards to lipids, lipoproteins, lipases and insulin resistance, when the waist
circumference was used to separate the 2 groups as compared to using WHR. This is
consistent with others who have also concluded that different indicators of body fat
distribution have different levels of association with parameters of lipid and carbohydrate 
182 * metabolism. There are limitations to the use of WHR as a marker of regional adiposity
distribution in that a high ratio may be obtained in an individual with small hip
circumference or a low ratio in an individual with large hip circumference. These two
individual may not necessarily differ with regard to the absolute amount of abdominal fat
and in their risk profile, but may be falsely concluded on the basis of their WHR. The
correlation of WHR with total body fat and visceral fat is too low to allow the use of
WHR as a surrogate for the other two fatness variable. Perhaps the use of WHR should be
abandoned in favour of more direct and absolute measurements of truncal-abdominal
obesity, such as those provided by truncal and abdominal skinfolds or by the waist
circumference.
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The effects of insulin resistance on the lipolytic enzymes were explored in detail. 
Whether one uses fasting insulin or the insulin resistance as derived by the HOMA 
model, there were no apparent effect on the postheparin LPL activity, although there was 
a negative but weak univariate correlation with fasting insulin. There was a suggestion 
that the insulin resistant group may have significantly higher postheparin HL activity and 
this was further supported by the stronger univariate correlation with fasting insulin and 
IR. The lack of correlation of insulin resistance with LPL levels could be explained by 
several reasons. Firstly, the use of fasting insulin or IR as a marker of insulin resistance, 
has its limitations. It is not a direct measure of the insulin resistance, unlike the clamp 
studies. Second, the range over which insulin was measured in fasting sample was small 
and the results depended on the precision of the insulin radioimmunoassay. This can be2jo
further compounded by the pulsatility of insulin secretion, uncertainty of whether 
proinsulin is being measured as insulin,220 and the effects of stress221 and exercise,222 
which could all affect interpretation of assay results. It is necessary to measure the fasting 
plasma insulin over a 15 minute period in subjects who are rested, to overcome the effects 
of pulsatile release and stress. In this study, however, only one single plasma insulin level 
was taken and therein lies the limitations in interpretation of insulin resistance. Despite 
the imprecision which limits the clinical application of HOMA estimates from a single 
blood sample, the significant correlation of HOMA estimates with independent 
measurements of B-cell function and insulin resistance supported the use of HOMA as a 
means to explore the effects of an insulin resistant state. It would appear that the insulin 
resistant individual tended to be obese, particularly central obesity, and had lowered LPL 
activity and higher HL activity. A lower LPL activity would delay triglyceride clearance 
and hence cause elevation in the level of plasma triglyceride and the VLDLi 
concentration. The larger VLDLi particles, are more likely to undergo neutral lipid 
exchange with LDL and HDL, resulting in the accumulation of more atherogenic dense 
LDL-III subfraction as well as the less efficacious HDL3 subfraction.
Both the VLDLi and VLDL2 had significant univariate correlation with all the markers of 
insulin resistance i.e. fasting insulin, fasting glucose and IR. This is probably mediated 
through the effects of insulin resistance on triglyceride. Likewise, there was significant 
negative univariate correlation between fasting insulin, glucose and IR with LDL-I and a 
positive correlation with LDL-III. The results shown in table 16 makes clear the 
relationship between the atherogenic lipoprotein phenotype and insulin resistance. It is 
assumed that the group with dense, LDL-III of greater than 100 mg lipoproteins/ dL 
plasma carried the atherogenic lipoprotein phenotype. It can also be seen that the group 
with the atherogenic lipoprotein phenotype had significantly higher levels of fasting 
insulin and IR. Consistent with arguments put forth in chapter 3, the group with 
atherogenic lipoprotein phenotype also had significantly lower levels of postheparin LPL 
activity and higher HL activity. There was obviously a close relationship between ALP 
and IRS but whether the IRS resulted in the ALP or vice versa, is a question which cannot 
be resolved with present data. Furthermore, whether they represent different 
manifestations of the same metabolic disorder or different spectrum of the same disease 
remains unclear.
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There appears to be a great overlap between the IRS, first proposed by Reaven, and the 
Atherogenic Lipoprotein Phenotype (ALP) first proposed by Austin. Perhaps they 
represent a spectrum of a greater underlying metabolic disorder and the full syndrome 
should include 1) raised triglyceride, 2)raised LDL-III concentration, 3) lowered HDL 
cholesterol and HDL2 mass, 4) raised VLDLi mass, 5) lowered lipoprotein lipase activity, 
6) raised hepatic lipase activity, 7) central obesity and 8) insulin resistance.
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Fig 14: VLDL Subfractions vs Insulin Resistance in Males
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Chapter 5 Families with Coronary Heart Disease
When pride comes, then comes shame; But with the humble is wisdom Proverbs 11:2
5.1 Introduction
The concept of ischaemic heart disease (IHD) as the product of genetic and 
environmental factors is generally accepted but the relative contributions of heredity and 
environment have remained more obscure. A genetic-epidemiologic study undertaken in 
white Colorado population of 207 patients who had a myocardial infarction before age 55 
years showed that heritability of IHD was 63% when monogenic forms of 
hyperlipoproteinaemia were included and 56% when they were excluded.223 Another 
study carried out in Finland showed that familial hyperlipidaemia was twice as common 
whilst familial hypertension was three times as common in families with premature 
coronary heart disease (CHD). This study concluded that familial aggregation of CHD 
was mediated by familial aggregation of hyperlipidaemia and hypertension.224 Family 
studies have consistently shown that there is a two and a half fold increase in risk of
225 226coronary deaths among first-degree relatives of coronary patients. ’
Cross sectional and epidemiological surveys have identified a number of genetic and 
environmental factors that predisposes subjects to CHD. These include raised plasma 
cholesterol (particularly the low density lipoprotein fraction), raised plasma triglyceride, 
reduced concentration of high density lipoprotein cholesterol and insulin resistance. In a 
typical study, middle-aged adults with these traits exhibit an increased incidence of 
disease over a 6 to 10 year period of observation. Studies on families with premature 
myocardial infarction showed 38% aggregation of premature CHD and 58% clustering of 
hyperlipoproteinaemia in siblings. Recent investigators, however, including the EC 
sponsored European Atherosclerosis Research study (EARS) project have indicated that 
lipid risk markers are expressed even in young adults (18-25 years) in families where the 
father had a history of premature MI (< 55 years). Surprisingly, the inheritability of 
coronary risk factors has never been formally explored in families “at risk”.
It is accepted that CHD is often an inherited condition but with the exception of familial 
hypercholesterolaemia, little has been done to discover what characterises the family at 
risk. Determination of lipid and apolipoprotein kinetics permit the identification of 
possible key components that when aberrant give rise to lipid-associated risk. Advice and 
therapy can then be offered in a rational and targeted fashion. The metabolic changes that 
underlie the plasma lipoprotein abnormalities seen in subjects with CHD have not been 
well defined and are in fact largely unexplored. This is due in part to the inherent 
difficulty of conducting metabolic experiments and the requirement until recently to use 
radioactive substances to measure kinetics. New advances in the use of stable isotope 
labelled tracers permit more rigorous examination of the inheritability of not just plasma 
lipid steady state levels but also lipid and lipoprotein production and elimination rates.
The hypothesis to be tested in the study described here are:
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a. that aberrations in lipid and glucose metabolism characterises the family at risk 
and are present in early adult life and
b. the defects of lipid and glucose metabolism are synergistic and could possibly be 
due to a common inherited genetic defect (e.g. insulin resistance).
A total of 13 extended families consisting of 27 nuclear families with 70 related family 
members were recruited from probands with premature atherosclerosis. Similarly, a total 
of 6 families were recruited from friends of probands with premature atherosclerosis. 
Independent normals were also recruited from staff and friends of staff, as well as 
newspaper advertisements, giving a total of 137 normals.
5.2 Socio-economic Profile
There was no difference in the gender distribution between the families with CHD (all 
subsequent reference to such families will be known as “at risk” families) and the normal 
controls. Likewise, there was also no significant difference in the distribution of age 
groups between the two groups. The predominant education level in both groups was at 
secondary levels. There was an apparent larger proportion of the normals with tertiary and 
post-graduate education but this did not reach statistical significance. The distribution in 
education levels concurred with the distribution in the occupation, with the “at risk” 
families having the largest proportion of clerical staff whilst the control groups had a 
larger proportion of professionals. Again, the difference failed to achieve statistical 
significance.
The only socio-economic factor that differed significantly between the two groups were 
the smoking habits. The “at risk” families had a significantly higher number of smokers 
compared to the normal control groups. The normal controls also had a significantly 
larger proportion who had given up the smoking habit. Not only were those from “at risk” 
families more likely to smoke, but they were also likely to be heavier smokers. 
Individuals from “at risk” families smoked at least 13 cigarettes per day, whilst the 
normals smoked an average of 4 cigarettes per day. There was no difference with regards 
to the alcohol consumption nor the dietary habits. The lack of difference in alcohol 
consumption was not surprising, as the level of consumption was generally high and 
many do not view alcohol consumption as a risk factor for CHD apart from causing 
excessive weight gain.
The study questionnaire (Appendix 5) also surveyed changes in dietary habits over the 
last six months prior to the study as well as the reasons for the change. It was interesting 
to note that although at least one family member of the “at risk” families had had an 
acute myocardial event, yet this failed to result in any significant change in the dietary 
habits of the rest of the family. The frequency of exercise (as defined by the 
questionnaire) was also surveyed. The exercise pattern revealed that “at risk” families 
tended to exercise more frequently than those that came from normal families. There was 
however no statistically significant difference in the exercise habits between “at risk” 
families and normal controls. Slightly more than one-third in both groups did not exercise 
even once a week.
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Table 17: Patient characteristics and Socio-economic status
Variable Families with prem ature CHD Normals P
Sex: Male 48.6% 48.0%
Female 51.4% 52.0%
Age 35.6±1.52 37.2110.8
0 C 2 =  1.987, D F= 1, P= 0.2
Education level
Secondary 53% 41%
College 26% 21%
Tertiary 10% 23%
Professional courses 10% 10%
Post-graduate 1% 5%
oc2 = 2.338, DF = 4, P=0.2
Occupation.
Professional 17% 38%
Manual worker 24% 13%
Clerical staff 29% 21%
Students 10% 5%
Housewife/unemployed 20% 23%
oc2 = 6.971, DF = 4, P>0.5
Smoking status
Smoker 40.4% 22.7%
Non-smoker 15.8% 13.6%
Ex-smoker 43.8% 63.6%
oc2'7.238, DF= 2, P<0.05
No of cigarettes 12.911.7 4.210.7 <0.001
Alcohol consumption
Yes 74% 87%
No 26% 13%
Amount of alcohol 9.6u±1.8 7.72u 11.5 ns
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Dietary change
Yes 40% 46%
No 60% 54%
oc2= 0.71, DF =1, P=0.5
Exercise habits
<once/ week 37.5% 40%
once/ week 25% 31.4%
2-3 times/ week 37.5% 28.6%
oc2 = 0.863, DF = 2, P >0.5 '
Differences between the two groups were determined by chi-square test.
5.3 Anthropometric indices
For purposes of analysis of data, all the probands from the diseased families as well as the 
age matched control families were removed from the data pool. The spouses of the 
families with CHD were considered as normal controls whilst the rest of the family were 
considered as families at risk. The “at risk” families were found to be significantly shorter 
than the normal controls. However there was no difference in weight, body mass index, 
waist, hip circumference. Thus apart from the difference in height, the “at risk” families 
and the control groups were well matched in terms of anthropometric indices and markers 
of obesity. The systolic blood pressure did not show any significant difference between 
the groups but the diastolic blood pressure was lower in families with CHD compared to 
the normals. The reason for the lower diastolic blood pressure in the “at risk” families 
was unclear.
Table 18: Anthropometric indices and Blood pressure
Variable Families with CHD 
(mean±SD)
Normals
(mean±SD)
P
Height (m) 1.65±0. 1 1.70±0.01 <0.001
Weight (kg) 67.4±12.1 70.6±12.1 ns
BMI (kg/m2) 24.7±3.6 24.7±3.5 ns
Waist (cm) 80.0±11.2 80.3±10.3 ns
Hip (cm) 96.7±8.4 98.6±7.5 ns .
WHR 0.82±0.1 0.81±0.1 ns
BP sys (mmHg) 123±16 123±14 ns
BP dias (mmHg) 75±10 80±9 <0.001
p value refer to significance of difference between the groups as determined by student's unpaired t-test. 
BMI; body mass index, WHR; waist to hip ratio.
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5.4 Lipids and Lipoproteins in family members
There was no difference in plasma cholesterol level between the “at risk” families and the 
normal controls. However, the plasma triglyceride was significantly higher in the “at risk” 
families than in normals. The other adverse atherogenic profile found in the “at risk” 
families was the cholesterol/HDL ratio, which was significantly higher and the HDL 
cholesterol, which was significantly lower in such families compared to normals. There 
was no difference between the two groups with regards to VLDL or LDL cholesterol. In 
the lipoprotein subfraction distribution, the “at risk” families had significantly lower 
HDL2 and HDL3 levels whilst having higher LDL-II levels. It was also interesting to note 
that there was no difference in the buoyant LDL-I or the dense LDL-III sub fractions. The 
VLDLi and VLDL2, non esterified fatty acids (NEFA) and Apo B levels were also higher 
in the “at risk” families. The postheparin lipoprotein lipase (LPL) activity was 
significantly lower but there was no difference in hepatic lipase activity (HL). The 
lowered postheparin LPL activity in the “at risk” family members could result in 
inefficient clearance of post-meal chylomicrons and triglyceride, and thereby increasing 
risk for CHD. This will be discussed in detail in Chapter 6 , when the effects of alimentary 
lipaemia is dealt with. Men have higher risk for CHD than women, and families with 
premature CHD are no exception. Hence, it was important to explore the differences 
between males and females with regards to CHD risks. The mean LDL-III concentration 
in males from the “at risk” families was 113.3 mg/dl plasma and this was above the 
threshold level of 100 mg lipoprotein/dL plasma, where Griffin et al had shown a 7 fold 
increased risk of CHD. 1 6 This was not so in the females from the “at risk” families, 
where the mean LDL-III concentration were similar to those in controls (table 20). There 
was no gender difference with regards to LDL-I subfractions. The differences in VLDL 
and HDL subfractions between the two groups remained significant when analysed by 
gender. The males from “at risk” families had significantly higher postheparin HL 
activity when compared to males from the controls. There was no difference in HL 
activity between the groups in the females.
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Table 19: Comparing the Lipids and Lipoprotein subfraction Profile
Variable Families with CHD 
(mean±sem)
Normals
(mean±sem)
P
Cholesterol (mmol/L) 5.28±0.1 5.19±1.1 ns
Triglyceride (mmol/L) 1.26±0.1 1.09±0.1 <0 .0 0 1
VLDL (mmol/L) 0.54±0.02 0.52±0.02 ns
LDL cholesterol (mmol/L) 3.52±0.1 3.3Q±0.1 ns
HDL cholesterol (mmol/L) 1.22±0.05 1.38±0.02 <0 .0 0 1
Chol/HDL 4.610.2 4.0±0.2 <0.05
Lipoproteins and subfractions
(mean±sem) (meanlsem) P
HDL2 (mg/dL) 52.8±5.3 77.813.1 <0 .0 0 1
HDL3 (mg/dL) 223.317.7 257.113.8 <0 .0 0 1
LDL-I (mg/dL) 72.515.5 72.213.1 ns
LDL-II (mg/dL) 197.119.5 170.815.5 <0 .0 1
LDL-III (mg/dL) 72.419.3 62.814.3 ns
VLDLi (mg/dL) 58.414.9 53.614.6 <0.05
VLDL2 (mg/dL) 43.812.9 36.912.3 <0 .0 1
Lp (a) (mg/dL) 29.815.2 27.712.5 ns
NEFA 0.5010.03 0.3710.02 <0 .0 0 1
Apo A1 116.813.1 1 2 1 .1 1 1 .6 ns
Apo B 95.213.2 88.512.4 <0.05
LPL 4.0410.23 5.3010.28 <0 .0 0 1
HL 15.8311.1 14.5610.9 ns
p value refer to significance of difference between the groups as determined by student's unpaired t-test 
VLDL; very low density lipoprotein, LDL; low density lipoprotein, HDL; high density lipoprotein, LPL; 
lipoprotein lipase, HL; hepatic lipase
Table 20: Differences in LDL Subfractions and HL between males and female
Families with CHD 
(meanlsem)
Normals
(meanlsem)
P
Male LDL-I 65.519.1 55.713.2 ns
Female LDL-I 76.617.0 86.214.7 ns
Male LDL-III 113.3120 86.918 ns
Female LDL-III 42.513.2 48.616.6 ns
Male HL activity 23.712.0 17.511.1 <0 .0 1
Female HL activity 1 0 .2 1 1 .1 11.510.7 ns
p value refer to significance of difference between the groups as determined by student's unpaired t-test
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5.5 Insulin Resistance in CHD families
The markers of insulin resistance were again indirect measures as in the analysis with the 
group of normal subjects (chapter 3). These markers included the fasting glucose and 
insulin, as well as insulin resistance (IR) calculated by the Homeostasis model assessment 
(HOMA). Only the fasting glucose levels were significantly higher in the “at risk” 
families. Other parameters of insulin resistance, including fasting insulin and IR failed to 
distinguish between the two groups.
Table 21: Comparing markers of insulin resistance
Variable Families with CHD 
(mean±sem)
Normals
(meanlsem)
P
Fasting glucose (mmol/L) 4.53±0.07 4.8810.05 <0 .0 0 1
Fasting insulin (mU/L) 8.2310.57 8.0610.37 ns
Insulin resistance 1.7010.13 1.7910.09 ns
p value refer to significance of difference between the groups as determined by student's unpaired t-test
5.6 Risk scoring
Plasma triglyceride, HDL cholesterol, dense LDL-III subfractions have been shown by 
others to be important risk factors for developing coronary artery disease and 
atherosclerosis. Likewise, there are also evidence from population studies227 that fasting 
hyperinsulinaemia is a risk marker. Smoking, which has been shown to increase risk for 
coronary events, is an important social characteristic of those at risk for premature 
atherosclerosis. Hence, the possibility of using the above 5 risk factors were explored to 
see if a scoring system could characterise the “at risk” families.
For plasma triglyceride, normality was taken as levels of 1.5 mmol/L and below, since it 
was shown in a previous chapter that when triglyceride exceeds 1.3 mmol/L, the VLDL 
and LDL subfraction distributions were affected. As for HDL cholesterol, normality was 
taken as being 1.0 mmol/L as studies like the Framingham study had shown that when 
levels are below 1.0 mmol/L in the presence of ‘normal’ cholesterol levels (less than 5.2 
mmol/1), then the risk for coronary events can be comparable to those with cholesterol 
levels of greater than 7.8 mmol/L. LDL-III concentrations had been shown previously by 
Griffin et al, that at levels above 100 mg/dl plasma, there is a seven fold increase in 
coronary risk. However, there was no available data on normal fasting insulin levels in 
the Scottish population. Hence, this was determined by taking the control group, 
removing extreme outliers and then deriving the mean plus 2  standard deviation for the 
fasting insulin. This was found to be 13.4 mU/L, and this was taken as being the upper 
limit of normality.
A score of 0 was given for triglyceride, LDL-III and insulin below the limits of normality 
and for HDL above 1.0 mmol/L. Likewise, scores of 1 were given for smokers and 0 were 
given for non smokers. A score of 1 was given for levels which exceeded the upper limits
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of normality or HDL below 1.0 mmol/L. Using this scoring, the data was used to explore 
the profile of families at risk and what characterises such families. The probands were 
excluded (as in the other analysis) in this scoring system as they would accentuate the 
difference between the groups. The Chi-square test was used to test for differences 
between “at risk” families and controls. It was apparent that there was a significant 
difference between “at risk” families and the normal controls. The percentage of “at risk” 
families with the different scores for risk factors are summarised in Table 22. The 
majority of normal controls had 0  or only 1 risk factor whilst half of the “at risk” families 
had 2 or more risk factors. This difference in distribution of risk scores between “at risk” 
families and normal controls was determined by chi-square to be significant at PO.OOl. 
Risk factors often cluster together and may in fact be synergistic and the clustering of risk 
factors in such families was explored. Using a score of 3 or more risk factors as predictive 
of “at risk” families, 21% of such families had high risk score (Table 23). There was 
significant difference between the controls and “at risk” families. Using a risk score of 2 
and above to represent the “at risk” families, there was even greater difference between 
the two groups. About 50% of family members from the “at risk” families had risk scores 
of at least 2  and above and this was contrasted sharply with the normal controls where the 
great majority (83.6%) had only 1 risk factor or none. A clustering of 2 or more risk 
factors characterises such families at risk and best distinguishes them from normal control 
groups.
Table 22: Coronary risk scoring between families and controls
Scoring 0 1 2 3 4 5
“At risk” families 29.8 26.3 22.8 10.5 7.1 3.5
Normal controls 63.0 20.7 8 .6  6 .0 1.7 0
oc2= 22.559, DF=5 , P<0.001. Difference 
determined by chi-square test.
in distribution of risk scores between the two groups were
Table 23: Distinguishing between families at risks and normals through risk 
scoring
Scoring < 2 risk factors > 3 risk factors
“At risk” families (% ) 79 21
Normal controls (% ) 92.2 7.8
oc2= 6.333, DF =1, PO.02. Difference 
determined by chi-square test.
in distribution of risk scores between the two groups were
< 1 risk factor > 2 risk factors
“At risk” families % 56.1 43.9
Normal controls % 83.6 16.4
oc2 = 15.219, DF =1, PO.OOl. Difference 
determined by chi-square test.
in distribution of risk scores between the two groups were
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5.7 Discussion
The statistical analysis in this section of the study posed a considerable problem because 
the family members from the diseased groups were not independent individuals but were 
linked genetically. Ideally, each family should be analysed as one occurrence rather than 
each family member accounting for one occurrence. However, that would entail 
recruitment of large number of families for reasonable statistical analysis and was beyond 
the resources of one investigator. Furthermore, the normals represented a heterogeneous 
group with related family members from non-diseased families as well as unrelated 
independent individuals. Scotland with its high prevalence of CHD presented a problem 
in recruitment of those without any family history of coronary heart disease. Hence there 
was a need to include independent individuals with the ‘normal’ families, to make up a 
reasonable number of controls. Normals were taken as independent individuals for the 
purpose of generating reference values for the Scottish population. The “at risk” families 
were then examined for deviation from this normality. The limitations of interpreting the 
statistical analysis from this study to the general population are well recognised because 
of the aforesaid problems. Nonetheless, the data does contribute further to the 
understanding of risk factors in families with premature atherosclerosis.
There does not appear to be any significant difference between the “at risk” families and 
the normal controls with regards to the socio-economic status or anthropometry, apart 
from the “at risk” family members being shorter and having a lower diastolic pressure. 
There was a suggestion that the normals were likely to have gone further in their 
education and were likely to be holding some form of professional job. However, this 
could be due to selection bias during recruitment, as individuals from a better educated 
background and professionals were more likely to be better informed about coronary risk 
and hence were likely to respond to newspaper advertisements and other programs to 
enlist normal volunteers. They were also likely to have the resources to make changes to 
their lives should there be any abnormalities detected during screening, and hence were 
more likely to participate in studies of such nature. Whether this be due to selection bias 
or otherwise, it would not be surprising that the better educated were more health 
conscious and better informed, and hence have made changes to lifestyle. This was 
supported by the evidence that the smoking habits continued to be high in “at risk” 
families. Smoking habit was the only social habit that distinguished between “at risk” 
families and normal controls. Individuals from “at risk” families were more likely to be 
smokers and also smoked more heavily. What is even more interesting is the greater 
proportion of those from the normal control groups who had given up smoking, perhaps a 
testimony to the effectiveness of health education on the better informed. The converse is 
also true and those who come from poorer socio-economic background, may not be as 
responsive to health education. However, when the dietary habits were examined, it was 
surprising to note that there were no difference in dietary change between “at risk” 
families and normals. This could be due to the fact that the questionnaires collected 
information about change in dietary habits over the past 6  months prior to enlistment into 
the study. For many “at risk families”, dietary habits could have changed significantly 
immediately after the myocardial events e.g. coronary bypass operation or myocardial 
infarction. Likewise, the control groups may have made changes in their diet beyond the 6  
month period and hence were not reflected in the questionnaire. Personal experience with
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counselling of the families however, suggested that many individuals from such families 
made no effort to change their lifestyle despite the occurrence of a major coronary event 
in the bread winner of the family.
The lipid profile of “at risk” families did not differ with regard to the total cholesterol, 
LDL cholesterol or VLDL cholesterol. The total cholesterol for both groups were 
surprisingly close to the recommended ideal limits of 5.2 mmol/L set by the European 
Atherosclerosis Society, although the mean cholesterol level for the Scottish population 
had been estimated at about 6.2 mmol/L. This may be due to the entry criteria for the 
study which effectively excluded probands with cholesterol level greater than 7.0 mmol/L 
and in so doing, excluded families which were likely to have familial 
hypercholesterolaemia. However, such “at risk” families had significantly higher plasma 
triglyceride and lower HDL cholesterol. This was consistent with our hypothesis that the 
insulin resistance in “at risk” families may account for the lipid abnormality 
characterising such families. The insulin resistance syndrome is characterised by the 
presence of central obesity, high plasma triglyceride, low HDL cholesterol and resistance 
to insulin mediated glucose disposal. Such syndromes are associated with impaired 
glucose metabolism as well as premature atherosclerosis. Recently, Reaven has also 
suggested that there may be a link between the insulin resistance syndrome and the 
atherogenic lipoprotein phenotype, since individuals with insulin resistance were also 
found to have predominance of dense LDL particles. However, not all individuals with 
insulin resistance syndrome demonstrated the dense LDL subfractions, and as explained 
in the preceding chapter, other factors may determine the manifestations of dense LDL 
subtractions. These include the HL and the need to exceed the triglyceride threshold of 
1.5 mmol/L. Many of the offspring in the “at risk” families are young, and may not yet 
have manifested all the features of the insulin resistance syndrome. It would be interesting 
to follow up such “at risk” families to determine what proportion of them eventually 
develop premature atherosclerosis. The fact that the mean plasma triglyceride levels are 
higher than normals, although still less than 1.5 mmol/L, and the HDL cholesterol are 
low, suggest that there are early indications of the presence of insulin resistance syndrome 
in such “at risk” families. Furthermore, the fasting glucose was significantly lower and 
the fasting insulin was higher (although this failed to achieve statistical significance), 
indicate that there was presence of hyperinsulinaemia and hence the lower fasting 
glucose. This is again indirect evidence of impaired insulin mediated glucose disposal in 
the “at risk” families. Although the Homeostasis model (HOMA) proposed by Matthews 
et al was used, this failed to detect a difference between “at risk” families and the 
normals.
The lipoprotein subtraction patterns provided further insights into the “at risk” families. 
The HDL2 and HDL3 subtractions were significantly lower than normals, but this was not 
unexpected since the total HDL cholesterol was lower in “at risk” families. The VLDLi 
and VLDL2 subtractions were significantly higher in the “at risk” families and we had 
demonstrated in the previous chapter that when the plasma triglyceride threshold is 
exceeded, triglyceride is preferentially carried as the larger VLDLi particles. Such 
triglyceride-rich lipoproteins are then subjected to neutral lipid exchange with LDL, to 
form dense LDL particles and smaller HDL3 subtractions. This pattern of VLDL 
subfraction distribution was not unlike what had been previously demonstrated in non
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insulin dependent diabetics. Although the mean LDL-III subfractions was higher than in 
normals, this failed to achieve statistical significance. The difference in LDL-III 
concentration was most apparent in the males but not in the females. The gender 
difference for the manifestations of dense LDL particles had been alluded to in the 
previous chapter. We know from Austin et al, that the manifestations of dense, LDL 
subfractions may be inherited in an autosomal dominant manner, but was also age 
dependent. 110 Many of our “at risk” family members are either offsprings or younger 
siblings of probands. Hence they may not have manifested the full blown atherogenic 
lipoprotein phenotype yet. This was borne out by the observations that in family members 
below the age of 30 years, 13% had LDL-III greater than 100 mg/dl plasma whilst in 
those above 30 years, 31% had LDL-III greater than 100 mg/dl plasma (data not 
shown).This was contrasted against the group of normals where none of those below the 
age of 30 years had LDL-III greater than 100 mg/dl plasma. It would appear that with 
increasing age, many of the “at risk” family members would develop the atherogenic 
lipoprotein phenotype. What was unexpected from this study was the fact that some of the 
younger family members were demonstrating high levels of LDL-III at a very young age. 
Whilst it is true that the manifestations of the atherogenic lipoprotein phenotype is age 
dependent, those from “at risk” families may manifest the phenotype early.
Postheparin LPL activity was lower in the “at risk” families when compared to normals. 
How does this translate into increased coronary risk is unclear. One possibility could be 
that the lowered LPL activity could result in delayed clearance of chylomicrons after a 
meal and thus lead to higher plasma triglyceride levels. The resultant high triglyceride 
then leads to shift in the various subfraction distribution i.e. lower H D L  cholesterol, 
lowered H D L 2  and H D L 3 , raised L D L -I I I  concentration. The post heparin hepatic lipase 
activity failed to show a significant difference between “at risk” families and normals 
although there was a suggestion that the activity was higher in “at risk” family members. 
This may be due to the fact that both males and females were analysed together and hence 
clouded the picture. This became obvious when the H L  activity were analysed separately 
by gender. The males from “at risk” families had significantly higher hepatic lipase 
activity compared to normals. This was not so when the females were analysed and 
activity levels was similar between the groups. The significance of this differential H L  
activity and its relationship to coronary risk is presently unclear. Hepatic lipase may not 
an important rate limiting factor in those with high H L  levels but may become a limiting 
factor in generating L D L - I I I ,  such as in the females with low H L  activity.
What profiles the “at risk” population?
The characteristics of the family at risk were assessed using scoring systems. Using a 
score of 0  for risk factors within ideal limits and 1 for those above the limits, it was 
interesting to note that whether a total risk score of 2 or 3 and above were used, the “at 
risk” families had significantly higher scores. The difference in distribution of risk scores 
between the “at risk” families and the control groups were immediately apparent as those 
from “at risk’ families were scattered across the spectrum of risk scores whilst the 
converse was true of the normal controls, which were mainly in the low end. The majority 
of normal controls had only one or no risk factors whilst about 50% of the “at risk” 
families had at least 2 or more risk factors. This difference between the two groups was
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highly significant. Although it can be argued that the scoring was selective in that only 
triglyceride, HDL cholesterol, LDL-III, fasting insulin and smoking habits were used and 
that other factors may be just as important, it is suffice to say that the aim of this risk 
score is to try and ascertain whether it may profile the “at risk” families and not claim to 
be an all encompassing scoring system. Certainly, it left out LDL cholesterol or total 
cholesterol and markers of obesity. However, in the entry criteria for the study, probands 
with total cholesterol of less than 7.0 mmol/L was chosen to exclude families with 
familial hypercholesterolaemia and also to assess families at risk of premature 
atherosclerosis apart from total or LDL cholesterol. Body mass index and other markers 
of obesity such as waist or waist to hip ratio were also omitted because the two 
populations were evenly matched with regards to anthropometry. All socio-economic 
factors captured by the questionnaire were examined and only smoking habit was 
significantly different between the two groups. It had been shown previously to be an 
important coronary risk and was thus included in the risk scoring.
It would appear that in families with premature atherosclerosis (excluding familial 
hypercholesterolaemia), the constellation of risk factors encompassed in the insulin 
resistance syndrome or the atherogenic lipoprotein phenotype was a significant 
contributory factor. Individuals with insulin resistance syndrome often present with low 
HDL cholesterol, high triglyceride, hyperinsulinaemia or insulin resistance, impaired 
glucose metabolism and increased coronary risk. This was not unlike what had been 
demonstrated in some of the family members. The increased risk scores of “at risk” 
families would support the concept of an inherited element but what was even more 
interesting was that young adults in their early twenties from such families were 
manifesting high concentration of dense LDL-III and other traits of the atherogenic 
lipoprotein phenotype. It would be interesting to follow up members of such “at risk” 
families and document at a later stage, those that eventually develop coronary heart 
disease.
The data showed that those from families with premature atherosclerosis were more 
likely to be smokers and were also more likely to smoke heavily. Smoking is a learned 
social behaviour conditioned by our external environment. In population with high 
prevalence of smokers e.g. Japan, one would expect high incidence of coronary events. 
This is not so as borne out by the Japanese population, this is sometimes also known as 
the Japanese paradox. This could be due to the fact that the mean cholesterol levels of the 
Japanese population are within acceptable ‘normal’ limits and hence despite the high 
prevalence of smokers, they do not have high incidence of coronary heart disease. The 
Japanese suffer from other problems such as strokes and chronic lung problems as a result 
of the smoking habits but they do not have high incidence of coronary heart disease. It 
would appear that smoking in the presence of high mean cholesterol levels could then be 
extremely harmful and this may be so in the Scottish population with mean cholesterol 
levels at 6.2 mmol/L. Other social habits such as exercise habits and dietary changes did 
not differ significantly between the “at risk” families and the control groups, 
questionnaire. It was surprising that there was no difference in the exercise habits of the 
two groups. More than half of both groups claimed to exercise at least once a week and 
does suggest that the Scottish population as a whole may be more physically active and 
thus may not discriminate between “at risk” families and the normal controls. It would
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appear that in families with higher lipids and lipoprotein risk factors, the effects of 
smoking may be an important contributory factor to the development of premature 
atherosclerosis. In summary, the family members from those with a history of premature 
atherosclerosis may have a clustering of risk factors that contribute to the overall risks. 
Such may not have very high levels of one risk factor but the different risk factors could 
act synergistically to contribute to overall risk.
5.8 Health Education and Lifestyle modifications
Family members with increased coronary risk required lifestyle modifications and these 
were usually done in the context of the family unit. Diseased probands were counselled 
together with their spouses and children regarding lifestyle and dietary changes. There 
was greater motivation for change in both probands and family members when they share 
similar risk profile. Changes in dietary habits and lifestyle within such “at risk” families 
must take place early. Making changes in adult life may be too late as the premature 
atherosclerosis may already be firmly established.
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Chapter 6 Alimentary Lipaemia and Coronary Heart Disease
How much better it is to get wisdom than gold! And to get understanding is to be chosen rather than silver.
Proverbs 16:16
6.1 Introduction
The topic of the present chapter is the mechanism by which insulin controls postprandial
triglyceride metabolism in particular postprandial lipaemia. The hypertriglyceridaemic
response of an individual to a fatty meal is believed to play a key regulatory role in
228governing HDL cholesterol concentration and subtraction distribution.
Lipoprotein lipase (LPL), the major enzyme catalysing the triglyceride hydrolysis in the
229circulation is reported to have a low activity in coronary heart disease patients. This 
would give rise to increased VLDL levels and an impaired ability to clear chylomicrons 
following a dietary fat load test, a phenomenon observed in previous studies of CHD1 flftpatients from our laboratory. LPL in adipose tissue and skeletal muscle is under strong 
hormonal control by insulin. A failure of insulin action in insulin resistance may lead to 
less LPL being elaborated in tissues, a reduced lipolytic capacity and the consequently 
exaggerated alimentary lipaemia.
Protocol
Subjects with coronary heart disease and age, sex and weight matched controls were 
administered a standardised fat meal to elicit a lipaemic response. Postheparin LPL 
activity was measured at the first visit in the fasting state and at the second visit, 6 hours 
after the ingestion of the fat meal. The measurement of LPL required the injection of 
heparin to displace the enzyme from its normal site attached to heparan sulphate on the 
capillary endothelial surface. This manoeuvre which interfered with triglyceride 
metabolism needed to be performed well before and at the end of a fat load test. The 
increment in LPL activity “6 hours post prandial minus fasting baseline” was compared to 
the extent of alimentary lipaemia, and between control and coronary heart disease 
patients. It was also compared to the insulinaemic response during the fat load test and to 
the insulinaemic response to an equivalent glucose load during a glucose tolerance test 
(containing the same amount of glucose as the fat meal) to ascertain if insulin alone 
elicited a rise in LPL, and if this rise was blunted in coronary heart disease patients. LPL 
and HL was also assayed in the non-heparinised state to monitor the natural release of the 
enzyme from capillary sites after the fat and glucose loads.
A total of 10 male, coronary heart disease patients and 7 matched controls were recruited 
for the study and they attended for three visits. The characteristics of the patients and 
controls are shown in Table 24. It can be seen that both the CHD patients and the controls 
were well matched with regard to their age, markers of obesity as well as the blood 
pressure. There were no difference between the two study groups when the baseline lipids 
and lipoprotein subfraction patterns (Table 25) were examined. Although the CHD 
patients tended to have higher LDL-III levels, this did not achieve statistical significance. 
The two groups also had similar baseline lipids and lipoprotein levels. Since normal 
subjects were recruited from friends of probands, it was assumed that they would be well
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matched in socio-economic factors. These were not known to have any coronary heart 
disease nor have any symptoms pertaining to ischaemic heart disease. A rather 
unexpected finding was the high concentration of LDL-III amongst the control group but 
this may be a reflection of the plasma triglyceride which were equally high amongst this 
group of normal controls (see chapter 3). The small sample size could also account for 
this finding. The similarity in baseline triglyceride levels facilitates comparison of the fat 
load responses between the CHD and control groups since the fasting triglyceride level is 
otherwise a major determinant of postprandial lipaemia.
Table 24: Profile of the study groups
CHD patients 
(mean ± SD)
Controls 
(mean ± SD)
P
Age 49.3±3.8 44.9±5.9 ns
Body mass index (kg/m ) 28.7±4.0 26.8±4.9 ns
Waist (cm) 96.3±12.3 93.4±10.6 ns
Waist hip ratio 0.99±0.1 0.94±0.1 ns
Systolic BP (mmHg) 134±16 126±13 ns
Diastolic BP (mmHg) 80±10 84±10 ns
p value refers to the significance of difference between groups as determined by student’s unpaired t-test
Table 25: Baseline Lipids and Lipoprotein Subfractions
CHD patients Controls P
Cholesterol (mmol/L) 6.4±0.2 5.8±0.4 ns
Triglyceride (mmol/L) 1.8±0.3 1.710.4 ns
HDL cholesterol (mmol/L) 1.1±0.1 1.110.1 ns
HDL2 (mg/dL) 43.7±7.4 40.317.4 ns
HDL3 (mg/dL) 273.7±13 233.712.6 ns
LDL-I (mg/dL) 47.7±10 52.8139 ns
LDL-II (mg/dL) 225.4±27 240.0154 ns
LDL-III (mg/dL) 126.3±26 104.7136 ns
HDL; high density lipoprotein, LDL; low density lipoprotein
p value refers to the significance of difference between groups as determined by student’s unpaired t-test
6.2 Comparing the fat meal and the glucose meal
The standardised fat meal had been studied extensively by other investigators and is now 
increasingly accepted as one of the tools for profiling the patients at risk of premature 
atherosclerosis. The fat meal is believed to elicit a rise in circulating LPL levels as the 
binding of LPL to the endothelium is thought to be weakened by local fatty acid 
accumulation that may result from lipolysis of plasma triglycerides. Whether this rise 
in plasma LPL levels during the fat meal is of any physiological significance remains to 
be proven. The fat meal is also known to elicit an insulin response and it is still unclear
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whether the hyperinsulinaemic response that occurs in CHD patients during the oral fat 
challenge, could be responsible for the rise in plasma LPL levels. Hence, this study 
sought to compare the response of the standardised fat meal to an equivalent amount of 
glucose in a non-fat meal (i.e. fat free yoghurt). This permitted an exploration of the 
effects of both free fatty acids, glucose and insulin on the responses observed.
In the standardised fat meal and the glucose meal pre-heparin lipases were measured to 
enable serial measurements during short term metabolic studies. However the metabolic
230relevance of pre-heparin lipases is unclear and were first studied by Eckel et al who 
found that pre and post heparin activities of LPL and HL were related and that the 
activities of both enzymes rose after an oral glucose load. Subsequent studies231 
confirmed that pre and post-heparin activities of HL but not LPL were correlated with 
each other and showed that the pre-heparin activities of both enzymes were associated 
with the LDL cholesterol levels. It was suggested that the enzymes bound to lipoprotein 
remnants.
The response between the standardised fat meal and glucose meals were first compared 
between CHD patients and normals. This did not show any significant difference between 
the two groups in any of the parameters and hence they were analysed together and results 
summarised in Table 26. The response for each of the parameter was plotted against time 
and the area under the response curve was calculated using the trapezoid rule. There were 
no significant difference in incremental areas (i.e. total area minus baseline area) and total 
areas, and in all subsequent discussions, area under the curves referred to total area 
obtained by the trapezoid rule. The fat meal obviously induced a much higher triglyceride 
response than the glucose meal. There was no difference in the glucose area under curve 
between the fat meal and the glucose meal presumably because the amount of glucose in 
the glucose meal was made equal to that found in the fat meal i.e. 22 g glucose. Despite 
the similarity in the glucose levels, it was interesting to note that there was a much higher 
insulin response with the fat meal than with the glucose meal, suggesting that the fat meal 
was a more potent stimulator of insulin secretion than glucose. The difference in insulin 
AUC achieved statistical significance. Circulating LPL was also significantly higher with 
the fat meal than with the glucose meal. This was presumably due to the weakening of 
binding of LPL to the endothelium as a result of accumulation of fatty acids or the 
presence of triglyceride rich particles. That there were no significant difference in free 
fatty acid levels between the meals does suggest that other mechanisms such as 
hyperinsulinaemia, may play a role in the rise in LPL levels. When the individual time 
points during the fat challenge were examined, there were again significant difference 
between the oral fat challenge and the glucose challenge. The insulin response did not 
differ between the two meals until the 2nd hour, and thereafter, the difference in insulinthlevels persisted until the 6 hour (Fig 17). The insulin response was also consistently 
higher throughout the oral fat meal than the glucose meal. The glucose on the other handth thdid not show any significant difference until the 4 and the 6 hours, where the glucose 
levels after the oral fat challenge remained higher (Fig 18). The preheparin LPL levels did 
not show any difference between the meals until the 4th hour and this persisted to the 6th 
hour (Fig 19). Free fatty acid levels were significantly different between the meals at the 
1st and 2nd hour, but thereafter were similar between the meals (Fig 20). It would appear
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that the LPL response patterned after the insulin response rather than the free fatty acid 
response.
Table 26: Differences between the fat meal and the glucose meal
Fat meal 
(mean ± sem)
Glucose meal 
(mean 1 sem)
AUC TG (mmol/l/hr) 22.112.4 11.211.3*
AUC Choi (mmol/l/hr) 37.211.4 36.811.7
AUC Insulin (mU/ml/hr) 157.1118 90.7116*
AUC Glucose (mmol/l/hr) 33.910.9 31.610.9
AUC LPL (nmolFA/mL/h2) 108.519.7 78.8i8.7t
AUC HL (nmolFAAnL/h2) 301130 302133
AUC FFA 2.910.3 2.610.2
AUC: Area under curve, TCi: Triglyceride, Choi: Cholesterol, LPL: Lipoprotein lipase, HL: Hepatic lipase, 
FFA: Free fatty acids
% p<0.01, *p<0.001, p value refers to the significance of difference between groups as determined by 
student’s unpaired t-test.
6.3 Postheparin plasma lipases following fat and glucose meals
We have previously found that there was absence of any significant correlation between 
pre and post-heparin LPL activities232 and indicates that the plasma and endothelial pools 
of enzyme are not in equilibrium. This dysequilibrium arises because the levels of LPL 
free in the circulation are kept low by avid uptake and degradation of the enzyme by the 
liver. Furthermore, the addition of heparin alters the enzyme’s apparent specific 
activity,233 either by post-translational activation of the enzyme or by increasing the 
fraction of enzyme transferred to the vascular endothelium at the expense of that 
degraded at the site of synthesis.234 The results of the study (Table 27) showed that there 
were no significant difference in the post-heparin lipoprotein and hepatic lipases activities 
between that taken in the fasting state, after the oral fat challenge and after the glucose 
meal. Although the pre-heparin LPL were significantly higher after the fat loading, this 
did not affect the post-heparin LPL which were similar across all three visits. This is 
consistent with our previous finding that there is a lack of correlation between the pre and 
post-heparin lipase activities. The magnitude of pre-heparin lipoprotein lipases released 
during meals is obviously small compared to that during post-heparin lipase release.
Table 27: Comparing Post-heparin lipases between meals
Fasting Post fat meal Post glucose meal
(meanlsem) (meanlsem) (meanlsem)
LPL (pmolFA/mL/h) 24.612.5 27.312.8 23.512.1
HL (pmolFA/mL/h) 8.411.3 8.310.8 7.210.7
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The results in Table 28 showed that the CHD patients had significantly higher post­
heparin HL levels and lower LPL levels than the controls even in these small groups. In 
chapter 2, we demonstrated that there were significant differences in post-heparin hepatic 
lipase levels between males and females, that males had about twice the levels found in 
females. The hepatic lipase activities may be important determinants of the LDL 
subtraction distribution.
Table 28: Differences 
normals
in post-heparin lipases between CHD patients and
CHD patients Controls P
(mean ± sem) (mean ±sem)
Hepatic lipase 30.6±2.6 16.0±2.6 <0.001
Lipoprotein lipase 10.4±1.9 5.6±0.9 <0.05
p value refers to the significance of difference between groups as determined by student’s unpaired t-test
6.4 Differences between CHD patients and normals during the fat meal
A delayed clearance of postprandial lipoproteins from the plasma may play a role in the 
aetiology of premature coronary atherosclerosis. Disturbance in the removal of 
chylomicron remnants from plasma would expose the vascular bed more intensively to 
the atherogenic lipoproteins and accelerate the atherogenic process. Table 29 showed the 
difference in metabolic response to an oral fat loading between the patients with 
documented coronary artery disease and a group of matched controls. Bearing in mind 
that the baseline lipids and lipoproteins between the two groups were similar, the 
dynamic response to a fat meal challenge may give further clues to the atherogenic 
potential in patients with premature CHD. When the area under the triglyceride curve was 
examined, there was no significant difference between the two groups. When the 
triglyceride levels between the two groups were examined at each time point during the 
oral fat loading, there was also no significant difference. This may be explained by two 
possible reasons. Firstly, it could be because of the small sample size and thus failed to 
detect a difference between the groups. However, the second and most likely reason is 
that metabolic study was terminated at the end of 6 hours whilst other studies which 
demonstrated a difference between CHD positive and negative patients did so after the 6th 
hour and this difference often persisted to the 12th hour. The reason this metabolic study 
was terminated at the 6th hour was because the aim of the study was predominantly to 
assess the effects of the fat meal on the lipases and its interaction with insulin secretion 
rather than on triglyceride levels per se.
The free fatty acid levels were significantly higher in the CHD patients than in the 
normals. The levels of FFA were similar until the 4th hour where normals began to show 
declining levels whilst that in CHD patients remained elevated (Fig 21). The difference in 
FFA levels persisted even at the 6th hour. The pre-heparin LPL levels were also 
significantly different between the CHD patients and normal controls (Fig 22) but there 
were no difference in hepatic lipase levels. Interestingly, there were also significant 
difference in glucose levels between the two groups. Although the area under curve for 
insulin did not show any difference between the groups, the levels of insulin did differ
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significantly at the 4th and the 6th hour (Fig 23). The higher glucose levels, together with 
insulin levels which were higher at every time point during the oral fat meal (Fig 23), 
suggest that the CHD patients were insulin resistant and hence demonstrated 
hyperinsulinaemic response. Resistance to insulin mediated glucose disposal would also 
result in higher glucose levels.
Table 29: Differences 
loading
between CHD patients and normals during oral fat
CHD patients 
(mean±sem)
Normals
(mean±sem)
AUC TG (mmol/L/h) 23.7±2.8 19.6±4.2
AUC Choi (mmol/L/h) 38.2+1.6 35.8±2.7
AUC Insulin (mU/ml/h) 179.2±26 125.5±20
AUC Glucose (mmol/L/h) 35.8±0.9 31.3±1.0t
AUC FFA 3.75±0.3 1.70±0.2*
AUC LPL (nmol/FA/ml/h2) 89.9±11 135.1±12t
AUC HL (nmol/FA/ml/h2) 66.8±9.5 95.9115
JPO.O l, *P<0.001, p value refers to the significance of difference between groups as determined by 
student’s unpaired t-test
6.5 Differences between CHD patients and normals during the glucose meal
The standardised fat meal is a convenient way of testing the triglyceride metabolic 
capacity but it contains a substantial amount of glucose. In the standardised fat meal the 
amount of glucose contained in the meal was about 22 gm. Eckel at al had previously 
shown that LPL rises even with a glucose load and not just a fat meal. If the mechanism 
of rise in pre-heparin LPL levels during an oral fat meal is due solely to the accumulation 
of free fatty acid disrupting the binding of LPL to the vascular endothelium, then this rise 
should not be demonstrated during a glucose meal. However, we know that LPL is also 
modulated by insulin, and in individuals with insulin resistance, such as those with 
premature atherosclerosis, the rise in insulin during an oral fat meal can be substantial, 
even if the amount of glucose contained in the fat meal may not be equivalent to the 
standard glucose tolerance test i.e. 75 g,. The results in Table 30 again showed that the 
CHD patients were insulin resistant, as they had hyperinsulinaemic response to the 
glucose meals, and the area under insulin curve were almost twice that in normal controls. 
Furthermore, the glucose area under curve in the CHD patients were also significantly 
higher than the normals (Fig 24), suggesting resistance to insulin mediated glucose 
disposal. Apart from the insulin and glucose, there were no difference between the two 
groups in the triglyceride, cholesterol, free fatty acid, and the lipases. The preheparin LPL 
levels were consistently lower in the CHD patients throughout all the time points during 
the glucose meal although this failed to achieve statistical significance. (Fig 25)
i l l
Table 30: Differences between CHD patients and Normals during glucose meal
CHD patients 
(meanlsem)
Normals
(meanlsem)
AUC TG (mmol/L/h) 12.211.5 9.712.1
AUC Choi (mmol/L/h) 37.911.6 34.913.5
AUC Insulin (mu/L/h) 116.3123 54 .1 il0 t
AUC Glucose (mmol/L/h) 33.311.2 29.110.8*
AUC FFA 2.710.2 2.310.3
AUC LPL (nmol/FA/ml/h2) 66.819.5 95.9115
AUC HL (nmol/FA/ml/h2) 281.5131 332.0169
T P<0.05 ? P<0.01, p value refers to the significance of difference between groups as determined by 
student’s unpaired t-test
6.6 Discussion
Fasting plasma triglyceride levels have been associated with increased risk of coronary 
artery disease. However, its role has been shrouded in controversy because in multivariate 
analysis, its inverse association with HDL cholesterol eliminates triglyceride as a risk 
factor for coronary artery disease. The individual’s triglyceride metabolic capacity, 
defined as the magnitude of lipaemia which occurs after a standardised oral fat load, is a 
strong determinant of his or her plasma HDL cholesterol, especially the HDL2 cholesterol 
level. Patsch et al235 have suggested that the metabolism of triglycerides is a critical 
determinant of cholesterol metabolic routing and that a challenge of triglyceride 
metabolism such as the postprandial lipaemia may be a better indicator of coronary risks 
than fasting triglyceride per se. Whether a ‘triglyceride tolerance test’ should become a 
routine risk factor screening, particularly in those with premature atherosclerosis but with 
“normal” cholesterol and triglyceride level remains unclear.
This chapter set out to explore several issues, some of which still remain unclear after 
completion of the study. There was no doubt that the plasma triglyceride rose to a higher 
level and remained high for a longer period of time than age matched normal controls. 
The results of the present study supported this finding although statistical significance 
was not achieved because of the small sample size and also because of the termination of 
test at the 6th hour. We did not set out primarily to look at triglyceride levels postmeal but 
rather at other aspects of the “triglyceride tolerance test”. One of the important areas 
explored in this study was the relationship between insulin resistance and the individual’s 
capacity to handle triglyceride. The results suggested that the CHD patients were insulin 
resistant whether one looks at the area under the glucose and insulin curve or individual 
time points during the oral fat meal challenge. CHD patients also had significantly higher 
glucose and insulin levels during the glucose challenge carried in an almost fat-free 
yoghurt meal. The hyperinsulinaemic response and the consequently higher glucose 
suggest a resistance to insulin mediated glucose disposal, although this can only be 
inferred and not conclusively drawn, since glucose clamp studies or other parameters for 
directly assessing resistance were not carried out. During the fat meal, it was also
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observed that the CHD patients had a significantly higher glucose levels compared to 
matched normals. The insulin response showed a parallel hyperinsulinaemic response 
although this did not achieve statistical significance except at the 4th and 6th hour. This is 
further support that the CHD patients are insulin resistant. Further, the greater insulin 
response during the fat meal suggested that free fatty acid and/or triglyceride was a more 
potent stimulator of insulin release than glucose alone.
The difference in postprandial lipaemia response between the CHD patients and normals 
revealed other interesting features. It was observed in- Table 29, that the free fatty acid 
levels in CHD patients were more than twice that of normals, and this difference achieved 
statistical significance. On the other hand, the pre-heparin lipoprotein lipase levels were 
significantly lower in the CHD patients. If the rise in pre-heparin LPL levels was due only 
to dissociation from binding to vascular endothelium by fatty acids, then it would be 
obvious that the LPL levels must be higher in the CHD patients because of the greater 
accumulation of free fatty acid.. This was however, not the case and other mechanisms 
must be at work to affect the pre-heparin lipoprotein lipase levels. Bearing in mind that 
the CHD patients were insulin resistant and had hyperinsulinaemic response to the fat 
meal and that insulin modulates LPL activities, it is possible that resistance of LPL 
activity to hormonal influence of insulin could result in lower levels during alimentary 
lipaemia. This would than contribute to the higher plasma triglycerides seen in CHD 
patients post fat meal challenge.
What then is the role of the standardised fat meal challenge in understanding lipid and 
lipoprotein metabolism? Notwithstanding the limitations mentioned above, I think that it 
is a useful tool in determining an individual’s triglyceride metabolic capacity. The 
individual with an impaired ability to clear chylomicrons and triglyceride post meal 
would be at increased risk of premature atherosclerosis. The accumulation of triglyceride- 
rich lipoproteins would affect the lipoprotein subfraction distribution whilst the 
prolonged exposure of such lipid moiety would increase the chances of atherogenicity in 
the vascular endothelium. The category of patients who should be subjected to the “fat 
tolerance test” should thus include those with documented atherosclerosis but without 
hypercholesterolaemia or hypertriglyceridaemia.
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Fig 20: Comparing FFA response between meals
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Fig 23: Insulin response during glucose meal
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Fig 24: Glucose response during glucose meal
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Chapter 7 Risk Factors in Normal Males in Singapore
By knowledge the rooms are filled with all precious and pleasant riches. Proverbs 24:4
7.1 Introduction
Singapore is a small island state which has a population of almost 2.7 million, consisting 
of 3 major ethnic groups i.e. Chinese, Malay and Indians. There are also many other 
groups represented, from Eurasians, Portuguese, Japanese, Thai, Sri Lankans, to various 
groups of European and American descent. Singapore is a city state and hence there is 
effectively no division into urban and non-urbanised areas. The majority live in high rise 
apartments and enjoy a good standard of living as well as medical care. It is unique in the 
epidemiological sense because the various ethnic groups live in a similar social economic 
milieu, unlike some countries where ethnic minorities may not enjoy the same privileges 
of life. The last population census showed that there are 77.6% Chinese, 14.2% Malay 
and 7.1% Indians with the other ethnic groups making up only 1.1% of the population. 
Although the standard of living is similar amongst the different races, yet it is interesting 
because many of the races have preserved their cultural heritage as well as dietary and 
eating habits. Hence it would not be surprising to find restaurants and other food outlet 
catering to the many differing tastes of both the local population and the increasingly 
large number of tourists from within the regions and other areas. The favourite pastime 
for many Singaporeans is dining and shopping. Obesity is an increasing problem, 
especially amongst the younger children because of the endless feasting and sedentary 
lifestyle. Many blame the problem on ‘westernisation’ of our diet, but that is being too 
simplistic. It is probably a combination of lifestyle changes and eating habits. 
Unfortunately, one of the prices we pay for such a lifestyle of good food and sedentary 
pleasures is increasing atherosclerosis, coronary heart disease and diabetes mellitus.
The prevalence of diseases amongst the various ethnic groups differ quite significantly. 
For example, Indians have the highest prevalence for diabetes mellitus followed by the 
Malays. Chinese have higher incidence of gut and colonic carcinomas than the other 
races. Even amongst the Chinese in Singapore, there are variation in disease patterns 
amongst the various dialect groups. The Cantonese (whose ancestors come from Canton, 
in China) have a much higher incidence of nasopharyngeal carcinoma whilst the 
Hokkiens (who have migrated from the province of Fujian, also in China) have higher 
prevalence of colonic carcinoma. This situation presents a fascination to the 
epidemiologist because it allows them to study the impact of both environmental and 
genetic factors on disease manifestations. Different ethnic groups living under similar 
conditions and yet having different susceptibility to diseases.
The last National Health Survey done in Singapore in 1992 (unpublished data), was a 
randomised survey involving more than 5000 males and females. This survey showed that 
the prevalence of diabetes had risen from 4.7% in 1984 to 8.6% in 1992 across all age 
groups (18-69 years of age). This same survey also showed that the mean cholesterol 
levels had fallen from 5.8 mmol/L to 5.3 mmol/L over the same period of time. This was 
largely through the efforts of intensive health education by the Health authorities. 
Unfortunately, this lowering of total cholesterol has not translated into a lowered
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incidence of coronary heart disease. Two possible reasons were offered for this 
observation. Firstly, there could be a lag phase between the lowering of cholesterol and 
the benefits in terms of lowering of CHD risk. Furthermore, despite the lowered levels, 
this level of cholesterol in Singapore still represents one of the highest in the region as 
many of our neighbouring countries have levels well below 5.0 mmol/L. Secondly, whilst 
the risk from cholesterol may be decreasing, the risk of premature atherosclerosis is 
increasing from the high prevalence of diabetes mellitus, the majority of whom are type II 
diabetics with insulin resistance. Singapore now has the dubious honour of having one of 
the highest incidence of coronary heart disease amongst the East Asian countries 
(excluding the Indian Subcontinent). The National Health survey also revealed many 
other interesting facts, amongst which was the small number who exercised regularly 
(only 14%). Although we would like to believe that the prevalence of obesity has 
remained the same as in 1984 (4.3% in 1984 vs 4.4% in 1992), the truth is that this survey 
only measured body mass index as a marker of obesity but did not capture other 
indicators of central obesity such as waist to hip ratio or waist circumference, which 
many now believed to be a more important risk factor than just body mass index. Hence it 
was with this background in mind that a study was designed to examine coronary risk 
factors in a group of young, male Singaporeans without any history of coronary heart 
disease or diabetes mellitus.
7.2 Aims and objectives
The primary aim of the study was to determine the prevalence of the atherogenic 
lipoprotein phenotype and insulin resistance in a group of normal, healthy Singaporean 
males aged between 30 and 45 years old, with total cholesterol below 6.0 mmol/L. A 
secondary aim was to determine the relationship between the atherogenic lipoprotein 
phenotype and insulin resistance and whether the relationship between the two were 
similar to that demonstrated in the Scottish population. The age group of 30 to 45 years 
was chosen because it represented a young cohort most of whom should not have 
established CHD. The total cholesterol levels of 6.0 mmol/L was chosen as the entry 
criteria to exclude familial hypercholesterolaemia as well as the polygenic form of 
hypercholesterolaemia. With the high prevalence of diabetes mellitus and coronary heart 
disease in mind, it was felt important to determine what were the risk of coronary heart 
disease in a group of young male apart from high total or LDL cholesterol. This would 
also allow us to compare the group with an age matched group from the Scottish cohort. 
The working hypothesis was that the high prevalence of diabetes mellitus and/or insulin 
resistance would predispose to the triad of high plasma triglyceride, low HDL cholesterol 
and a predominance of dense, LDL particles.
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7.3 Subject recruitment
Subjects were recruited from various sources, including hospital staff and their friends. 
Advertisements were also placed in the local newsletters at various worksites, so as to 
ensure a selection of males that were representative of the Singaporean males in this age 
group. Those who had no previous history of hypercholesterolaemia or hypertension, but 
were found at entry into study with total cholesterol of more than 6.0 mmol/L or had 
blood pressure of greater than 160/95 mmHg were excluded. Diabetes mellitus were 
excluded by sampling the fasting blood sugar, insulin and glycosylated haemoglobin and 
in borderline cases an oral glucose tolerance test was conducted. Consent was obtained 
from all and the study was approved by the hospital ethical committee, as well as the 
Medical Research Council of the Ministry of Health, Singapore. This study was also 
sponsored by a grant from the National Medical Research Council of Singapore. Results 
were made known to volunteers through the mail and advice were given to all who 
participated, regarding risk factors. Those with high risks were advised to seek medical 
consultation, and all volunteers were given the option to speak to the principal 
investigator to clarify any doubts that may arise from the results.
7.4 Profile of the Young, Male Singaporean
A total of 141 young, male Singaporeans without any previous history of hypertension, 
diabetes mellitus or coronary heart disease or dyslipidaemia were finally recruited. There 
were divided into various ethnic groups with 74.5% Chinese, 9.9% Malays, 9.2% Indians 
and 5.7% others and these were all Eurasians. The ethnic mix in the study sample were 
fairly similar to the population distribution of ethnic groups with the exception of the 
Eurasians, who were over-sampled for purposes of statistical evaluation. Amongst this 
group of males, there were 29% smokers and 71% non-smokers and this was again fairly 
similar to the National Health survey which showed that between 18 to 20% of the 
population smoked. The mean age of this group was 38 years, the body mass index (BMI) 
23.9 kg/m2 and waist to hip ratio(WHR) 0.87. In the last National Health survey (1992), 
obesity was defined as BMI of greater than 30 kg/m2 whilst a BMI of between 25 and 30 
kg/m2 was considered overweight. Based on this classification, 2% of the study subjects 
were obese and 21% were overweight. This was again similar to the National survey with 
5% and 21% respectively. The average systolic and diastolic blood pressures were well 
within normal limits. The volunteers came from diverse social backgrounds, from manual 
labourers to professionals, as well as differing educational levels. Care was taken to 
ensure there was no over representation from any particular social class.
Table 31: Anthropometry and Blood pressure
Variable Mean±SD
Age in years 38±5.0
Body Mass index (kg/m2) 23.9±2.7
Waist to hip ratio 0.87±0.05
Systolic blood pressure (mmHg) 121±11
Diastolic blood pressure (mmHg) 80±9
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7.5 Lipid Profile and Insulin resistance
The mean cholesterol of the study sample was 5.3 mmol/L whilst the mean HDL 
cholesterol was 1.13 mmol/L. This values were consistent with the results of our National 
Health survey done in 1992, where the mean cholesterol and HDL cholesterol levels were 
5.3 and 1.1 mmol/L respectively. Since the lipid levels between the study sample and the 
population means were similar, it was fair to assume that the study sample was 
representative of the normal, young, male Singaporeans. It was surprising that the mean 
plasma triglyceride levels were higher than expected, although the level of 1.87 mmol/L 
were still within the normal reference range. Unfortunately, the National Health survey 
did not report triglyceride levels and does not provide for comparison of the study sample 
with the population means.
LDL-I levels were lower than that observed in the Scottish population whilst the LDL-III 
levels were higher. The mean LDL-III concentration of the study sample was 97.5 mg 
lipoprotein/ dL plasma, was very close to the level of 100 mg/dL, at which increased risk 
of atherogenesis is believed to occur. It was even more remarkable that amongst this 
group of normal males, 54% had LDL-III levels above 100 mg lipoproteins/dL plasma. 
The mean fasting glucose of 5.15 mmol/L and fasting insulin of 10.11 mU/L were 
unremarkable. However, the insulin resistance (IR) as calculated from the Homeostasis 
Model assessment appeared to be high, with mean levels of 2.38. This may not be 
surprising considering the high prevalence of diabetes mellitus in the Singapore 
population. In the Singapore study, three fasting samples of glucose and insulin were 
taken over a 15 minute period and the average of the three readings were used in the 
calculation of insulin resistance. This may be a better reflection of insulin resistance than 
either glucose or insulin alone.
Table 32: Lipid profile and markers of insulin resistance
Variable Mean±sem
Total cholesterol(mmol/L) 5.3±0.1
Plasma triglyceride (mmol/L) 1.87±0.09
HDL cholesterol (mmol/L) 1.13±0.02
LDL cholesterol (mmol/L) 3.5±0.11
Apo A (g/L) 1.42±0.02
Apo B (g/L) 1.23±0.02
Lp (a) (mg/dL) 17.3±1.45
LDL-I (mg/dl) 32.0±3.0
LDL-II (mg/dL) 126.1±5.9
LDL-III (mg/dL) 97.9±7.4
Fasting glucose (mmol/L) 5.15±0.05
Fasting insulin (mU/L) 10.11 ±0.92
IR 2.38±0.25
HDL; high density lipoprotein, LDL; low density lipoprotein, IR; Insulin resistance
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7.6 Factors predicting plasma lipids
In univariate analysis, plasma triglyceride, WHR, waist, IR and age exhibited significant 
correlation with total cholesterol. In general linear model, only triglyceride and waist to 
hip ratio remained significant predictors of cholesterol together accounting for almost 
17% of the variability. For plasma triglyceride, there were significant correlations with 
total cholesterol, HDL cholesterol, BMI, WHR and waist. Using the general linear model 
involving all these factors, only cholesterol and HDL remained significant predictors, and 
together accounted for 23% of variability in plasma triglyceride levels. As for HDL, there 
were significant correlations with triglyceride, BMI, WHR and waist. In the general linear 
model, only plasma triglyceride remained as a significant predictor of HDL cholesterol 
levels. Apart from the significant univariate correlation with total cholesterol, it was 
surprising that IR did not show any correlation with the other lipid levels.
Table 33: Predictors of Lipids
Variable Cholesterol Triglyceride HDL
Uni GLM Uni GLM Uni GLM
r2 r2 r2 r2 r2 r2
Choi - - 13.4* 9.6* 0.2 2.2
TG 13.4* 11.3* - - 28.9* 15.5*
HDL 2.2 0.3 28.9* 13.7* - -
BMI 1.0 0.3 3.9J 0.1 19.6* 0.9
WHR 26.2* 5.4* 6.21* 1.0 5.4t 0.1
Waist 59.6* 0.1 5.7* 1.1 14.4* 0.7
IR 3.2J 0.02 2.1 0.4 1.1 0.1
Age 8.0| 0.3 2.2 0.7 0 0.1
BMI, body mass index; WHR, waist/hip ratio; HDL-C, high density lipoprotein-cholesterol; Choi, 
cholesterol; TG, triglyceride; IR, Insulin resistance
* PO.OOl, t  PO.01, t  P<0.05 refer to the significance of the association r^ (correlation coefficient 
squared) determined by linear regression in univariate analysis or by a multivariate analysis of variance 
General Linear Model including all of the tabled parameters.
7.7 Predictors of LDL Subfractions
The factors predicting LDL subtractions (Table 34 and 35) were next explored to 
determine if the relationship with the various lipids and anthropometric factors were 
similar to that observed in the Scottish population. Plasma triglyceride had a strong, 
negative correlation with LDL-I subtractions whilst HDL had a strong positive 
correlation. The other factor with significant negative, univariate correlation with LDL-I 
was BMI. In multiple regression using the general linear model, only plasma triglyceride 
and total cholesterol remained as significant predictors of LDL-I. Together, these 
accounted for 23% of the variability in LDL-I levels. There were significant correlations 
of triglyceride, cholesterol, HDL cholesterol, BMI and WHR with LDL-III levels. In the 
multiple regression using the general linear model, only three factors remained significant 
and these were triglyceride, total cholesterol and insulin resistance. Together they 
accounted for almost 17% of the variability of LDL-III.
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In detailed analysis of the relationship of the LDL subfractions with plasma triglyceride, it 
was interesting to note that there were differences in this relationship between the 
Scottish population and the Singapore population. LDL-I levels showed a significant 
negative relationship with plasma triglyceride across the normal ranges of triglyceride 
levels (Fig 26). This was similar to that seen in the Scottish population and the fall off in 
LDL-I was similar in both population. The mean LDL-I fell from about 50 mg/dL at 
plasma triglyceride of 0.5 mmol/L to 20 mg/dL at a plasma triglyceride of 2.3 mmol/L, 
similar to that seen in the Scottish population, where the mean LDL-I fell from 100 
mg/dL to 40 mg/dL over the same triglyceride range. However, it was obvious that over 
the same plasma triglyceride range, the Singapore males had lower LDL-I. The difference 
could be due to gender, since the Scottish study included both males and females, and 
females have higher levels of LDL-I. In a sub-analysis of the Scottish study, the mean 
LDL-I levels of age-matched Scottish males was 60 mg/dL versus 32 mg/dL in the 
Singaporean males. When the relationship of LDL-II with plasma triglyceride were 
examined, there were distinct differences. There was a strong negative relationship with 
plasma triglyceride demonstrated across the range of normal triglyceride levels, 
r2=24.8%, pO.001. Unlike the group of Scottish males which showed a bimodal 
relationship, the Singapore males showed only a negative relationship with plasma 
triglyceride (Fig 27). In the Scottish population, there was a positive association of LDL- 
II with plasma triglyceride when the latter was less than 1.3 mmol/L and a negative 
relationship at higher plasma triglyceride levels. The relationship of LDL-III with plasma 
triglyceride showed a strong positive correlation across the range of plasma triglyceride 
levels, similar to that demonstrated in the Scottish study (Fig 28). The relationship of 
LDL-III with plasma triglyceride at level below 1.5 mmol/L had a regression equation of 
LDL-III = 1.8 + 41.1TG, and r*= 12.6, p<0.01, whilst at triglyceride levels above 1.5 
mmol/L, the relationship was represented by the equation LDL-III = 41.6 + 4.4TG, with r2 
=18.4% and p<0.001. A comparison of the slopes of the two equation using pairwise 
slopes and non parametric testing (Mann Whitney), showed significant difference in 
gradient of slopes (pO.OOl).
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Table 34: Predictors of LDL-I
Variable Univariate: r2(%) GLM: S ( % )
Triglyceride 25.9 (-)* 16.9*
Total cholesterol 0 5.9f
HDL cholesterol 20.2(+)* 1.4
Body mass index 5.0(-)t 0.1
Waist to hip ratio 0.4(-) 0.02
Insulin resistance 0.6(0 0.02
Table 35: Predictors of LDL-III
Variable Univariate: r2 (%) GLM: r2 (%)
Triglyceride 51.2(+)* 14.0*
Total cholesterol 25.4(+)* 1.2f
HDL cholesterol 21.9(-)* 1.2
Body mass index 7.8(+)t 0.3
Waist to hip ratio 10.0(+)* 0.2
Insulin resistance o.i (+) 1.5t
¥ P<0.001, T PO .O l, I P<0.05 refer to the significance of the association x2- (correlation coefficient 
squared) determined by linear regression in univariate analysis or by a multivariate analysis of variance 
General Linear Model including all of the tabled parameters. The sign refer to the direction of the 
relationship.
7.8 Differences between the Ethnic groups 
Differences in Anthropometry
The different ethnic groups were well matched in terms of the various parameters of 
anthropometry. None of the parameters used as indicators of obesity showed any 
significant differences between the ethnic groups. However, it would appear that Indians 
and Malays tended to be more obese than the Chinese or Others, who were predominantly 
Eurasians. The Indians were also more centrally obese than the other races. These results 
were again consistent with our National Health survey (1992), which showed that the 
Indians had the highest proportion of obese persons followed by the Malays. This is 
further support that the sample of males in this study is representative of the population of 
Singapore.
Table 36: Ethnic differences in anthropometry
Variable
(mean±sem)
Chinese Malays Indians Others
BMI(kg/m2) 23.5±0.3 25.1±0.6 25.4±0.5 23.8±0.7
WHR 0.87±0.00 0.85±0.01 0.88±0.01 0.87±0.02
Waist(cm) 83.2±0.8 . 84.3±2.1 88.7±2.0 82.7±3.6
Differences in Plasma Lipids and LDL Subfractions
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The different ethnic groups showed differences in their plasma lipids and LDL 
subtractions (Table 37 and 38). The mean cholesterol levels were highest in the Malays 
followed by the Indians, the Chinese and Others in descending order. The differences 
however, did not achieve statistical significance. The plasma triglyceride however, 
showed significant ethnic differences. Malays had the highest levels of triglyceride 
followed by Chinese and then the Indians. The Other races had the lowest level of 
triglyceride and there were significant differences between them and all the other ethnic 
groups. The levels of triglyceride found in the Other ethnic groups were similar to those 
in the Scottish male population. This was interesting as all the subjects in this group were 
Eurasians and were of mixed descent with the majority having some European ancestry. 
The HDL cholesterol demonstrated the reverse pattern, with the Malays having the lowest 
mean levels whilst the Chinese and Others had the highest levels. The differences in HDL 
cholesterol concentrations between the highest group, the Chinese, and the lowest group, 
the Malays, were statistically significant.
The LDL subtraction distribution were next explored and here again, there were 
significant ethnic differences. The Chinese males had the highest plasma concentrations 
of buoyant LDL-I subtractions whilst the Indians had the lowest levels. However, none of 
the differences achieved statistical significance. The plasma concentrations of LDL-I in 
the Chinese and the Others were similar. The levels of LDL-II did not pattern those seen 
in plasma lipids or LDL-I concentrations. LDL-II plasma concentrations were highest in 
the Others, followed by the Malays, Chinese and Indians. The significance of this is 
unclear. Concentrations of LDL-III were highest in the Malays. The Indians had the next 
highest mean concentrations and it was interesting to note that both the Malays and 
Indians had levels above 100 mg lipoproteins/dL plasma. The Chinese had concentration 
of LDL-III which were lower than the Indians although they had higher plasma 
triglyceride levels. The Others had the lowest mean concentrations of LDL-III, and again 
it was interesting to note that the levels in this group of normal males were similar to that 
demonstrated in the Scottish males. The difference between the highest group, the 
Malays, and the lowest group, the Others, achieved statistical significance.
Table 37: Ethnic differences in plasma lipids
Variable
(mean±sem)
Chinese Malays Indians Others
Chol(mmol/L) 5.28±0.1 5.44±0.2 5.35±0.3 5.18±0.3
TG(mmol/L) 1.92±0.1°t 2.04±0.2dt 1.67±0.2eJ 1.17±0.2
HDL(mmol/L) 1.16±0.02af 0.98±0.04 1.05±0.14 1.16±0.08
a: difference between Chinese and Malays, b: difference between Chinese and Indians, c: difference 
between Chinese and Others, d: difference between Malays and Others, e: difference between Indians and 
others
*p<0.001, tp <0.01, tp<0.05, refers to the significance of difference between the ethnic groups by student’s 
unpaired t-test
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Table 38: Ethnic differences in LDL Subfractions
Variable
(mean±sem)
Chinese Malays Indians Others
LDL-I(mg/dL) 34.2±3.7 25.0±8.0 20.9±5.7 32.4±7.2
LDL-II(mg/dL) 123.4±7.1 134.7±1.9 115.4±11.0 156.3±19.0
LDL-III(mg/dL) 96.3±8.7 124.8±24.0dt 100.5±25.0 64.3±16.0
a: difference between Chinese and Malays, b: difference between Chinese and Indians, c: difference 
between Chinese and Others, d: difference between Malays and Others, e: difference between Indians and 
others
*p<0.001, tp<0.01, }p<0.05, refers to the significance of difference between the ethnic groups by student’s 
unpaired t-test
Differences in Insulin Resistance
In Singapore, there is a high prevalence of diabetes mellitus, particularly non-insulin 
dependent diabetes mellitus. However, we also know that the prevalence of diabetes 
mellitus amongst the different ethnic groups differ significantly, and hence it would be 
interesting to explore the ethnic difference in insulin resistance amongst the study groups. 
When the average fasting insulin were examined, the Malays and Indians had the highest 
levels followed by the Chinese. The Others had levels which were significantly lower 
when compared to the other 3 ethnic groups. The average fasting glucose levels did not 
demonstrate significant difference amongst the ethnic groups but the differences were 
similar to that noted in the fasting insulin. The IR, as calculated by the HOMA model, 
showed that Indians again had the highest level of insulin resistance, followed by the 
Malays and then the Chinese. The difference in IR between the Others and the 3 ethnic 
groups were statistically significant. However, there were no statistical difference in IR 
between the Chinese, Indians and Malays, although the trends were noted. The results 
showed that the Indians had the highest prevalence of insulin resistance followed by the 
Malays. The Others had the lowest prevalence of insulin resistance. Results of this study 
was again consistent with the National Health survey (1992), where the prevalence of 
diabetes mellitus was highest in the Indians and then the Malays, with the Chinese a close 
third. It was suggestive that the prevalence of insulin resistance could be high in the 
Asian population because of genetic influence and hence the difference between the 
Others, with their European ancestry and the other 3 ethnic groups of Asian descent.
The mean IR for the whole study group was 2.38. The group was then divided into 2 
groups with one above the mean and the other group below the mean IR (Table 40). It 
became obvious that the group with high IR had significantly higher plasma triglyceride, 
lower HDL cholesterol, and higher levels of LDL-III. The insulin resistant group were 
also more obese as indicated by the higher BMI, as well as being more centrally obese, 
reflected by the WHR. This group with insulin resistant thus had the classical features of 
insulin resistance, represented by the more atherogenic lipid and lipoprotein profile as 
well as central obesity. This is further support of the close relationship between the 
insulin resistance syndrome and the atherogenic lipoprotein phenotype.
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Table 39: Ethnic differences in Insulin Resistance
Variable
(mean±sem)
Chinese Malays Indians Others
Insulin(mU/L) 10.2±1.2CJ 10.7±1.3dt 10.6±1.7eJ 6.8±0.9
Glucose(mmol/L) 5.14±0.05 5.17±0.12 5.38±0.41 4:89±0.11
IR 2.41±0.3ct 2.48±0.3'*t 2.60±0.5eJ 1.48±0.2
a: difference between Chinese and Malays, b: difference between Chinese and Indians, c: difference 
between Chinese and Others, d: difference between Malays and Others, e: difference between Indians and 
others
*p<0.001, tp<0.01, tp<0.05, refers to the significance of difference between the ethnic groups by student’s 
unpaired t-test. IR: Insulin resistance as derived by Homeostasis Model assessment.
Table 40: Difference between the Insulin Resistant and Non Insulin Resistant
Variable Non-insulin resistant 
(mean±sem)
Insulin resistant 
(mean±sem)
Cholesterol(mmol/L) 5.22±0.1 5.38±0.1
T riglyceride(mmol/L) 1.66±0.12 2.23±0.16f
HDL (mmol/L) 1.18±0.03 1.07±0.04{
LDL-I(mg/dL) 34.2±3.4 27.6±5.7
LDL-II(mg/dL) 136.9±6.9 105.7±11.0J
LDL-III(mg/dL) 84.5±8.0 123.3±14.0t
WHR 0.86±0.01 0.89±0.01f
BMI(kg/m2) 23.0±0.3 25.4±0.4*
*p<0.001, tp<0.01, tp<0.05, refers to the significance of difference between the insulin resistant and non 
insulin resistant groups by student’s unpaired t-test
WHR; Waist to hip ratio; BMI; body mass index, LDL; low density lipoprotein
7.9 Discussion
The study was carried out in a group of young, male, Singaporean aged between 30 to 45 
years old. The characteristics of this sampled group suggest that they were representative 
of the males in Singapore. The distribution of the various ethnic groups, the proportion of 
smokers as well as proportion of obese individuals were similar to the general population. 
The mean cholesterol and HDL cholesterol levels were also similar to the population 
means. As the other ethnic groups (apart from the Chinese, Malays and Indians) 
represented only 1% of the population, these were over-sampled in our study so as to 
enable ethnic differences to be studied. It was thus reasonable to assume that the sampled 
group was representative of the young male population in Singapore. The ethnic 
differences in BMI were similar to that found in the National Health survey, with Indian 
males being more obese and particularly that of central obesity. The problems of obesity 
amongst the Indians and Malays is strongly linked to their dietary habits. A typical Indian 
diet or Malay diet, in Singapore would consists of rice with generous servings of deep 
fried fish or meat cooked in coconut milk based curry. Often the rice is not steamed but 
also fried or cooked in oil with herbal flavourings. This is unlike the Chinese diet which 
consists mainly of steamed rice and much lesser amounts of curry and deep fried foods.
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Hence it is not surprising to find a greater proportion of obese individuals amongst the 
Indians and Malays. However, the difference between the Chinese and the other races 
may not persist, as many Chinese are now abandoning their traditional carbohydrate 
based diet in preference for more meat and oil based diet. This is reflected in the growing 
problem of obesity amongst schoolchildren in Singapore.
The plasma lipids in the study subjects were again similar to the population means. In our 
subjects, the mean cholesterol level was 5.3 mmol/L, consistent with the findings of the 
National survey. Although this level of total cholesterol is similar to that found amongst 
Scottish male population, it is higher than in the United States and represents one of the 
highest levels in this region. The HDL cholesterol is again similar to that in the Scottish 
cohort but what was surprising was the high levels of fasting plasma triglyceride. The 
mean levels in our study was 1.87 mmol/L whilst the Scottish cohort had a mean plasma 
triglyceride level of only 1.2 mmol/L. The high levels of triglyceride may be an indication 
of the carbohydrate-based and oil-based diet or it could be an indication of underlying 
insulin resistance. When the lipid levels were analysed by ethnic groups, there were again 
differences. The Malays had the most atherogenic profile as the mean cholesterol and 
triglyceride levels were highest, whilst the HDL cholesterol levels were the lowest. The 
Indians had similar lipid profile and were also subjected to much higher coronary risk 
compared to the Chinese and Others. The adverse coronary profile in the Malays and 
Indians were further aggravated by the fact that they were generally more obese and 
particularly central obesity. What was particularly interesting was the very significant 
difference in lipid profile between the Eurasians (classified as others) and the other 3 
major ethnic groups. This was despite the fact that the Eurasians have diet which are 
equally rich in oil and carbohydrate. Many Eurasians have Indian ancestry (apart from the 
European ancestry) and also have diets similar to the Indian community, and it was thus 
surprising to find that they had levels which were significantly lower than that seen in the 
Indians. However, it can be argued that because of the small sample size and the over- 
representation of the Eurasians in this study, the difference could simply be a sampling 
error. However, the differences in the lipoprotein subfraction distribution lends support to 
the fact that this difference may be real and not simply a sampling error.
Data in table 34 and 35 showed the various predictors of LDL-I and LDL-III respectively. 
The plasma triglyceride, HDL cholesterol and BMI all showed significant univariate 
correlation with LDL-I concentration. In multivariate analysis, only plasma triglyceride 
and cholesterol remained significant predictors and together predicted 23% of variability 
in LDL-I concentrations. In LDL-III, the factors which had significant univariate 
correlation were plasma triglyceride, cholesterol, WHR, BMI as well as waist 
circumference. In the multivariate analysis, the plasma triglyceride, cholesterol as well as 
IR remained as significant predictors of the variability in LDL-III. Together, they 
accounted for about 17% of the variability of LDL-III. There were differences between 
the different ethnic groups. The Indians and the Malays had higher plasma concentrations 
of LDL-III and lower levels of the buoyant LDL-I. It was interesting to note that in this 
group of ‘normal’ males, the Indians and Malay had mean concentration of LDL-III 
which exceeded 100 mg/dL. Although the Chinese males had lower LDL-III 
concentrations, than either the Malay or Indians, the mean concentration of LDL-III was
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very close to 100 mg/dL. There were no significant difference in LDL-III concentrations 
amongst the 3 major ethnic group. In contrast, the Eurasians had mean LDL-III 
concentrations which were significantly lower than the other 3 ethnic groups. In fact, this 
group had plasma concentrations of LDL-III which were similar to that in the Scottish 
male cohorts.
The relationship of the LDL subfractions with plasma triglyceride across the normal 
range were explored. As the plasma triglyceride increases, the concentration of LDL-I fell 
as demonstrated by Figure 26. This relationship of plasma triglyceride with LDL-I is 
similar to that observed in the Scottish population except that the gradient of slope was 
much steeper. In the relationship of plasma triglyceride with LDL-II, there were 
significant difference from the Scottish cohort. Unlike the bimodal response seen in 
Scottish males, the Singapore males showed a strong negative correlation with plasma 
triglyceride (fig 27). Finally, the LDL-III relationship with plasma triglyceride were noted 
to be similar to that seen in the Scottish cohort, demonstrating a sharper increase in LDL- 
III levels when triglyceride exceeded 1.5 mmol/L. The difference in LDL subffaction 
relationship with plasma triglyceride between the Scottish cohort and the Singapore 
cohort is presently unclear but may be a reflection of the higher prevalence of insulin 
resistance and/or atherogenic lipoprotein phenotype in our population.
As mentioned in the preceding paragraphs, most of those classified under others in our 
population survey would be Eurasians and in this present study, all were Eurasians. The 
Eurasians are of mixed descent but many have European ancestry together with some 
Indian ancestry. There appears to be a clear distinction between those who are 
predominantly of Asian origin ie. Chinese, Malays and Indians, and those who have some 
European descent. It can be seen in the differences in plasma triglyceride, HDL 
cholesterol and LDL subfractions between the Eurasians and the 3 ethnic groups. Austin 
et al had previously suggested that the atherogenic lipoprotein phenotype occurs in about 
30% of the population, 3 but if this sampled group were representative of the general 
population, then the prevalence of the ALP may be much higher in Singapore. This study 
found that 54% of the males in this study had LDL-III above 100 mg lipoprotein/dL 
plasma, if all ethnic groups were considered together.
The markers of insulin resistance in this Singapore study were similar to those used in the 
Scottish cohort, with the exception that three fasting samples of glucose and insulin were 
taken to minimise the limitations of the use of HOMA model, as mentioned previously in 
chapter 4. There are no normal values for fasting insulin in our population but the mean 
fasting insulin in this group of males was noted to be higher than the Scottish cohort. 
Likewise, the IR, calculated from the HOMA model appeared to be higher than the 
Scottish cohort. This is not surprising, since insulin resistance is closely associated with 
diabetes mellitus, especially type II non-insulin dependent diabetes mellitus. The ethnic 
groups again showed differences with regards to the fasting insulin and IR. Indians had 
the highest levels of IR, followed by the Malays and then the Chinese. Likewise, the 
fasting insulin was highest in both Malays and Indians with the Chinese a close third. 
What is interesting is the clear distinction between these three ethnic groups and the 
Eurasians. If the presence of diabetes mellitus and insulin resistance has a strong genetic 
component, then it would not be surprising to find the high levels of insulin resistance
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amongst individuals of Asian origin. This pattern of insulin resistance is similar to the 
prevalence of diabetes mellitus in Singapore, which is highest amongst the Indians 
(12.8%), followed by Malays (9.3%) and then the Chinese (8.0%).
The results in table 40 summarises the characteristics of the insulin resistant individual. 
Such were more likely to have high plasma triglyceride, low HDL cholesterol. They 
would also have lower levels of buoyant LDL-I and LDL-II whilst having significantly 
higher concentration of dense, LDL-III. They are also more likely to be obese, especially 
central obesity. The Singapore study also confirms the studies done in Scotland showing 
the close relationship between the insulin resistance syndrome and the atherogenic 
lipoprotein phenotype. It also demonstrated significant ethnic difference in lipid and 
lipoprotein subfraction profiles in population living under similar social environment. 
The ethnic difference may be the result of a combination of dietary and genetic influence.
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Chapter 8 Conclusions
Give instruction to a wise man, and he will still be wiser; Teach a just man, and he will increase in 
learning. Proverbs 9:9
8.1 Introduction
The aggregation of coronary artery disease (CAD) in families had been reported by 
several authors but the mechanisms of familial transmission of CAD are not fully
238understood. Inherited CHD is most apparent in families of young patients. Studies in
239twins have also suggested that the genetic component is stronger in early-onset than in 
late onset CAD. Hence associations and mechanisms for familial transmission are 
probably more developed in prematurelv developed CAD. For example the recent 
European Atherosclerosis Study (EARS)2 0 showed that male offsprings of patient with 
premature CAD manifested some of the classical risk factors linked to CHD. Hence the 
study (chapter 5) carried out in Scotland sought to address the issue of environmental 
versus genetic factors in the manifestation of coronary risk factors in families with 
patients having premature atherosclerosis. The exclusion of probands with total 
cholesterol of more than 7.0 mmol/L was designed to exclude families with familial 
hypercholesterolaemia. There is no doubt that cholesterol, especially LDL cholesterol 
plays a major role in the atherosclerotic process but the family studies’ objectives were to 
assess the impact of other CAD risks apart from hypercholesterolaemia.
The link between the insulin resistance syndrome (IRS) and the atherogenic lipoprotein 
phenotype (ALP) had been alluded to by Reaven and Krauss and this link was explored 
further throughout this thesis. Both conditions increases susceptibility to premature 
atherosclerosis and it was obvious that the links between the two needed further study. 
This was particularly important in Singapore, where 8.6% of the resident population 
suffer from diabetes mellitus and we also have one of the highest incidence of myocardial 
infarction rates in the region. Our last National Health survey on more than 5000 males 
and females, showed that the prevalence of diabetes mellitus had almost doubled over the 
last 10 years. Although the mean cholesterol levels, had fallen from 5.8 mmol/L to 5.3 
mmol/L, we still rank as one of the highest in the region. The Singapore myocardial 
infarct registry had also shown that the incidence rates for acute myocardial infarction had 
remained at about 76 per 100,000 Singaporeans aged 20 to 64 years from the mid eighties 
to the present time. This was alarming because the reduction in cholesterol had not 
translated into a reduction in CAD and I suspect it was partly because of the dramatic rise 
in diabetes mellitus and its accompanying dyslipidaemia. It was thus appropriate to study 
a group of normal Singapore males to determine the prevalence of insulin resistance and 
ALP in such a cohort. The prevalence of diabetes in Singapore is about four times that in 
Scotland and this would certainly have an impact on both insulin resistance and the ALP. 
Hitherto, we have been unable to diagnose the atherogenic lipoprotein phenotype in 
Singapore because of limitations of laboratory support in determining LDL subfractions. 
With the setup and transfer of technology from Glasgow to Singapore, we were able to 
fractionate the LDL by the density gradient ultracentrifugation and this allowed us to 
profile the ALP and document the prevalence of such profile in our local population. Of 
particular interest was the comparison between matched population of Scottish males and 
Singapore males as discussed further in this chapter. If the prevalence of the ALP is
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higher in a group of Singapore males as compared to the Scottish cohort, it would lend 
further support to the hypothesis of a link between the insulin resistance syndrome and 
the atherogenic lipoprotein phenotype.
This thesis also explored the link between insulin resistance and the triglyceride 
metabolic capacity through the oral fat meal challenge. The majority of a person’s time is 
spent in the post-prandial period, during which time the vessel walls are exposed to post­
prandial lipoproteins which have been suggested to be particularly atherogenic.241 The 
ability to handle triglyceride would be a strong determinant of the HDL cholesterol levels 
and the individual with IRS would often have low HDL cholesterol and high triglyceride, 
suggesting impaired triglyceride metabolic capacity.
8.2 Genetic Factors versus Lifestyle Factors
The statistical analysis in family studies posed a great challenge as there were no easy 
methods available. It was also difficult to tease apart the impact of genetic factors, 
environmental and lifestyle factors as they often occur together in families. Even studies 
on obesity in families have suggested that many members of obese families have similar 
eating habits and that could account for the obesity rather than genetic factors. From the 
study on families in chapter 5, it would appear that there are elements of both and it is 
likely that a combination of genetic factors and environmental influence determine 
susceptibility to premature atherosclerosis. Males from families with premature 
atherosclerosis were more likely to carry the ALP than the females, hence suggesting 
influence of gender on manifestations.of ALP. Austin et al suggested that the ALP is not 
manifested until adult life but we found that males below the age of 30 years in such 
families manifested the ALP. This highlights the importance of genetic influence on the 
appearance of ALP probably moderated by the plasma triglyceride as discussed in chapter
3.
Garrison et al242 suggested that environment was an important determinant of familial 
lipid relationships. They noted that the correlation of lipid levels in dizygotic twin pairs243 
was higher than the correlation which they observed in non-twin sibling pairs. This was 
attributed to the greater sharing of environment by members of dizygotic twin pairs than 
by members of non-twin sibling pairs. However arguments against this observation have 
suggested that methodological and/or seasonal factors could have explained the 
quantitative differences between the twin pair and sibling pair correlation. Others have 
examined lipid relationships of families residing in kibbutzim and the families showed 
little evidence of total cholesterol familial aggregation.244 Sosenko et al had shown that 
there were greater correlation of total cholesterol and HDL cholesterol levels between 
child and mother than between child and father, and suggested that this was due to a 
greater sharing of environment between child and mother than between child and 
father.245 Obviously, predisposition to premature atherosclerosis is both a combination of 
inherited risk factors as well as environmental factors.
I sought to develop a risk scoring based on a combination of both lipid and lipoprotein 
associated factors as well as environmental influence, in particular smoking habits, to 
profile the families at risk. The data showed that family members of patients with
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premature atherosclerosis were more likely to manifest at least 2 or more risk factors 
whilst those without family history of premature atherosclerosis had 1 or no risk factors. 
The use of this risk scoring appeared to distinguish between family members at risk and 
those who did not have family history of premature atherosclerosis. There was an 
aggregation of CAD risk which were determined by genetic as well as environmental 
influence, in such families with premature atherosclerosis. The social characteristics 
which distinguished families with premature atherosclerosis from the control group was 
the smoking habit. Family members were more likely to be smokers and were also more 
likely to be heavier smokers. Perhaps, it represents a learned habit, as children learn from 
their parents at a young age the smoking habits. Children brought up in families where the 
parents smoke, will accept smoking as part of the norms of life. Such social habits may be 
appropriately considered as ‘inherited’ social traits. Taken together, the results are 
compatible with the hypothesis that occurrence of CAD requires an interaction of both 
unfavourable genetic and environmental influences. Thus in families who do not have 
familial hypercholesterolaemia but have premature atherosclerosis, a clustering of risk 
factors are likely. These factors include higher plasma triglyceride, low HDL cholesterol, 
higher VLDLi subtractions and LDL-III particles, some of which have a genetic element. 
The presence of insulin resistance is also closely associated and it is likely that the risk 
factors act synergistically, contributing to the overall risks for premature atherosclerosis.
8.3 Modification of Risk Factors in Families with CHD
In the counselling of families with premature atherosclerosis, it became apparent that it 
was not possible to separate the genetic factors from the environmental influence. There 
are risk factors such as the ALP and insulin resistance, which are inherited but these are 
also modified by environmental influence. Furthermore, many family members have 
similar dietary patterns and in counselling at risk individuals about dietary change, I have 
found that it is ineffective to counsel them apart from the rest of the family. Pressures 
from within the family during meal times made it impossible for such individuals to 
adhere to any form of dietary plans. It was far more effective to counsel family units 
rather than individuals, particularly when we are dealing with high risk families. When 
the family changes its dietary habits, the patients are subjected to less temptations. 
Furthermore, family members can no longer have a detached attitude because they were 
able to see for themselves the risks that runs in their family, and this encourages all to 
change. This was particularly effective if each one had a set of results regarding his or her 
own coronary risks. It was also prudent to develop in the children at a young age, healthy 
eating habits rather than try to change their habits when it had been established. As 
mentioned previously, the smoking habits of such families have stood out as important 
socio-economic factors. The smoking habit is a learned behaviour and may even be 
considered an “inherited” trait. Again if patients are to succeed in quitting the smoking 
habit, the pressures from smokers within the family must be addressed. The benefit of 
cessation of smoking habits within the family unit cannot be understated. The support 
from family members would go a long way in helping “at risk” individual change their 
habits and lifestyle.
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8.4 The Role of Plasma Triglyceride on Lipoprotein metabolism
There has been a lack of consensus on the role of triglyceride as an independent risk 
factor for CAD. The Paris Prospective study246 concluded that when interaction of 
cholesterol and triglyceride are considered, triglycerides are an independent risk factor. 
The Framingham study247 concluded that elevated triglyceride levels were a highly 
significant independent risk factor for CAD in women. Most agree that the lack of 
consensus may be related to flaws in the currently available statistical approaches to 
analysing triglyceride levels. The identification of subclasses of HDL and LDL particles, 
may lead to identification of more precise markers for possible underlying mechanisms 
related to risk of cardiovascular disease. In hypertriglyceridaemic subjects, the structure 
of LDL and HDL are altered by processes of lipid exchange (cholesteryl ester for 
triglyceride) and lipolysis. The resultant LDL and HDL are small, dense with the former 
becoming more atherogenic and the latter lower in concentration and less 
cardioprotective. Furthermore, there could be reduced clearance of VLDL particles, 
resulting in products of incomplete delipidization ie. VLDL remnants, which are 
potentially atherogenic. The results shown in chapter 3, Table 8 further supports the 
impact of hypertriglyceridaemia on lipoprotein metabolism, especially on the subtraction 
distribution. The group with triglyceride above 1.5 mmol/L had significantly higher levels 
of VLDLi and lower levels HDL2. The decreased amounts of HDL2, a particle which 
remains in the circulation for a longer period and is more efficient as acceptor of tissue 
cholesterol, means that the group with higher plasma triglyceride had a higher atherogenic 
potential. Similarly, the presence of a greater amount of LDL-III, which is more 
susceptible to oxidation and uptake by macrophages, translates into a greater atherogenic 
potential.
The risk of CAD in hypertriglyceridaemia may also depend on the presence of other risk 
factors such as hypertension, obesity, diabetes and cigarette smoking. It is known that 
subjects with isolated hypertriglyceridaemia have only limited increase in CAD risk. In 
contrast, the risks of CAD is considerably increased if the HDL cholesterol content is 
reduced and presumably replaced in part by triglyceride. Thus when 
hypertriglyceridaemia occurs in the presence of high cholesterol in familial combined 
hyperlipidaemia, the risk is particularly high.
The thesis also explored the significance of the alimentary challenge in predicting an 
individual’s triglyceride metabolic capacity. It had been argued that the fasting plasma 
triglyceride may not be truly reflective of the totality triglyceride metabolism. Studies 
have shown that patients with CAD have an exaggerated triglyceride response after an 
oral fat meal challenge and the hypertriglyceridaemia remains for a longer period of time
tf» tlisuch that there is greatest distinction between normals and CAD patients at the 6 to 12 
hour post meal. The ability to handle the fat meal is dependent on the lipoprotein lipase 
activity, and this had been shown to be subjected to hormonal influence such as insulin. 
The study on CAD proven men showed that pre-heparin LPL activity were decreased 
when compared to age-matched controls, and this may be related to the exaggerated 
triglyceride response post meal. The CAD patients were also insulin resistant and 
exhibited a hyperinsulinaemic response both to the standardised fat meal as well as to the 
modified glucose meal. The free fatty acid levels in CAD patients were higher than the
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normals during the fat meal and yet these had a lower preheparin LPL level, suggesting 
that other mechanisms apart from the free fatty acid, may be responsible for the rise in 
LPL during a fat meal challenge. A resistance to the hormonal influence of insulin on 
LPL activity in CAD patients may be one possible mechanism for the observed difference 
in LPL levels. However, the significance of impaired preheparin LPL activity is unclear at 
the present moment as there are no correlation with postheparin LPL activity nor to the 
adipose and skeletal muscle LPL activity.
8.5 Comparing the Singapore males with the Scottish males
As the results of the study in Singapore were completed, it became increasingly apparent 
that there were significant differences between the Scottish male population and the 
Singapore males. These differences are summarised in table 41. A total of 141 
Singaporean males and 65 Scottish males matched for age, were compared for differences 
in the lipids, lipoproteins and carbohydrate metabolism. Bearing in mind that the mean 
cholesterol levels for the Scottish population is about 6.2 mmol/L, it was not surprising 
that the cholesterol levels' in the Scottish cohorts were significantly higher than those in 
the Singapore counterparts. However, what was remarkable were the differences in the 
other lipid and lipoprotein parameters. The Singapore males had significantly higher 
levels of plasma triglyceride whilst manifesting significantly lower levels of HDL 
cholesterol. There were also significant differences in the LDL subfraction patterns. The 
Scottish cohorts had significantly higher levels of buoyant LDL-I, as well as LDL-II 
whilst the Singapore males had significantly higher levels of the atherogenic LDL-III. 
There were also ethnic differences in the concentrations of LDL-III as those of Asian 
descent had levels of LDL-III close to or greater than 100 mg lipoprotein/ dL plasma, 
whilst the group with some European ancestry i.e. the Eurasians, had levels which were 
similar to that seen in the Scottish cohort. Taken together, the higher plasma triglyceride, 
lower HDL cholesterol as well as higher levels of LDL-III, it was obvious that the 
Singapore males manifested the atherogenic lipoprotein phenotype with greater frequency 
than its Scottish counterpart. More than half of the Singapore subjects had concentrations 
of LDL-III above 100 mg lipoprotein/ dL plasma.
The differences between the Singapore males and the Scottish males could be attributed 
to genetic influence, since both the insulin resistance and ALP are thought to be inherited, 
perhaps modified by other environmental factors. Given the high prevalence of diabetes 
mellitus in Singapore, it is reasonable to assume that there is a high gene pool of insulin 
resistance and hence the equally high prevalence of the atherogenic lipoprotein 
phenotype. Others may argue that the Singaporean males and the Scottish males have 
very different lifestyle and dietary habits and that alone may account for the difference, 
especially when the mean plasma triglyceride levels are high in the Singapore cohort. 
However, the ethnic differences in the Singapore study would lend further support to 
strength of the genetic influence, as the Eurasians, have similar lifestyle and dietary 
patterns to the typical Singaporean male but they have lipid and lipoprotein levels that 
were dramatically different. The data suggest that Eurasians in Singapore have lipid, LDL 
subfraction patterns and carbohydrate metabolism more akin to the Scottish population 
than the other ethnic groups in Singapore.
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The lack of any significant fall in CAD incidences in Singapore over the past 10 years 
may in part be attributed in part to the rise in diabetes mellitus, insulin resistance and 
perhaps the atherogenic lipoprotein phenotype. In the past, the traditional Asian diet and 
poverty may have prevented those of Asian descent from suffering the manifestations of 
diabetes mellitus, insulin resistance and the atherogenic lipoprotein phenotype. Today, 
with increasing affluence and changing lifestyle and dietary patterns, such protection is no 
longer in place in a population with high genetic susceptibility.
Table 41: Differences between the Singapore and Scottish males
Variable Singapore males 
(mean±sem)
Scottish males 
(mean±sem)
P
Cholesterol(mmol/L) 5.30±0.1 5.64±0.1 <0.05
T riglyceride(mmol/L) 1.87±0.1 1.32±0.1 <0.001
HDL-Chol(mmol/L) 1.13±0.02 1.21±0.03 <0.05
LDL-I(mg/dL) 31.9±3.0 67.2±4.6 <0.001
LDL-II(mg/dL) 126.1±5.9 187.5±8.4 <0.001
LDL-III(mg/dL) 97.9±7.4 69.6±8.5 <0.01
Fasting insulin(mU/L) 10.1±0.9 8.6±0.7 ns
Fasting glucose(mmol/L) 5.15±0.05 5.15±0.08 ns
Insulin resistance 2.38±0.3 1.96±0.2 ns
p value refers to the significance of difference between groups as determined by student’s unpaired t-test
8.7 The Metabolic Dyslipidaemic Syndrome
Many patients with coronary artery disease have more than one metabolic risk factor. This 
is not unexpected because obesity, hypertension, glucose intolerance and dylipidaemia are 
each very prevalent. However, such clustering of risk factors is greater than would be
248expected by chance. This has led to the hypothesis that these disorders may be 
pathophysiologically related.
The term insulin resistance had been originally and generally used to indicate impaired 
insulin action on glucose metabolism in skeletal muscle, adipose tissue, and the liver. 
However, the term is now more widely used to indicate abnormal insulin activation of 
other pathways such as antilipolysis, lipoprotein lipase activity, and hepatic lipoprotein 
metabolism.249 It is believed that insulin resistance increases the risk of CHD in non­
diabetic subjects partly from the concomitant dyslipidaemic state. Prevalence data suggest 
that up to 25% of the non-diabetic population may be characterised by a state of insulin 
resistance.13 However, we do not know whether this prevalence holds true in population 
with high prevalence of diabetes mellitus such as Singapore and Hong Kong. In a small 
study conducted previously, we have found that up to 40% of non-diabetic, non obese, 
young hypertensive males in Singapore had insulin resistance. The presence of the 
dense, LDL phenotype is associated with hypertriglyceridaemia, low HDL cholesterol as 
well as insulin resistance.74. Thus an insulin resistant state appears to be a central 
component of the dyslipidaemic condition associated with hyperinsulinaemia. Although 
genetic factors are thought to play a significant role in insulin resistance and NIDDM, no
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deleterious mutations of candidate genes have yet been found to explain the disease. It 
must be borne in mind that the association between variations in insulin sensitivity and 
plasma lipoprotein levels is only moderately high, suggesting that other factors , such as 
the variation in genes involved in lipoprotein metabolism, may modulate the magnitude
250of the dyslipidaemic state associated with insulin resistance.
There are no consensus as to whether the changes in lipid metabolism are secondary to 
insulin resistance or vice versa. Prospective study have shown that insulin resistance 
precedes other changes and supports the hypothesis that insulin resistance is the 
underlying factor.251 Others have argued that the primary change is in fat metabolism, and 
the increase in fat oxidation leads to insulin resistance in obesity and eventually to the
252high incidence of non-insulin dependent diabetes mellitus.
In conclusion, the data reviewed in this thesis highlights the close relationship between 
insulin resistance and the atherogenic lipoprotein phenotype. Of particular interest was 
the significant difference between the Singapore cohort and the Scottish cohort, 
suggesting that genetic influence may play a significant role in the manifestations of 
insulin resistance and the dense LDL particles. It was further supported by the ethnic 
differences between those of Asian descent and those with some European ancestry, who 
despite living in similar social environment yet had differing profiles. Insulin resistance is 
a major risk factor in the development of a group of complications that increases risk for 
coronary heart disease. It is likely that insulin resistance and the atherogenic lipoprotein 
phenotype are part of a closely linked metabolic and cardiovascular syndrome. This 
concept has important clinical and therapeutic implications since effective treatment 
aimed solely at any given component of the syndrome may be completely offset by 
aggravation of other factors.
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Appendix 1
Suppliers of Reagents, Equipment and Software
Abbot Laboratory
Rep of Ireland
Butterfly® -21 Venisystems™
Baker Instruments Ltd
Rusham Park, Whitehall Lane, Egham, Surrey, TW20 9NW, UK.
Encore Chemistry System Centrifi Chem®
Beckman Instruments, Spinco Division
Beckman Instruments (UK) Ltd Analytical Sales and Service Operation 
Progress Road, Sands Industrial Estate, High Wycombe, Bucks. HP 12 4JL, UK. 
L8-60M Ultracentrifuge L8-70 Ultracentrifuge
Prep UV Scanner AnF rotor
SW 40 rotor Ti 60 rotor
Ultra-clear™ centrifuge tubes Ti 50.4 rotor
Polycarbonate centrifuge bottles and caps Spinkote 
Silicone Vacuum grease Tube Sheer
Becton Dickinson
Dublin, Eire
Microlance®2 21G Needles Syringes
BDH Laboratory Supplies
McQuilkin and Co., 21 Polmadie Avenue, Glasgow G5 OBB, UK 
Triethylamine Folin-Ciocalteau Reagent
Boehringer Mannheim GmbH
Boehringer Mannheim UK (Diagnostics and Biochemicals) Ltd 
Bell Lane, Lewes, East Sussex BN7 1LG, UK.
ATP (MV 602)
Kit No. 310328 (free cholesterol)
Kit No. 704121 (cholesterol)
CP Pharmaceuticals Ltd
Wrexham, UK 
Hepsal® (10 units per mL)
Multiparin® (100° Per mL)
Immunogenetics NV
Antwerp, Belgium 
Innotest Lp(a)
Microsoft Corporation
Hitachi 717 automatic analyser 
Kit No. 69184 (phospholipid) 
Kit No. 704113 (triglyceride)
Multiparin® (5000 ^ ts Per ml)
1 Microsoft way, Redmond, WA, USA.
MS Word for Windows 3.1
Minitab Inc
3081 Enterprise Drive, State College, PA 16801-3008 USA.
PC Version of Minitab Release 9 for Windows
Paar Scientific Ltd
594 Kingston Road, Raynes Park, London SW 20 8DN, UK 
Digital densitometer DMA 35
Technicon (Ireland) Ltd
Swords Co. Dublin, Eire.
Autoanalyser® II
Achema Pte Ltd
2 Soon Wing Road #03-11, Soon Wing Industrial Building, Singapore 1334 
20-100uL single channel pipetter, 200-1000uL single channel pipettor 
Stand for 6 Treff pipettors
Ismatech 8 channel peristaltic pump 2 colour coded stoppers Tygon tubings
Syringe infusion pumps
Beckmann Instruments Singapore Ptd Ltd
331 North Bridge Road, #07-01/02 Odeon Towers, Singapore 0718 
Du650 Spectrophotometer and Colour monitor 
External storage device
Single cell holder Flow cell and tubing kit
Fraction recovery system
SW 40 Ti rotor set 50.3 Ti rotor set
Cap for lipoprotein floatation
Ultra clear centrifuge tubes for SW 40Ti rotor
Ultra clear centrifuge tubes for 50.3 Ti
GS-15 Table top refrigerated centrifuge
F1010 Fixed angle rotor
3-5 ml Adapters 10 ml Adapters
Rotor cleaning kit
Laboratory Equipments Pte Ltd
153 Kampong Ampat, #02-04 Junjie Industrial Building, Singapore 1336 
DMA 35 Digital Density Meter for liquids 
Multisize tube racks 
Test-tube peg racks
Schmidt Scientific Ptd Ltd
2 Jalan Kilang Barat, Singapore 0315
10 ml Vacutainer plain tubes 10 ml Vacutainer EDTA tubes
3 ml Vacutainer plain tubes 3 ml Vacutainer fluoride oxalate tubes
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Quintech Scientific Pte Ltd
9 Chin Bee Avenue, Singapore 2261 
1 ml Kimax Volumetric flask
Innovative BioTech Pte Ltd
77 Ayer Rajah Crescent, #03-04 Ayer Rajah Industrial Estate Singapore 0513 
Sigma Maxidens
Sigma Diagnostics Protein Assay kit
Appendix 2
INCLUSION CRITERIA FOR CASES IN FAMILY STUDIES (Scotland)
1. Probands must be aged 55 and below
2. At least 3 months post CABG
3. Positive family history of siblings and or parents with documented history of
premature ischaemic heart disease/ myocardial infarction(<55 years of age).
4. Members of family of proband must be accessible and willing to participate in the
study.
Generation I Parents
Generation II Probands, siblings and spouses
Generation III Children of probands and probands' siblings
Adopted children and half sibs are excluded. All other members of family will be
recruited
Exclusion Criteria:
1. Familial Hypercholesterolaemia
2. Diabetes Mellitus
INCLUSION CRITERIA FOR CONTROLS
1. Age under 55 years old
2. No family history of CHD in parents or siblings(<70 years of age)
3. No history of Diabetes mellitus, hypertension, hyperlipidaemia or CHD
4. At least 10 members of controls must be accessible and willing to participate in 
the study. All members of family will be recruited.
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Appendix 3
Volunteer Consent Form
I, _____________________________________ , understand that Professor Janies
Shepherd, Dr Chris Packard, Professor AR Lorimer, Professor Wheatley and Dr Chee- 
Eng Tan are undertaking investigations on coronary risk factors in families with and 
without premature coronary heart disease.
The studies involve the following:
1. Filling in a questionnaire on lifestyle assessment and medical history.
2. Taking 60 mL of fasted blood samples.
3. Taking a 75 gm glucose drink as part of an oral glucose tolerance test after (2),
followed by half hourly blood sampling of 5 mL, for 2 hours.
I understand that my involvement in this study is entirely voluntary and that I may 
withdraw at any time.
Patient's signature    Date
Attending Physician's signature ____________________  Date
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Volunteer Consent Form (Heparin Study)
I understand that a team of researchers under the supervision of Professor James 
Shepherd are investigating key factors which control blood fat levels in people.
The studies involve the following:
1. Taking a small initial blood sample for a full blood count.
2. Assessment by a Physician regarding my suitability to participate in the study.
3. Taking a larger fasting blood sample.
4. On the same occasion as (3) above, the administration of heparin followed by a
small blood sample.
This nature of this study has been clearly explained to me by Dr CE Tan and my 
involvement in the study is entirely voluntary.
Patient's signature:   Date: __________________
Attending Physician's
Signature:   Date: __________________
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Appendix 4
Heparin Administration Medical Questionnaire
Volunteer - Name _________________________________
Date of Birth _________________________________
Dear Volunteer,
Thank you for participating in our study. You will be given an injection of heparin to 
enable us to measure the activity of key factors involved in fat metabolism. In order for us 
to be certain that it is safe to give you the heparin, would you please answer the questions 
and sign the sheet when you have finished. If you have any further questions or something 
is unclear, please ask.
1. Are you quite fit at the moment? Yes/No
2. Are you receiving any medical treatment? Yes/No
(including non-steroidal anti-inflammatory drugs)
If so, please specify:_______________________________________
3. Have you taken aspirin recently? Yes/No
4. As far as you know, are you sensitive to heparin? Yes/No
5. Do you have haemophilia or any other diagnosed bleeding disorder?Yes/No
6. Have you ever suffered from a stroke? Yes/No
7. Have you had rheumatic fever? Yes/No
8. Have you had a recent surgery? Yes/No
9. Have you had a recent head injury or trauma requiring hospital admission?Yes/No
Height: Weight:
Blood pressure:
Signature: _____________ ________________________
Date:
152
Appendix 5
LIFESTYLE ASSESSMENT QUESTIONNAIRE Serial N o :D D D
Groups: CH
Family order: D
PATIENT PARTICULARS
Date of Registration:_________________
Forename:__________________________
Surname:__________________________
Address:___________________________________________________________
Tel:__________________ _____________
Occupation:_________________________
Educational level:
Date of Birth:
Sex:
Height(without shoes) 
Weight
D/ M/ Y□□□□□□
□
□ □ □ . □  cm
□□an kg
l=male, 2=female
Blood pressure: To be taken seated from the right arm after 15 minutes rest and 5 minutes 
interval between readings.
Systolic
Diastolic
Waist
Hip
1st reading 
n O n  mmHg
n n n  mmHg
nnn.n cm
cm
2nd reading (nearest 2mmHg)nnn mmHg
EH C O  mmHg (Korotkov V)
(Waist is defined as the narrowest 
circumference below the ribs and 
above the umbilicus)
(Hip is defined as the broadest 
circumference between the superior 
border of iliac crest and the thigh)
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Social History
Please fill up all columns and put in 0 if not applicable
Smoker □ l=yes, 2=no
If current smoker Q Q  cigarettes/day
If Ex smoker ED ED cigarettes/day
No of years of smoking □ □
No of years since stopping smoking E D D  
(if applicable)
Alcohol consumption □ l=yes,2=no
Alcohol intake in units per week E ]E D E D  
(NB: lunit=half pint beer, 1 glass wine or 1 tot spirit)
Level of Exercise □
At work or in your leisure, how often are you physically active for a period of at least 20 
minutes during which you become short of breath and perspire?
l=less than once per week, 2=once per week, 3=at least 2-3 times per week
Diet
Has your dietary pattern improved recently? ED l=yes, 2=no 
(in the last 6 months)
If yes, why? EH
l=relative recently diagnosed to have CHD, 2=Health education through the media, 
3=Doctor's advice, 4=Personal motivation, 5=others
Medical History
Diabetes mellitus ED l=yes,2=no
Age of onset of diabetes D C ]
No of years of Diabetes ED ED
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Treatment of Diabetes d
l=Diet only, 2=drug, 3=insulin, 4=drug+insulin, 5=others, please specify
Impaired glucose tolerance d l=yes, 2=no
(excluding Diabetes mellitus, ie. if you are already a diabetic, please fill this as 0)
Hypertension d l=yes, 2= no
(ie. diagnosed by GP, hospital, nurse practitioner or those already on treatment)
No of years of hypertension d d
No of years of treatment d d
Type of Treatment d __________________
l=Diuretics, 2=Beta blockers, 3=Calcium antagonist, 4=ACE inhibitors, 5=Diuretics + 
beta blockers, 6=no treatment, 7=others and specify
Coronary Heart Disease(CHD) d l=yes, 2=no
(CHD includes angina, myocardial infarction, ischaemic heart disease)
How was the diagnosis of CHD made? d
l=Chest pain, angina, 2=ECG changes, 3=positive threadmill test, 4=coronary 
angiogram, 5=others, please specify
Duration of CHD dd (in years)
Dyslipidaemia D  l=yes, 2=no
Duration of Dyslipidaemia d (in years)
Type of Treatment d _______
l=diet only, 2=resin binders, 3=fibrates, 4=statins, 5=olbetam, 6=combinations, please 
specify, 7=no treatment, 8=others, please specify
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Other Medical History: d l  (You may fill more than one box)□□□
l=Stroke, 2=Cancer, 3=kidney disease, 4=prostate disese, 5=respiratory disease,6=liver 
disease, 7=neurological problems, 8=surgical procedures, please specify, 9=others, 
please specify
Any family history of coronary heart disease? CH l=yes, 2=no
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Appendix 6
Volunteer Consent Form: Visit 1 (fat meal study in Scotland)
I understand that a team of researchers under the supervision of Professor James 
Shepherd are investigating key factors which control blood fat levels in people.
The studies involve the following:
1. Taking a small initial blood sample for a full blood count.
2. Assessment by a Physician regarding my suitability to participate in the study
3. Taking another larger fasting blood sample.
4. On the same occasion as (3) above, the administration of heparin, which thins the
blood, followed by a small blood sample.
This study has been clearly explained to me by Dr CE Tan and my involvement in the 
study is entirely voluntary.
Patient's signature: ________________________ Date: __________________
Attending Physician's
Signature:__________________________________ Date: __________________
Volunteer Consent Form: Visit 2
I understand that a team of researchers under Professor James Shepherd are investigating 
the effects of dietary fat on key factors which control blood fat levels in people.
The studies involve the following:
1. Taking a small fasting blood sample.
2. Taking of a standardised fat meal
3. Taking of small blood samples at half hourly interval for 2 hours, and then 2
hourly interval up to the 6th hour.
4. Heparin will then be given at the 6th hour and a final blood sample 12 minutes
later.
The nature of this study has been clearly explained to me and I understand that my 
involvement in this study is entirely voluntary.
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Patient's signature:   Date:
Attending Physician's
signature:   Date:
Volunteer Consent Form: Visit 3
I understand that a team of researchers under Professor James Shepherd are investigating 
the effects of dietary glucose on key factors which control blood fat levels in people.
The studies involve the following:
1. Taking a small fasting blood sample.
2. Taking of a 22 g glucose load.
3. Taking of small blood samples at half hourly interval for 2 hours, and then 2
hourly interval up to the 6th hour.
4. Heparin will then be given at the 6th hour and a final blood sample 12 minutes
later.
The nature of this study has been clearly explained to me by Dr CE Tan and I understand 
that my involvement in this study is entirely voluntary.
Patient's signature: ________________________ Date: ________________
Attending Physician's
signature:__________ ________________________ Date: ________________
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Appendix 7
VISIT 1 (Alimentary Lipaemia study) 
PATIENT PARTICULARS
Date of Registration:_____ ____________
Forename:
Surname:
Address:
Tel:
Occupation:
Educational level:
Date of Birth:
Sex:
Height(without shoes) 
Weight
D/ M/ Y□□□□□□
□
□ □ □ . □  cm
mound kg
l=male, 2=female
Blood pressure: To be taken seated from the right arm after 5 minutes rest and 5 minutes 
interval between readings.
Systolic
Diastolic
Waist
Hip
1st reading 
□ □ □  mmHg
□ □ □  mmHg
□ □ □ . □  cm
cm
2nd reading (nearest 2mmHg) 
Q O d  mmHg
□ □ □  mmHg (Korotkov V)
(Waist is defined as the narrowest 
circumference below the ribs and 
above the umbilicus)
(Hip is defined as the broadest 
circumference between the superior 
border of iliac crest and the thigh )
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Social History
Please fill up all columns and put in 0 if not applicable
Smoker d l=yes, 2=no
If current smoker O O  cigarettes/day
If Ex smoker [ZD cigarettes/day
No of years of smoking d d
No of years since stopping smoking d d  
(if applicable)
Alcohol consumption d l=yes,2=no
Alcohol intake in units per week ddd •
(NB: lunit=half pint beer, 1 glass wine or 1 tot spirit)
Level of Exercise d
At work or in your leisure, how often are you physically active for a period of at least 20 
minutes during which you become short of breath and perspire?
l=less than once per week, 2=once per week, 3=at least 2-3 times per week
Any family history of coronary heart disease? d l=yes, 2=no
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Appendix 8
CORONARY RISK FACTORS STUDY (IN SINGAPORE)
INCLUSION CRITERIA Date:
Category: EH
Age: 30 to 45 years IC No:_________
Sex: Male
Normals must have HbAlC<6.5%
Cholesterol must be less than 6.0 mmol/L
PATIENT PARTICULARS
Name:
Address:
Tel:
Occupation: Educational level:
Date of Birth:
Sex:
Height(without shoes) 
Weight
D/ M/ Y□□□□□□
□
□ □ □ . □  cm
□ □ □ . E H  kg
l=male, 2=female
Blood pressure: To be taken seated from the right arm after 5 minutes rest and 5 minutes 
interval between readings.
Systolic
Diastolic
Waist
Hip
1st reading 
EHDEH mmHg
D O D  mmHg
□ □ □ . □  cm
cm
2nd reading (nearest 2mmHg) 
t Z D E H  mmHg
E D E Z O  mmHg (Korotkov V)
(Waist is defined as the narrowest 
circumference below the ribs and 
above the umbilicus)
(Hip is defined as the broadest 
circumference between the superior 
border of iliac crest and the thigh
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Social History
Please fill up all columns and put in 0 if not applicable
Smoker d l=yes, 2=no
If current smoker d d  cigarettes/day
If Ex smoker dd cigarettes/day
No of years of smoking d d
No of years since stopping smoking dd 
(if applicable)
Alcohol consumption d • l=yes,2=no
Alcohol intake in units per week ddd
(NB: lunit=half pint beer, 1 glass wine or 1 tot spirit)
Level of Exercise d
At work or in your leisure, how often are you physically active for a period of at least 20 
minutes during which you become short of breath and perspire?
l=less than once per week, 2=once per week, 3=at least 2-3 times per week
Any family history of coronary heart disease? d l=yes, 2=no
Medications:_______________________________________________________________
Consent
I , ________________  , understand that Dr CE Tan and his team of
doctors are conducting a study on risk factors for heart disease in patients and this 
requires taking of 3 samples of blood at 5 minutes interval after a 10 hour fast. I also 
understand that my consent and participation in this study is entirely voluntary and that I 
may withdraw from the study at any time.
Patient's Signature and Date
Physician's Signature and date
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Glossary
CHD: Coronary Heart disease
CAD: Coronary artery disease
NIDDM: Non insulin dependent diabetes mellitus
IDDM: Insulin dependent diabetes mellitus
IR: Insulin resistance
IRS: Insulin resistance syndrome
ALP: Atherogenic lipoprotein phenotype
HDL: High density lipoprotein
VLDL: Very low density lipoprotein
LDL: Low density lipoprotein
HL: Hepatic lipase
LPL: Lipoprotein lipase
AUC: Area under curve
sem: Standard error of mean
SD: Standard deviation
BMI: Body mass index
WHR: Waist to hip ratio
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